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Abstract
Non-motor symptoms such as dementia and visual hallucinations are key 
determinants of long-term outcome and quality of life in Parkinson’s 
disease (PD). Attempting to understand these issues better was the 
motivation behind this thesis.
A major aim of the study was to characterise the visual symptoms 
experienced by patients with PD and PD dementia, focussing not just on 
complex visual hallucinations, whose prognostic implications are already 
well-described, but also on a range of other visual symptoms including 
illusory misperceptions, sensations of passage and presence and double 
vision. A major objective was to define key measures of visual exploration 
strategy during visuocognitive assessment and examine the link between 
strategy, cognition and visual and motor symptoms. We also set out to 
examine the utility of retina-specific visual assessment techniques to 
define the potential role of retinal dysfunction in visual impairment and 
symptomatology.
A major finding of this study was that not all visual symptoms share a 
common pathophysiological basis. Our results argue in favour of splitting 
hallucinations into separate phenomenological groups in order to better 
define causation and predictive value in future longitudinal studies. In 
addition, exploration strategy on a variety of visual tasks was 
demonstrated to be significantly less efficient in subjects with perceptual 
difficulties, providing insight into the interaction between cognition and eye 
movements in PD. Retinal structure, as assessed by optical coherence 
tomography, was not significantly altered in PD and our results would 
caution against the use of this technique as a disease biomarker until 
more is known about the limitations of this method. Finally, our 
neurophysiological assessment hints at the retina as the site of diminished 
visual acuity in PD despite there being no striking differences in central 
and peripheral retinal responses between control and PD subjects.
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1. Overview
1.1 Background
Parkinson’s disease (PD), the second commonest neurodegenerative 
disorder in the UK, has an ever widening clinical phenotype encompassing 
a range of motor and non-motor symptoms. Dementia and visual 
hallucinations are key non-motor determinants of long-term outcome and 
quality of life, and a better understanding of these symptoms is central to 
improvements in care (Lo et al., 2009, McKinlay et al., 2008). In addition to 
complex visual hallucinations (CVH), other visual symptoms reported in 
PD include illusory misperception, feelings of presence and passage in the 
visual periphery and double vision (diplopia).
The link between CVH and cognitive decline is clearly defined and CVH 
remain strong predictors of nursing home placement and mortality 
(Aarsland et al., 2000, de Maindreville et al., 2005, Goetz and Stebbins, 
1993, Goetz and Stebbins, 1995, Goetz et al., 2006). Although illusions, 
passage and presence often co-occur with CVH, they also exist in 
isolation and may not have the same predictive value in terms of the 
development of PD dementia (PDD) (Llebaria et al., 2010). The 
association between cognition and visual phenomena such as illusions, 
presence and passage has not been specifically addressed.
The pathophysiology of hallucinosis in PD remains a subject for debate, 
but interactions between impaired visual input (Santhouse et al., 2000, 
Teunisse, 1997, Teunisse et al., 1999), brainstem and higher cognitive 
dysfunction (Benke, 2006, Manford and Andermann, 1998, Ohayon, 2000, 
Manni et al., 2002, Onofrj et al., 2002, Pacchetti et al., 2005), particularly 
impaired attention and executive function, have all been implicated 
(Collerton et al., 2005, Diederich et al., 2005). Prior to this study, 
presence, passage and illusions have often been collectively defined as 
“visual hallucinations”, an approach that implicitly, and perhaps 
inaccurately, assumes a common aetiological basis.
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Whilst some of the visual symptoms common in PD are likely to stem from 
“central”, or more accurately “cortical” visual processing deficits, others 
may be related to lower level disturbances of visual function. Visual acuity 
(VA) (Matsui et al., 2006), contrast sensitivity (CS) (Bodis-Wollner et al., 
1987, Uc et al., 2005), colour perception (Pieri et al., 2000, Price et al., 
1992) and motion perception (Castelo-Branco et al., 2008) are all impaired 
in PD, with retinal dysfunction advanced as one possible explanation for 
these findings.  
Non-invasive imaging techniques such as optical coherence tomography 
(OCT) have demonstrated changes in retinal structure in PD, albeit in 
relatively small numbers of carefully selected, younger patients (Altintas et 
al., 2007, Inzelberg et al., 2004, Moschos et al., 2010, Cubo et al., 2010, 
Hajee et al., 2009). In addition, the amplitude and latency of the pattern 
electroretinogram (PERG) response is altered in PD, providing further 
evidence that the disease process in PD targets the retina (Langheinrich 
et al., 2000, Sartucci et al., 2006a). The functional implication of these 
findings, in terms of visual symptoms, has not been addressed in any 
studies to date. It has also been argued that OCT might prove a useful 
biomarker for assessing disease progression in PD. However, to be 
considered as a viable potential biomarker, altered retinal morphology in 
PD would need to be a robust and repeatable finding in larger cohorts, 
preferably with longitudinal follow-up, and be applicable to a typical cohort 
of elderly PD patients with a variety of co-morbidities.
Dopamine plays an important role in retinal signalling by modulating the 
flow of rod-driven visual information (Dacey, 1990, Kolb et al., 1990, 
Pourcho, 1982, Voigt and Wassle, 1987, Bloomfield and Dacheux, 2001, 
Witkovsky et al., 1993) and mediates the retinal transition from a dark-
adapted to light-adapted state (Cahill, 1996, Doyle et al., 2002b, Ribelayga 
et al., 2008, Tosini and Menaker, 1996). Electrical responses to pattern 
stimuli can be measured both at the retinal (PERG) and visual cortical 
level (visual evoked potential (VEP)) and separate visual pathways can be 
preferentially activated by manipulating the spatial and temporal 
characteristics of the stimuli used. The response of a dopamine-deficient, 
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dark-adapted retina may be tipped in favour of reporting rod-driven 
responses, ultimately manifesting as fleeting, peripheral sensations of 
visual passage (Harris et al., 1992, Wink and Harris, 2000). Techniques 
such as OCT and the PERG potentially provide a way of distinguishing the 
retinal contribution to visual impairment in PD from more cortically-
mediated deficits.
Selection of visual information in a complex scene is achieved by 
deploying sequences of fixations interspersed with rapid eye movements 
(saccades) (Henderson and Hollingworth, 1999). Cortical control of eye 
movements is achieved through the coordinated actions of the frontal and 
parietal eye fields (Rivaud et al., 1994, Pierrot-Deseilligny et al., 1995, 
Pierrot-Deseilligny et al., 1991b, Muri et al., 1996) in conjunction with the 
prefrontal and posterior parietal cortex (Pierrot-Deseilligny et al., 1995, 
Pierrot-Deseilligny et al., 2005). These areas project, via the superior 
colliculus, thalamus and basal ganglia to brainstem structures concerned 
with saccadic eye movements (Hikosaka et al., 2000). 
Eye movement abnormalities are well recognised in patients with PD but 
evidence for disease-specific disruption of saccades in PD is contradictory. 
Whereas some studies have demonstrated increases in saccadic latency, 
reductions in amplitude and increased error rates (Rascol et al., 1989, 
Kennard and Lueck, 1989, Briand et al., 1999, Hood et al., 2007, 
MacAskill et al., 2002, van Stockum et al., 2008), others have not 
replicated these findings (Vidailhet et al., 1994, Briand et al., 1999, Briand 
et al., 2001, Lueck et al., 1990, Vidailhet et al., 1999, Mosimann et al., 
2005). Both the properties of the stimulus used, medication effects and 
cognitive heterogeneity of study cohorts are important determinants of 
saccadic metrics and may help explain some of the inconsistencies in the 
literature (Chambers and Prescott, 2010, Michell et al., 2006, Hood et al., 
2007, Hodgson et al., 1999, Mosimann et al., 2005). Aside from the 
absolute metrics of saccades and fixations, visual exploration strategies 
can be used to provide insights into the cognitive processes required for 
more “real-world” tasks such as emotion recognition, text- and clock-
reading (Hodgson et al., 2002, Mosimann et al., 2004a, Lueck et al., 2000, 
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Ogrocki et al., 2000). Taken together, the characteristics of saccades, 
fixations and exploration strategies may help to illustrate the complex 
interplay between cognitive sub-domains in PD and provide a precise and 
objective measure of cognition for future interventional studies. Visual 
exploration strategies during a variety of tasks may also offer clinical 
insights into motor and non-motor symptoms such as CVH and visually-
induced gait freezing. For example, PD patients with visual hallucinations 
perform less well on visuoperceptual tasks than non-hallucinators, 
suggesting an association between the “perceptual” impairment and the 
development of visual symptoms such as hallucinations (Mosimann et al., 
2004b, Koerts et al., 2010, Meppelink et al., 2008). In a similar fashion, 
impairment in the processing of  “spatial” visual information may be 
associated with motor complications such gait freezing and postural 
instability, although evidence is lacking to support this hypothesis.
The four main studies in this thesis approached the visual system in a 
systematic fashion, beginning with a detailed characterisation of visual 
symptoms in PD across cognitive groups, followed by an examination of 
the evidence for retinal dysfunction in PD and its potential functional 
implications. The final chapter of the thesis describes the visual 
exploration strategies of PD subjects, with and without cognitive 
impairment, to examine, first, the role such measures might play in 
predicting visual and motor disability, and second, what insights are 
provided into cognitive impairment in PD.
1.2 Outline of study aims and hypotheses
• To characterise the range of visual symptoms seen in a cohort of 
patients with PD and PDD and assess their correlations with ocular 
pathology and cognition, exploring the following hypotheses:
✦ complex visual hallucinations, illusory misperception, 
sensations of presence and passage do not share a common 
pathophysiology and will have different clinical predictors.
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✦ cognitive impairment contributes to the reduced visual acuity 
and contrast sensitivity seen in PD by interfering with test 
performance.
• To compare retinal structure in a PD and healthy age-matched 
control cohort for evidence of retinal nerve fibre or macular thinning 
in the PD group and assess the utility of this approach as a potential 
biomarker for disease progression in PD.
✦ PD patients will demonstrate thinning of the peri-papillary 
retinal nerve fibre layer and macula compared to healthy 
controls.
✦ the role of Optical Coherence Tomography as a potential 
biomarker may be limited by the co-occurrence of retinal 
disease (macular degeneration, glaucoma) and tolerability of 
the procedure in a representative PD sample. 
• To examine the magnocellular and parvocellular responses of the 
retina (PERG) and early visual cortex (VEP) in PD and correlate 
these with visual symptoms.
✦ magnocellular (peripheral retina) responses in the PD group 
will differ from controls and correlate with the presence of 
“passage” symptoms, whereas parvocellular (central retina) 
responses will be equivalent in both groups.
• To examine visual exploration strategies in patients with PD and 
PDD with the following hypotheses:
✦ visual exploration is impaired in patients with PD compared to 
HC and this impairment is more marked as overall cognitive 
function declines.
✦ impairment of visual exploration, reflecting the interaction 
between visuoperceptual abilities, attentional and executive 
function, will be predictive of poorer performance on the eye 
tracking battery.
✦ impaired exploration strategies on visuospatial tasks will be 
predictive of freezing of gait, whereas exploration strategies on 
visuoperceptual tasks will predict the presence of complex 
visual hallucinations.
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2. General Introduction
2.1 Parkinson’s disease
Parkinson’s disease (PD) is the second commonest neurodegenerative 
disorder in the UK after Alzheimer’s disease. Although traditionally thought 
of as a movement disorder, the broad clinical phenotype of PD, embracing 
a range of both motor and non-motor symptoms, would suggest it is better 
thought of as a multi-system neurodegenerative disorder. 
2.1.1 Clinical features
James Parkinson’s original description of “the shaking palsy” in 1817 
focused on the motor features of the disorder – tremor, bradykinesia and 
rigidity (Kempster et al., 2007, Parkinson, 2002). Between patients, there 
is considerable variation in the presentation of motor features (Foltynie et 
al., 2002). For example, tremor is not a universal feature of PD, although 
patients presenting with a tremor-dominant phenotype, or in whom this 
phenotype dominates over time, may have a more favourable prognosis 
and slower disease progression (Ebmeier et al., 1990, Hershey et al., 
1991). Conversely, postural instability and gait difficulty (PIGD) is much 
more common in PD patients with dementia (PDD) and transition from a 
tremor-dominant to PIGD phenotype is associated with an increased risk 
of dementia (Burn et al., 2003, Alves et al., 2006). There is a reduction in 
life expectancy associated with the diagnosis of PD, with mortality hazard 
ratios varying between 1.3 and 4.1 (Herlofson et al., 2004, Marras et al., 
2005). Independent predictors of mortality include age at diagnosis, 
disease severity at presentation, early visual hallucinations and 
development of balance disorders and dementia, indicating that it is a 
combination of motor and non-motor problems that contributes to 
increased mortality rates in PD (Lo et al., 2009). 
As part of the evolving clinical phenotype of PD, non-motor aspects of the 
disease are increasingly recognized. These include neuropsychiatric 
disturbances such as anxiety, depression, delusions and visual 
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hallucinations (Cummings and Masterman, 1999, Lemke et al., 2004, 
Martinez-Martin et al., 2007), cognitive decline and dementia (Aarsland et 
al., 2003, Foltynie et al., 2004, Hely et al., 2008), sleep disorders such as 
rapid eye movement (REM) sleep behaviour disorder (Comella, 2006), 
hyposmia (Bohnen et al., 2007) and autonomic failure (Allcock et al., 2006, 
Lucetti et al., 2006, Wullner et al., 2007). As the disease progresses, these 
non-motor symptoms become increasingly important determinants of 
quality of life in people with PD (Chaudhuri et al., 2006, Martinez-Martin et 
al., 2007).
2.1.2 Visual symptoms in PD
Visual symptoms are common in PD and include blurred vision and 
difficulty reading (Hutton and Morris, 2001), dry eyes and diplopia 
(Biousse et al., 2004, Chaudhuri et al., 2006), feelings of presence and 
passage in the visual periphery and CVH (Aarsland et al., 1999, Fenelon 
et al., 2000, Mosimann et al., 2006). Whilst some of these symptoms are 
likely to stem from cortical visual processing deficits, others may be 
related to lower level disturbances of visual function. Symptoms such as 
perceptual disturbances and CVH will be covered in more detail later in 
the introduction. 
Biousse et al. (2004) studied the ophthalmic features of a group of 30 PD 
participants and found complaints of dry, gritty eyes were present in over 
60% of the PD cohort, with objective evidence of increased tear film break 
up time in over 50% of the group (compared with 22% of healthy controls). 
Clinically apparent oculomotor abnormalities are also evident in PD with 
reductions in the amplitude of vergence eye movements, reduced blink 
frequency and convergence insufficiency all significantly more common in 
PD than age-matched HCs (Biousse et al., 2004, Repka et al., 1996). 
Although complaints of double vision were uncommon in the Biousse and 
Repka studies, diplopia has been reported in 22% of a much larger cohort 
(n = 123) of patients in a questionnaire study of non-motor symptoms in 
PD (cf. 4% of a control group) (Chaudhuri et al., 2006). The cause of 
diplopia in PD is unclear. Whilst convergence insufficiency is a possible 
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explanation, this is a common feature in older adults and is likely to cause 
diplopia only for near visual tasks. An alternative explanation would be 
oculomotor abnormalities resulting in ocular misalignment, although no 
studies have specifically looked at this possibility.
2.1.3 Diagnosis 
There are no serological or cerebrospinal biomarkers with robust 
sensitivity and specificity for identifying PD and despite advances in 
structural and functional brain imaging, the diagnosis of the disorder 
remains largely clinical. Central to this clinical process is the 
demonstration of “parkinsonism”, manifest by slowness and poverty of 
movement (bradykinesia/akinesia), in conjunction with other key features 
such as a (coarse) resting tremor, rigidity of muscle tone and postural 
instability. Together, these cardinal “motor” features are the cornerstone of 
the UK Brain Bank criteria for PD diagnosis (Table 1) (Hughes et al., 
1992). Such a diagnosis must be supported by clinical features typical of 
idiopathic PD and an absence of findings that might point to an alternative 
explanation for the parkinsonism. 
Nevertheless, diagnostic inaccuracy remains problematic. In community 
studies of patients with suspected PD, misdiagnosis rates vary from 5 to 
15%, with conditions such as vascular parkinsonism and essential tremor 
being most frequently misclassified as PD (Newman et al., 2009, Schrag 
et al., 2002). The clinical features of dystonic tremor can also closely 
resemble those of PD, often requiring functional dopamine imaging to 
differentiate the two conditions (Schneider et al., 2007). Even in patients 
with advanced disease, examined at specialist centres, neuropathological 
studies suggest an incorrect diagnosis in around 10% of cases, with other 
extrapyramidal conditions such as Multiple System Atrophy (MSA) and 
Progressive Supranuclear Palsy (PSP) making up the bulk of erroneous 
diagnoses (Hughes et al., 2001). 
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Table 1. UK Brain Bank Criteria for a Diagnosis of Parkinson’s 
Disease (Hughes et al., 1992).
2.1.4 Epidemiology of Parkinson’s disease
Methodological differences between studies make comparing the 
worldwide prevalence of PD difficult. Crude estimates in European 
populations suggest a prevalence range in the general population of 100 
to 200 per 100,000 inhabitants (Alves et al., 2008, von Campenhausen et 
al., 2005). The strongest risk factor for developing PD is increasing age, 
with prevalence estimated at 1% in the over 60s and 4% in the over 80s 
(de Rijk et al., 1995, Nussbaum and Ellis, 2003). Hence, one might expect 
PD prevalence in the developing world, where life expectancy is lower, to 
be less. Estimates from work in Asia and Africa suggest this may be the 
case, with age-standardized figures of between 50-175 per 100,000 and 
64 per 100,000 inhabitants, respectively (Dotchin et al., 2008, 
Muangpaisan et al., 2009). However, with the developing world ageing 
faster than was historically true for now developed countries, the global 
prevalence of PD is likely to rise further.
Criteria for the diagnosis of probable and possible PDD
Probable PDD
A. Core features: Both must be present 
B. Associated clinical features:
• Typical profile of cognitive deficits including impairment in at least two of the four core cognitive domains (impaired attention which may 
fluctuate, impaired executive functions, impairment in visuo-spatial functions, and impaired free recall memory which usually improves with 
cueing)
• The presence of at least one behavioral symptom (apathy, depressed or anxious mood, hallucinations, delusions, excessive daytime sleepiness) 
supports the diagnosis of Probable PD-D, lack of behavioral symptoms, however, does not exclude the diagnosis
C. None of the group III features present
D. None of the group IV features present
Possible PDD
A. Core features: Both must be present 
B. Associated clinical features:
• Atypical profile of cognitive impairment in one or more domains, such as prominent or receptive-type (fluent) aphasia, or pure storage-failure 
type amnesia (memory does not improve with cueing or in recognition tasks) with preserved attention
• Behavioral symptoms may or may not be present 
OR
C. One or more of the group III features present 
D. None of the group IV features present
UK Brain Bank Diagnostic Criteria for PD 
Step 1 – Diagnosis of Parkinsonian syndrome 
Bradykinesia plus at least one of the following:
• Rest tremor
• Rigidity
• Postural instability
Step 2 – Exclusion criteria including:
Step 3 – Supportive prospective criteria (at least three required):
Presence of atypical features (such as):
• early falls
• supranuclear gaze palsy
• ataxia and cerebellar features
• early autonomic features
• early cognitive decline
• poor L-DOPA response
OR        History of:
• repeated strokes
• neuroleptic medication use
• head injury
• definite encephalitis
• Unilateral onset
• Rest tremor present
• Evidence of 
progression
• Persistent 
asymmetry
• Excellent response 
to L-dopa
• L-dopa-induced 
dyskinesias
• L-dopa response 
for 5+ years
• Clinical course of 
10+ years
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Incidence figures, being independent of mortality, may be a more accurate 
reflection of the frequency of PD in the population. European and North 
American studies suggest an incidence range from 8.6 to 19.0 per 
100,000 inhabitants (Twelves et al., 2003), the lower limit of this range 
agreeing well with incidence estimates from Muangpaisan et al. (2009) in 
their systematic review of studies from Asia.
2.1.5 Genetic and environmental factors
The factors influencing the development of PD are still poorly understood 
and most cases are thought to be due to an interaction between genetic 
profile and environmental exposure. Several gene mutations lead to 
familial PD, both with autosomal dominant (α-synuclein, leucine-rich 
repeat kinase 2 (LRRK-2)) and autosomal recessive (parkin, DJ-1, 
PINK-1) patterns of inheritance (Bonifati et al., 2003, Kitada et al., 1998, 
Paisan-Ruiz et al., 2004, Polymeropoulos et al., 1997, Valente et al., 2004, 
Zimprich et al., 2004). The clinical characteristics of these Mendelian PD 
cases are often rather different from the “typical” features of idiopathic PD; 
with the exception of LRRK-2, all result in juvenile- or young-onset PD. In 
addition, few cases to date have come to post-mortem, and it remains to 
be seen how closely the pathology matches that seen in idiopathic PD. 
Nonetheless, they provide insight into the mechanisms underlying the 
development and progression of neurodegeneration in PD by highlighting 
proteins and cellular pathways that may be central to the disease process. 
This has led to hypotheses suggesting that an interplay between oxidative 
stress and dysfunction of both ubiquitin-proteasomal and mitochondrial 
systems contributes to neurodegeneration in PD (Eriksen et al., 2003, 
Shen and Cookson, 2004).
Despite this important work, monogenic PD accounts for less than 5% of 
all cases and twin studies in patients developing PD after the age of 50 
years have failed to identify significant genetic factors (Tanner et al., 
1999). Marder et al. demonstrated only a small increase in risk of 
developing PD in first-degree relatives of patients compared to controls 
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(relative risk 2.3) (Marder et al., 1996). This has fueled interest in the role 
of environmental factors in the development of PD. It is beyond the scope 
of this discussion to cover such a topic comprehensively. However, there 
is consistent and convincing evidence to suggest that occupational 
exposure to pesticides is associated with an increased risk of developing 
PD (Lai et al., 2002, Priyadarshi et al., 2000), whereas smoking and 
caffeine intake are associated with a lower incidence of the disease 
(Hernan et al., 2002, Ross et al., 2000). Whilst the precise nature of 
caffeine and nicotine’s effects remain unclear, actions on the adenosine A2 
receptor for the former, and nicotinic receptors for the latter, have been 
postulated for this potential protective effect.
2.1.6 Pathology and pathogenesis
The motor features of PD are a manifestation of dysfunction and 
neurodegeneration in dopaminergic cells of the substantia nigra (SN) in 
the brainstem. The consequence of this damage is a reduction in 
dopaminergic projections to the striatum. Associated with this cellular 
dysfunction is the accumulation of a misfolded protein (α-synuclein) into 
spherical pale intracellular inclusions known as Lewy bodies. In addition to 
the “classic” Lewy body structures seen in PD, α-synuclein 
immunohistochemistry can identify less well-defined inclusions within 
neuronal cell bodies as well as spindle-like and branching Lewy neurites in 
the neuronal cell processes themselves (Spillantini et al., 1997, Braak et 
al., 1999). Synuclein accumulation is also seen in related 
neurodegenerative conditions such as dementia with Lewy bodies (DLB) 
and Multiple System Atrophy, which share some of the clinical features of 
PD and PDD. 
Accumulation of α-synuclein within cells is associated with dysfunction and 
cell death, although the precise nature of this process is the subject of 
much debate. Certain neuronal cell populations are particularly vulnerable 
in PD and these are projection neurons with long, thin, sparsely or 
unmyelinated axons (Braak et al., 2004). As such, the process of cell 
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damage is neither random nor is it solely confined to dopaminergic cell 
populations. Indeed, cholinergic, serotonergic and noradrenergic neurons 
are all affected in PD. One compelling hypothesis, based on 
neuropathological studies of early- and late-stage PD, suggests that motor 
symptoms present at a point where α-synuclein pathology has ascended 
from the lower brainstem (medulla and pons) to affect the substantia nigra 
(Braak et al., 2003). The so-called Braak hypothesis goes on to postulate 
that pre-motor symptoms of PD may be accounted for by the initial 
accumulation of abnormal protein in lower brainstem centres as well as in 
the olfactory bulb. As PD progresses over time, α-synuclein pathology 
involves the limbic system as well as the prefrontal and neocortex, leading 
to widespread and debilitating non-motor complications of PD such as 
dementia and visual hallucinations (Aarsland et al., 2005, Braak et al., 
2006). As such, it has been suggested that synuclein pathology in PD may 
behave much like prion pathology in patients with Creutzfeldt Jakob 
disease, advancing through the brain from cell-to-cell via synaptic contacts  
(Olanow and Prusiner, 2009). 
The validity of the Braak staging hypothesis is supported, in part, by work 
from a recent longitudinal PD cohort study, complete with autopsy data. In 
“typical” cases with relatively early symptom onset and slow disease 
progression, the spread of synuclein pathology mirrored the Braak staging 
hypothesis closely (Halliday et al., 2008). Unlike these younger-onset 
patients however, those patients in the same study presenting at an older 
age had a more aggressive disease course with quicker progression to 
dementia. In addition, they exhibited more mixed neuropathology, 
including greater amounts of β-amyloid – a protein more commonly 
associated with Alzheimer’s disease (AD). Indeed, AD-like changes of β-
amyloid and tau protein accumulation often co-exist with α-synuclein 
changes in PDD and seem likely to be influencing disease progression in 
at least a subset of PD patients (Jellinger, 2003). Arguing against a simple 
association between synuclein pathology and disease progression is 
recent work from Parkkinen et al. (2008) highlighting the presence of such 
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pathology in patients seemingly unaffected by either parkinsonism or 
dementia. It would appear that some subjects are able to tolerate 
significant synuclein burden without ill effect, perhaps supporting the 
hypothesis that such cellular inclusions are potentially cytoprotective and 
not directly involved in cell death (Tanaka et al., 2004).
The pathological findings in PD are therefore heterogeneous, progressive 
and involve a range of different neuronal cell types in a variety of brain 
regions.   Whilst the precise nature of the neurodegeneration seen in PD 
remains a subject of considerable debate, what is beginning to emerge is 
the consensus that the clinical manifestations of PD are due to a dynamic 
interaction between advancing age, still the strongest predictor of poor 
outcome, the location and extent of α-synuclein, β-amyloid and tau 
pathology and the subsequent impact these have on cellular integrity 
through mitochondrial dysfunction and oxidative stress (Levy, 2007).
2.1.7 Cognition and PD
Prominent among the non-motor complications of PD are cognitive 
impairment and dementia, the latter now a well-recognised complication of 
PD. A systematic review of 12 studies of PD estimates the point-
prevalence of PD dementia (PDD) in established cohorts to be 25-30% 
(Aarsland et al., 2005). More recent studies, with prevalent case selection 
and longitudinal follow-up, suggest this figure may be an underestimate, 
with a four-year cumulative dementia prevalence of 35-50% and 8-year 
figures of 78% (Aarsland et al., 2003, Hobson and Meara, 2004). These 
figures are in broad agreement with a long-term, longitudinal study of 
incident PD cases, which has demonstrated the presence of dementia in 
over 80% of 20-year survivors (Hely et al., 2008). To date, only one study 
has been published examining the cognitive profile at follow-up of an 
incident, early-stage PD cohort. Here, 10% of patients fulfilled criteria for 
PDD at a mean of 3.5 years from diagnosis, although 57% demonstrated 
cognitive impairments falling short of dementia criteria (Williams-Gray et 
al., 2007). As such, incidence figures for cognitive impairment in PD range 
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from 30-107 per 1000 person years (Hobson and Meara, 2004, Williams-
Gray et al., 2007) with an estimated 6-fold increase in risk of dementia for 
patients with PD (Aarsland et al., 2003). 
The definition of dementia in PD has varied widely between studies but 
usually involves;
a) scores on selected cognitive assessment below a pre-defined cut-
off and 
b) fulfilment of DSM-IV criteria for a diagnosis of dementia (DSM-IV, 
1994) 
Recently, a Movement Disorder Society task force developed consensus 
clinical diagnostic criteria for PDD (Table 2) requiring a diagnosis of PD 
according to UK Brain Bank criteria, a dementia syndrome of insidious 
onset and slow progression, with cognitive deficits severe enough to 
impair daily life, independent of impairment ascribable to motor or 
autonomic symptoms (Emre et al., 2007). 
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Table 2. Consensus criteria for a diagnosis of Parkinson’s disease 
dementia.
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Features of dementia associated with Parkinsonʼs disease 
I. Core features
1. Diagnosis of Parkinson’s disease according to Queen Square Brain Bank criteria 
2. A dementia syndrome with insidious onset and slow progression, developing within the context of established Parkinson’s
disease and diagnosed by history, clinical, and mental examination, defined as:
• Impairment in more than one cognitive domain
• Representing a decline from premorbid level
• Deficits severe enough to impair daily life (social, occupational, or personal care), independent of the impairment ascribable to motor or 
autonomic symptoms
II. Associated clinical features
1. Cognitive features:
• Attention: Impaired. Impairment in spontaneous and focused attention, poor performance in attentional tasks; performance may fluctuate 
during the day and from day to day
• Executive functions: Impaired. Impairment in tasks requiring initiation, planning, concept formation, rule finding, set shifting or set 
maintenance; impaired mental speed (bradyphrenia)
• Visuo-spatial functions: Impaired. Impairment in tasks requiring visual-spatial orientation, perception, or construction 
• Memory: Impaired. Impairment in free recall of recent events or in tasks requiring learning new material, memory usually improves with 
cueing, recognition is usually better than free recall 
• Language: Core functions largely preserved. Word finding difficulties and impaired comprehension of complex sentences may be present 
2. Behavioral features:
• Apathy: decreased spontaneity; loss of motivation, interest, and effortful behavior
• Changes in personality and mood including depressive features and anxiety
• Hallucinations: mostly visual, usually complex, formed visions of people, animals or objects
• Delusions: usually paranoid, such as infidelity, or phantom boarder (unwelcome guests living in the home) delusions
• Excessive daytime sleepiness
III. Features which do not exclude PD-D, but make the diagnosis uncertain
Co-existence of any other abnormality which may by itself cause cognitive impairment, but judged not to be the cause of dementia, e.g. 
presence of relevant vascular disease in imaging
Time interval between the development of motor and cognitive symptoms not known 
IV. Features suggesting other conditions or diseases as cause of mental impairment, which, when present make it impossible 
to reliably diagnose PD-D
Cognitive and behavioral symptoms appearing solely in the context of other conditions such as: Acute confusion due to
a. Systemic diseases or abnormalities
b. Drug intoxication Major Depression according to DSM IV
Features compatible with “Probable Vascular dementia” criteria according to NINDS-AIREN (dementia in the context of cerebrovascular disease as 
indicated by focal signs in neurological exam such as hemiparesis, sensory deficits, and evidence of relevant cerebrovascular disease by brain imaging 
AND a relationship between the two as indicated by the presence of one or more of the following: onset of dementia within 3 months after a 
recognized stroke, abrupt deterioration in cognitive functions, and fluctuating, stepwise progression of cognitive deficits)
Criteria for the diagnosis of probable and possible PDD
Probable PDD
A. Core features: Both must be present 
B. Associated clinical features:
• Typical profile of cognitive deficits including impairment in at least two of the four core cognitive domains (impaired attention which may 
fluctuate, impaired executive functions, impairment in visuo-spatial functions, and impaired free recall memory which usually improves with 
cueing)
• The presence of at least one behavioral symptom (apathy, depressed or anxious mood, hallucinations, delusions, excessive daytime sleepiness) 
supports the diagnosis of Probable PD-D, lack of behavioral symptoms, however, does not exclude the diagnosis
C. None of the group III features present
D. None of the group IV features present
Possible PDD
A. Core features: Both must be present 
B. Associated clinical features:
• Atypical profile of cognitive impairment in one or more domains, such as prominent or receptive-type (fluent) aphasia, or pure storage-failure 
type amnesia (memory does not improve with cueing or in recognition tasks) with preserved attention
• Behavioral symptoms may or may not be present 
OR
C. One or more of the group III features present 
D. None of the group IV features present
UK Brain Bank Diagnostic Criteria for PD 
Step 1 – Diagnosis of Parkinsonian syndrome 
Bradykinesia plus at least one of the following:
• Rest tremor
• Rigidity
• Postural instability
Step 2 – Exclusion criteria including:
Step 3 – Supportive prospective criteria (at least three required):
Presence of atypical features (such as):
• early falls
• supranuclear gaze palsy
• ataxia and cerebellar features
• early autonomic features
• early cognitive decline
• poor L-DOPA response
OR        History of:
• repeated strokes
• neuroleptic medication use
• head injury
• definite encephalitis
• Unilateral onset
• Rest tremor present
• Evidence of 
progression
• Persistent 
asymmetry
• Excellent response 
to L-dopa
• L-dopa-induced 
dyskinesias
• L-dopa response 
for 5+ years
• Clinical course of 
10+ years
Distinct from dementia, cognitive impairment not deemed severe enough 
to impact on activities of daily life can be found even in early, incident 
(Foltynie et al., 2004, Muslimovic et al., 2005) and drug-naïve cohorts of 
PD patients (Aarsland et al., 2009). Again, definitions of cognitive 
impairment vary between studies, and incidence and prevalence figures 
depend heavily upon the cognitive assessment tools utilised (Riedel et al., 
2008, Uc et al., 2009). For example, using a generic cognitive screen such 
as the mini-mental state examination (MMSE) (Folstein et al., 1975), 
cognitive impairment can be demonstrated in 17.5% of a prevalent cohort 
of PD patients, whereas a more disease-specific tool for assessing 
cognition in PD (Parkinson Neuropsychometric Dementia Assessment) 
detected cognitive impairment in 41.8% of the same group (Riedel et al., 
2008). 
More detailed neuropsychological assessment of individual cognitive 
domains such as memory, attention, executive and visuospatial function in 
non-demented PD patients has also been used in an attempt to define 
mild cognitive impairment (MCI). As there is no accepted definition of MCI 
in PD, methodology varies considerably between studies. Most define MCI 
as deviation from the mean for a control group in one or more cognitive 
domains under examination – in line with established criteria for 
diagnosing MCI in populations at risk of developing AD (Petersen, 2004). 
The magnitude of such deficits range from 1 to 2 standard deviations from 
the normative sample mean and, depending on definition, demonstrate 
cognitive impairment in 18.9% (Aarsland et al., 2009), 24% (Muslimovic et 
al., 2005) and 36% (Foltynie et al., 2004) of incident cases.
The profile of cognitive impairment in PD is qualitatively different from the 
type of MCI seen in the general ageing population. In the latter, an 
amnestic phenotype predominates (Petersen et al., 1999), whereas the 
most frequent deficits in PD are in non-amnestic domains such as 
attention, executive and visuospatial function (Aarsland et al., 2009, 
Foltynie et al., 2004, Janvin et al., 2006a, McKinlay et al., 2010). That MCI 
is an evolving rather than stable condition is demonstrated by a faster rate 
of progression to dementia in PD-MCI cohorts compared to PD non-MCI 
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groups (60% progression to PDD in MCI cf. 20% in non-MCI) (Janvin et 
al., 2006b) and the association between verbal memory, executive, 
attentional and visuospatial deficits in prevalent PD cohorts and the 
development of dementia (Levy et al., 2002, Mahieux et al., 1998). There 
is debate, however, about the predictive value of early cognitive deficits in 
PD and the subsequent evolution of dementia, with some workers arguing 
that pure executive deficits are not necessarily of sinister portent, 
compared with dysfunction in other domains such as semantic fluency and 
pentagon copying (Williams-Gray et al., 2007). If confirmed, these 
observations would have implications, not only for the pathophysiological 
basis of “MCI”, but also for potential prognostic and management 
decisions.
2.2 Clinical features of Parkinson’s disease dementia (PDD)
A diagnosis of PDD, with its resultant increase in mortality, has far 
reaching consequences both for patients and their families (Marder et al., 
1991). Their is a significant impact on caregiver quality of life (Aarsland et 
al., 1999) and the combination of motor and neuropsychiatric features are 
key contributors in admissions to institutional care (Aarsland et al., 2000). 
Factors associated with an increased risk of developing PDD, include 
patient age (Aarsland et al., 2007b), motor phenotype (Alves et al., 2006, 
Burn et al., 2003), presence of cognitive impairment (Janvin et al., 2006b) 
and visual hallucinations (Aarsland et al., 2003, Aarsland et al., 2004). 
2.2.1 Cognitive phenotype
Multiple cognitive domains are affected in PDD including memory (Kuzis et 
al., 1999, Whittington et al., 2006), executive function (Aarsland et al., 
2003, Litvan et al., 1991), attention (Ballard et al., 2002, Beatty et al., 
2003) and visuospatial and visuoconstructive abilites (Cormack et al., 
2004, Crucian and Okun, 2003, Emre et al., 2004, Mosimann et al., 
2004b). The pattern of such deficits, with marked attentional, executive 
and visuospatial dysfunction and less dramatic memory disturbance, not 
only mirrors the cognitive changes in early PD but is also strikingly similar 
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to DLB, with which PDD shares many features in terms of clinical 
presentation. Whilst it remains possible to demonstrate neuropsychometric 
differences between PDD and AD in early and moderate dementia, as the 
disease progresses, there is increasing convergence of cognitive 
phenotypes (Aarsland et al., 2003, Bronnick et al., 2007).
2.2.2 Visual cognition in Lewy body disorders
Visuoperceptual and visuospatial deficits are characteristic of the cognitive 
decline in PD and become more marked both as disease progresses or as 
cognition declines (Levin et al., 1991). A wide range of deficits in visual 
attention, spatial and motion perception and visual and verbal working 
memory can be seen in non-demented PD patients and both cognitive and 
visual factors impact negatively on measures of functional independence 
(Uc et al., 2005). PDD and DLB patients are well matched in 
visuocognitive impairments such as pentagon copying (Cormack et al., 
2004), visual discrimination, object-form perception and space-motion 
perception (Mosimann et al., 2004b) and these deficits are more marked 
than in AD patients or controls. In addition, those suffering visual 
hallucinations (VH) perform less well on these visuoperceptual tasks than 
PDD or DLB patients without VH (Mori et al., 2000, Mosimann et al., 
2004b). Indeed, even in non-demented PD patients, differences in 
cognitive profiles can be demonstrated between hallucinators and non-
hallucinators both in terms of executive function (Barnes and Boubert, 
2008), visuoperceptual abilities and sustained attention (Koerts et al., 
2010, Meppelink et al., 2008).
This pattern of cognitive deficits in PD and PDD suggests dysfunction of 
widespread cortical and subcortical regions including fronto-parietal 
attentional and executive networks as well as occipito-temporal and 
occipito-parietal visuoperceptual and visuospatial processing streams. The 
cognitive phenotype is also highly relevant when considering the genesis 
of clinical features such as VH, where impairments in attention and visual 
perception in particular may play an integral role (Collerton et al., 2005, 
Diederich et al., 2005).
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2.2.3 Neuropsychiatric disturbance
Behavioural and neuropsychiatric symptoms such as low mood (58%), 
apathy (54%), anxiety (49%) and delusions (25%) all contribute to the 
complex behavioural phenotype of PDD (Aarsland et al., 2007a) and form 
one of the cornerstones of the consensus diagnostic criteria (Emre et al., 
2007). When grouped into clusters, based on the relative patterns of 
cognitive symptomatology, low mood and apathy groups emerge as the 
predominant reported features (11% and 24% respectively), with agitation 
and psychosis clusters making up a smaller percentage. In a community-
based sample, application of formal diagnostic criteria gives a lower rate of 
major depression in PDD of 13%, compared to 9% for non-demented 
patients, and 19% for patients with DLB (Aarsland et al., 2001, Aarsland et 
al., 2007a). There is increasing evidence linking depression in general, 
and apathy specifically, with risk of cognitive decline in PD (Santangelo et 
al., 2009).
2.2.4 Visual hallucinations
Hallucinations occur both in population- and hospital-based studies of PD 
with a prevalence of 20 – 40% (Fenelon et al., 2000, Goetz et al., 2001) 
rising to 60 – 80% in studies of patients with PDD and DLB (Aarsland et 
al., 2001, Emre, 2003, McKeith et al., 2004). Other visual experiences, 
often defined as  “visual hallucinations” in clinical studies of PD, include a 
sensation of movement in the visual periphery, a sense of presence in the 
room and illusory misperceptions of a visual stimulus (Fenelon et al., 
2000, Mosimann et al., 2006). 
Once assumed to be a consequence of dopaminergic therapy, evidence 
now suggests that there is no clear association between levodopa dose 
and CVH, although dopamine agonists as a class are associated with an 
small increased risk of CVH (Fenelon et al., 2000, Goetz et al., 1998, 
Williams et al., 2008). There are historical reports of hallucinations 
complicating late-stage PD in the pre-levodopa era (Fenelon et al., 2006) 
and DLB patients frequently experience florid CVH despite no exposure to 
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dopaminergic therapy. Once present, CVH are persistent and progressive, 
causing increasing neuropsychiatric impact and remain strong predictors 
of nursing home placement and even mortality (Aarsland et al., 2000, de 
Maindreville et al., 2005, Goetz and Stebbins, 1993, Goetz and Stebbins, 
1995, Goetz et al., 2006). Illusory misperception, feelings of presence and 
passage often co-occur with CVH but also exist in isolation and may not 
have the same predictive value in terms of the development of PDD 
(Llebaria et al., 2010). 
Visual hallucinations are not unique to PD and DLB and are seen in a 
variety of other neurological, psychiatric and ophthalmological conditions. 
A broad range of hallucinatory experiences are reported by psychologically 
normal people in the setting of significant visual impairment – the so-called 
Charles Bonnet Syndrome (CBS). In this condition, patients experience a 
variety of visual phenomena from simple visual disturbances (flashes of 
light) through to well-formed CVH of people, animals and panoramic 
scenes (Santhouse et al., 2000, Teunisse, 1997, Teunisse et al., 1999). 
Visual loss is typically due to age-related macular degeneration although a 
wide variety of other causes are also recognised (Nesher et al., 2001, 
Ashwin and Tsaloumas, 2007, Khan et al., 2008). Insight is typically 
retained in CBS, while CVH seem to occur most commonly in situations of 
dim light or low arousal. Non-disclosure of CVH is common, with patients 
typically fearful of the response of doctors or worried about being branded 
“insane” (Teunisse et al., 1996). 
Functional MRI (fMRI) imaging in actively hallucinating CBS patients has 
implicated the inferior occipitotemporal cortex, fusiform face area and 
posterior fusiform gyrus in the genesis of specific hallucinatory 
experiences (Ffytche et al., 1998). There are many differences in the 
clinical context in which VH occur in CBS and PD. Visual acuity is 
classically significantly impaired in CBS, in contrast to PD, and simple 
visual disturbances outweigh CVH in terms of frequency (ffytche and 
Howard, 1999).  Nevertheless, the concept of “de-afferentation” of the 
visual cortex by ocular disease (Burke, 2002, Cogan, 1973) priming the 
system for VH-generation has been offered as a potential explanation for 
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the development of hallucinations in CBS and may provide some insight 
into CVH in PD and PDD.
Vivid nocturnal hallucinatory experiences are also seen in some patients 
with brainstem disorders, where they are referred to as “peduncular” 
hallucinations (Benke, 2006) and transient hallucinations are also seen in 
the hypnopompic (waking up) and hypnagogic (falling asleep) state in 
narcolepsy, and indeed in the general population as well (Ohayon, 2000, 
Ohayon et al., 1996). Extracampine hallucinations are so-called due to 
their unique feature of occurrence outside the normal field of vision, often 
in the absence of an accompanying “visual” experience (Manford and 
Andermann, 1998). Peduncular and extracampine hallucinations share 
phenomenological features with “presence” hallucinations seen in PD and 
PDD, and raise the possibility of links between sleep disorders, brainstem 
dysfunction and the development of hallucinations in PD (Manni et al., 
2002, Onofrj et al., 2002, Pacchetti et al., 2005). 
2.3 PD and sleep 
Sleep disorders are common both in PD and PDD with insomnia, loss of 
muscle atonia during REM sleep, frank REM sleep behaviour disorder 
(RBD) and excessive daytime somnolence (EDS) all being more frequent 
than in control populations (Comella, 2006). Daytime somnolence, present 
in over 50% of patients, is now included in the diagnostic criteria for PDD 
as a core clinical feature (Emre et al., 2007; Boddy et al., 2007). Even in 
non-demented PD cohorts EDS is well-recognised, affecting 15% of 
patients at baseline in one study, with follow-up demonstrating an increase 
in prevalence at four years (29%) in the same study group (Gjerstad et al., 
2002, Tandberg et al., 1999). In these and other studies, EDS was 
associated with increased rates of cognitive decline, visual hallucinations 
and motor disability (Fenelon et al., 2000). Similarities have been drawn 
between the somnolence of PD and that seen in narcolepsy, a condition 
where loss of the hypocretin-secreting neural population of the 
hypothalamus leads to EDS and disrupted sleep architecture (Arnulf et al., 
2000). Indeed, hypocretin cells are diminished in post-mortem studies of 
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PD (Thannickal et al., 2007, Fronczek et al., 2007), although to a lesser 
degree, and without the detectable drop in cerebrospinal fluid levels of 
hypocretin-1 typically seen in narcolepsy (Compta et al., 2009).
RBD, where the loss of normal muscle atonia results in dream enactment, 
with risk to patient and bed partner, is another common sleep disorder in 
PD (Onofrj et al., 2002). Indeed, in longitudinal follow-up of subjects with 
so-called idiopathic RBD, around 40% have been shown to go on to 
develop neurodegenerative synucleinopathies such as PD, DLB and MSA 
(Olson et al., 2000). Recently, RBD both in its idiopathic form and in the 
context of PD has been associated with cognitive impairment (Gagnon et 
al., 2009). Vivid dreams and nightmares are a frequent accompaniment to 
RBD in PD and are associated with, but not predictive of, the presence 
and severity of CVHs (Goetz et al., 2005). 
Several studies have suggested that RBD is an independent risk factor, 
along with cognitive impairment, for developing visual hallucinations in PD 
and, intriguingly, a small study using ambulatory polysomnography 
demonstrated temporal relationships between both REM and non-REM 
sleep and hallucinations in 30% of a PD cohort (Manni et al., 2002, Onofrj 
et al., 2002, Pacchetti et al., 2005). This has led some authors to suggest 
that CVH in PD might be the result of the intrusion of abnormal dream 
imagery into periods of wakefulness. However, these studies included 
presence, passage and illusions in the same category as CVH and hence 
may not have taken into account potential differences in aetiology between 
separate hallucinatory experiences. In addition, most studies to date have 
suffered from small group numbers or the lack of a control group and a 
clear correlation between RBD, CVHs and motor and non-motor outcome 
has not been confirmed in other studies (Lavault et al., 2010, Meral et al., 
2007).
2.4 The visual system in PD
There is dysfunction at several levels of the visual pathway in PD. This 
includes psychophysical, electrophysiological and morphological evidence 
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of disruption of retinal structure and function, in addition to disorders of 
“higher” (cortical) visual processing. In order to appreciate the impact 
Parkinson’s disease has on the visual system, we must break it down into 
its composite parts - retina, subcortical visual pathways, primary (striate) 
and associated (extra-striate) visual cortex and those areas that provide 
“top-down” modulation of the incoming visual information. 
First we will re-visit some of the basic retinal anatomy described by Cajal 
in 1892 (Figure 1). The organisation of the retina, with the photoreceptors 
arranged abutting the retinal pigment epithelium (RPE), means that, with 
the exception of the fovea, light has to penetrate the cell bodies and 
unmyelinated fibres of more superficial structures before striking the light-
sensitive photoreceptors. This may seem counterintuitive at first but is 
necessitated by the reliance of photoreceptors on the RPE for visual 
pigment regeneration as well as to facilitate absorption of light escaping 
the photoreceptor array, preventing back-scatter and subsequent image 
degradation. The human retina contains two types of photoreceptor; rods, 
present in both the parafoveal and peripheral retina and designed for low-
light (scotopic) vision and cones, found predominantly in the macula and 
specialised for bright-light (photopic) colour vision (Curcio et al., 1990). 
Retinal signalling occurs in two directions – vertically and horizontally. 
Vertical neurotransmission takes place predominantly from photoreceptor 
to bipolar cell to retinal ganglion cell (RGC) and it is the RGC that acts as 
the final common pathway in the flow of visual information to the optic 
nerve. Photoreceptors synapse with bipolar cells in the outer plexiform 
layer (OPL) and bipolar cell to RGC neurotransmission occurs in the 
synaptic zones of the inner plexiform layer (IPL). The principal 
neurotransmitter of the vertical system is glutamate, in general terms, 
acting via excitatory ionotropic and inhibitory metabotropic glutamate 
receptors.
In addition, there are cells mediating horizontal neurotransmission in both 
the OPL and IPL, and these are vital in shaping the temporal and spatial 
qualities of scotopic and photopic vision. Horizontal cells synapse in the 
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OPL, affecting photoreceptor/bipolar cell interactions, while amacrine cells 
perform a similar role in the IPL for bipolar to ganglion cell transmission. 
This horizontal transmission is mediated primarily by the inhibitory 
transmitters, GABA and glycine in addition to electrical gap junctions. 
Signal transmission occurs on a one-to-one basis for cone-to-bipolar cell 
and bipolar-to-ganglion cell in the central fovea, facilitating high acuity 
colour vision. In contrast, there is considerable convergence in the rod-to-
ganglion cell pathway, allowing this part of the retina to detect low intensity 
signals but at the cost of much lower spatial resolution.
Figure 1. Schematic of human retina.
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RGC axons become myelinated at the optic nerve head and the majority 
carry information to the lateral geniculate nucleus (LGN) of the thalamus. 
Larger RGCs, more prominent in the peripheral retina, and known as 
magnocellular RGCs (M-cells) carry information on movement and 
contrast, whereas parvocellular RGCs (P-cells), most prominent in the 
central retina, signal fine feature and colour information to higher visual 
centres (Ferrera et al., 1992, Ferrera et al., 1994, Malpeli et al., 1996, 
Maunsell et al., 1990, Nealey and Maunsell, 1994, Tobimatsu et al., 1995). 
It is beyond the scope of this discussion to cover in detail the retinal 
mechanisms of colour opponency involved in generating colour vision. 
However, it should be noted that, although the central retina is traditionally 
described as the seat of colour vision, considerable processing of colour 
vision occurs in the peripheral retina as well, albeit with larger receptive 
fields and altered sensitivity to temporal-frequency modulation (Martin et 
al., 2001, Solomon et al., 2005, Solomon and Lennie, 2007).
Aside from the LGN, other subcortical targets for these retinal efferents 
are the superior colliculus, the pulvinar complex of the dorsal thalamus 
and the mid-brain tectum.  It is the axons of LGN neurons that project to 
striate visual cortex in a retinotopic fashion, initially terminating in area V1. 
From here visual information passes into the extra-striate visual areas (V2-
V5). Beyond the striate and early extra-striate regions visual information 
flows into the parietal lobes in the form of a “dorsal stream” and the 
temporal lobes in the form of a “ventral stream.” The dorsal stream seems 
particularly specialized for movement and spatial perception, whereas the 
ventral stream is responsible for perception of object form (Goodale and 
Westwood, 2004, Goodale and Milner, 1992, Ungerleider and Mishkin, 
1982, Ungerleider and Haxby, 1994). In a similar fashion, visual 
information from the superior colliculus and retina is integrated with 
information from the visual cortex in the pulvinar, projecting extensively 
both back to the striate and extra-striate cortices as well as to parietal and 
temporal lobes (Yeterian and Pandya, 1997, Kaas and Lyon, 2007, Grieve 
et al., 2000).  In addition to its inputs to the pulvinar, the superior colliculus 
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is also responsible for integrating responses to visual, auditory and 
somatosensory stimuli. 
Whilst this description is an over-simplification of the hugely complex 
structural organisation of the visual system, it serves to illustrate the 
hierarchical nature of the visual system from retina to cortex. A more 
detailed discussion of the cortical processing of visual information will be 
provided later, but for now, it should be borne in mind that the “anterior” 
visual system does not exist in isolation and many abnormalities of visual 
function can be attributed to cortical as well as retinal dysfunction. 
2.4.1 Retinal physiology
Photoreceptors exist in a depolarised state in the dark, constantly 
releasing glutamate, and hyperpolarise when stimulated by light. Unlike 
most other neurons, they do not produce action potentials but instead 
respond to changing light stimuli with graded alterations in membrane 
potential. When light excites a photoreceptor, glutamate release from the 
hyperpolarised cell is reduced. Because bipolar cells express either 
ionotropic or metabotropic glutamate receptors, the reduction in 
photoreceptor glutamate release results in either inhibition or disinhibition 
in different subtypes of bipolar cell. 
Each RGC is influenced by light falling on a discrete area of the retina. 
This is known as the receptive field of the RGC and its size and 
photosensitive properties are dependent on the extent of synaptic contact 
made in the OPL and IPL, and the degree of convergence of 
photoreceptors onto bipolar cells. This means that receptive fields in the 
peripheral retina, where sometimes hundreds of rods converge on a single 
bipolar cell, are consequently much larger than those in the macula. 
An important functional component of the receptive field is that, under 
photopic conditions, any given cone photoreceptor is excited (or inhibited) 
from a small central circular stimulus and oppositely affected by 
stimulation of a broader peripheral zone (Figure 2). Hence a further layer 
of complexity is added to the light response, with a “centre and surround” 
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component to RGC receptive fields and both ON-centre and OFF-centre 
ganglion cell responses to light. This means that RGCs give information 
on contrast rather than absolute light intensity, enabling us to distinguish 
contours and forms (Baylor et al., 1971, Hartline, 1940, Shapley and Perry, 
1986, Werblin, 1991, Werblin and Dowling, 1969). 
Figure 2. Diagrammatic representation of the centre-surround 
concept of lateral inhibition in retinal ganglion cell receptive fields. 
Note the opposing responses of on centre and off centre ganglion 
cells. Based on Kuffler (1953).
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In reality, there are numerous subtypes of bipolar cells, RGCs, amacrine 
and horizontal cells, utilising different neurotransmitter systems and 
making synaptic contact in specific sub-layers of the IPL and OPL. Only 
those with potential relevance to PD will be discussed later. One of the key 
concepts of early retinal processing is that, with such considerable cellular 
interactions, both vertically and horizontally, and due to the exquisite 
sensitivity of the retina for colour, contrast and movement, extensive 
modification of visual information has occurred long before it reaches the 
visual cortex (Baccus and Meister, 2002, Solomon et al., 2004).  The 
retina is not the only part of the visual pathway involved in contrast 
processing, however, with contrast adaptation also taking place centrally in 
the striate cortex (V1) as well as extra-striate regions V2, V3 and human 
V4 (Gardner et al., 2005, Kohn and Movshon, 2003, Ohzawa et al., 1985). 
Appreciation of the multiple sites of, for instance, contrast modulation is 
vital if we are to localise PD-specific alterations in such processing to the 
anterior or posterior visual system.
2.4.2 Dopaminergic neurons in the retina
Observations from Malmfors in 1963 first highlighted the role 
catecholamines might play in rat retinal function (Malmfors, 1963). It was 
noted that rats, pharmacologically depleted of catecholamines using 
reserpine, showed marked photosensitivity despite their small pupil size. 
Study of the rabbit retina demonstrated dopaminergic (DA) neurons 
(Haeggendal and Malmfors, 1963), which have subsequently been 
identified in the INL of the human retina (Frederick et al., 1982). The 
principal DA cell in the retina is an amacrine subtype called A18 although a 
second, less well-defined DA cell has also been identified in primate and 
rodent retinas (Kolb et al., 1990, Mariani, 1990, Mariani, 1991, Witkovsky 
et al., 2005). The density of A18 neurons is low but their widespread 
dendritic arborisation and long fine axons ensure overlap with 
neighbouring DA cells as well as other amacrine cells and bipolar cells 
(Figure 3) (Dacey, 1990, Kolb et al., 1990, Pourcho, 1982, Voigt and 
Wassle, 1987). The inputs to DA amacrine cells are still not precisely 
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defined anatomically although it is known that A18 cells receive input 
predominantly from rod bipolar cells (Kolb et al., 1990). From a functional 
standpoint it is clear that DA neurons are depolarized by light onset and 
this occurs under both scotopic and photopic conditions, implying input 
from depolarizing bipolars of both rod and cone varieties (Zhang et al., 
2007).
Figure 3. Dopaminergic cells in the rat retina visualized by 
immunohistochemical staining with an antibody against tyrosine 
hydroxylase. Courtesy of Paul Witkovsky.
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DA neurons contact two other types of amacrine cell belonging to the rod 
pathway – the AII and the A17 amacrine cell (Bloomfield and Dacheux, 
2001). The AII amacrine cells receive input from rod and cone bipolar cells 
and pass this information forward to ON and OFF RGCs (Dacheux and 
Raviola, 1986, Famiglietti and Kolb, 1975). AII cells are coupled to cone 
ON bipolars by gap junctions allowing rod signals to flow into the ON cone 
pathway (Xia and Mills, 2004). They also make glycinergic synapses onto 
OFF RGCs, inhibiting them under scotopic conditions. Thus, not only are 
the AII amacrine cells involved in the so-called “horizontal” processing of 
retinal signalling but also play a pivotal role in channelling visual 
information “vertically” through the retina in low light states. In addition, AII 
cells, via gap junctions, contact other AII amacrine cells forming a 
functional syncytium across the retina (Strettoi et al., 1992). A17 cells 
receive input from large numbers of rod bipolar cells but feed this back to 
the same cell types, presumably modulating the scotopic threshold of the 
retina (Nelson and Kolb, 1985). 
AII cells express D1-subtype dopamine receptors and gamma-
aminobutyric acid type-A (GABAA) receptors; activation of the former 
leading to “excitation” (Contini and Raviola, 2003, Veruki, 1997, Veruki and 
Wassle, 1996). Given that DA cells also contain GABA, this suggests that 
both neurotransmitters are involved in modulating amacrine function 
(Wulle and Wagner, 1990). In return, DA cells receive 
“excitatory” (glutamatergic) bipolar cell and “inhibitory” (GABAergic and 
glycinergic) amacrine cell inputs which alter the action potential firing rate 
and hence DA release (Feigenspan et al., 1998, Gustincich et al., 1999, 
Gustincich et al., 1997). As well as direct synaptic effects on amacrine and 
bipolar cells, diffusion of dopamine in the retinal extracellular matrix exerts 
a paracrine effect, obviating the need for direct synaptic contact, and 
extending the range of action over many microns (Witkovsky et al., 1993). 
Knowledge of these anatomical connections demonstrates that 
dopaminergic A18 cells, via their complex interactions with rod and cone 
bipolars, AII and A17 cells have a pivotal role in modulating the flow of rod-
driven visual information through the retina. 
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Dopamine acts through G-protein coupled receptors, which regulate 
production of cyclic AMP. Dopamine receptor subtypes D1 and D5, often 
collectively referred to as the D1- receptor family, increase cAMP levels 
and, in this context, are excitatory, whereas subtypes D2, 3 & 4, part of the 
D2-receptor family, act in an opposing fashion. Rod and cone 
photoreceptors are inhibited by activation of D2 family receptors whereas 
bipolar, horizontal, RGCs and amacrine cells are excited by D1 receptors. 
Dopaminergic cells themselves utilise an autoreceptor of the D2 family to 
modulate their own DA release (Muresan and Besharse, 1993, Nguyen-
Legros et al., 1997, Veruki, 1997). Dopamine has direct effects on gap 
junction permeability both at the level of rod and cone interactions with 
horizontal cells (He et al., 2000, Nelson, 1977, Xin and Bloomfield, 1999) 
and at the level of AII:AII and AII:cone bipolar cell communication (Xia and 
Mills, 2004). The net effect is a reduction in gap junction permeability with 
rising dopamine concentrations and a resultant reduction in receptive field 
size (Ribelayga et al., 2008)
In addition to this highly variable excitatory and inhibitory feedback 
system, there is a more “tonic” diurnal variation in retinal dopamine 
concentration, with low levels at night and higher levels during the day. 
This circadian rhythm is in counterphase with the retinal concentrations of 
melatonin, and indeed, DA and melatonin have mutually inhibitory effects 
on each other’s production – acting as a “biological clock” for the retina 
(Doyle et al., 2002a). Because of this light-sensitive variation in DA 
concentration it has been postulated that DA plays a role in the transition 
from a dark-adapted to light-adapted state (Cahill, 1996, Doyle et al., 
2002b, Ribelayga et al., 2008, Tosini and Menaker, 1996).
2.4.3 Summary – Dopamine and the retina
DA acts in the outer and inner retina at multiple levels, producing 
alterations to the flow of visual information in a complex fashion. 
Experimental evidence in mammalian and sub-mammalian retinas points 
to dopaminergic regulation of the “centre-surround” field size as well as 
promoting diminution of signals from rod photoreceptors through effects on 
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amacrine cells (Deans et al., 2002, Hampson et al., 1992, Jensen, 1989, 
Jensen and Daw, 1984, Witkovsky et al., 1988). In essence therefore, 
dopamine is a chemical messenger for light adaptation, promoting the flow 
of information through cone circuits while diminishing that through rod 
circuits.
2.5 Testing visual function
In order to interpret accurately the results of research in this field some 
understanding of the tools used to probe retinal function is necessary. 
These range from simple tests of visual acuity through to retinal 
electrophysiology and complex psychophysical measures of contrast 
sensitivity.
Visual acuity (VA) is usually measured with high contrast target recognition 
tasks, such as the Snellen, logMAR or Illiterate E charts. Test objects here 
are large enough that stimulus detection is not the limiting factor, but 
rather acuity measures are dependent on the eye’s ability to resolve the 
critical detail of the stimulus i.e. the width of the letter strokes and the 
adjacent gaps. In Figure 4a, the letter ‘E’ falls on a specific area of the 
retina, measured in degrees and minutes of visual arc (one degree = 60 
minutes). The area of retina exposed to the stimulus depends on the size 
of the letter and the distance from the eye. Hence, Snellen VA is defined 
by the distance at which the chart is read and the size of the letters 
discriminated. “Normal” Snellen VA (6/6 or 20/20) describes the ability to 
discern a letter ‘E’, subtending 5 minutes of visual arc on the retina 
(Snellen line 6), when presented at 6 metres (20 feet).
Measures of visual acuity can also be defined in terms of the spatial 
frequency of the stimulus discriminated and this can best be understood 
by picturing a high-contrast black and white grating. The grating has a 
spatial frequency dependent on the width of the bars and their spacing – 
high spatial frequency gratings having narrow bars, close together. The 
grating alternates between high- and low-contrast and therefore spatial 
frequency is measured in cycles per degree (cpd). For instance, 6/6 
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Snellen acuity would equate to a spatial frequency of 30 cycles per degree 
Figure 4b & c. 
Despite its familiarity to patients and clinicians, as well as the ease of use, 
the Snellen chart is not without practical limitations. The unequal number 
of letters on each line and lack of a constant ratio of letter heights between 
adjacent lines makes precise measurement of VA difficult, particularly at 
lower levels of acuity. These problems have led to the increasing use of 
the logMAR system for measuring VA. Here, each line contains 5 letter 
optotypes, each assigned an individual logarithmic value according to the 
angle of resolution at the retinal level. This allows conversion of a 
geometric letter sequence to a linear scale, providing a more statistically 
robust measure of VA.
The retina is designed to report on contrast, allowing the discrimination 
and identification of objects across a variety of illumination levels. This 
contrast detection of the retina is typically explored using visual stimuli 
such as gratings, although checkerboard patterns or simple letter 
optotypes can also be utilised. All tests of contrast are dependent on the 
luminance of the stimulus and grating patterns have the advantage of 
allowing contrast to be varied in a sinusoidal fashion without affecting the 
average stimulus luminance and allowing isolation of specific channels of 
retinal neurons that respond optimally to that given spatial frequency. 
Contrast can be lowered until grating detection is impossible, a fact best 
illustrated by the Campbell-Robson grating shown in (Figure 4d). Here, 
spatial frequency increases from left to right with decreasing contrast from 
bottom to top. It will be evident when viewing the grating that both very low 
and very high spatial frequencies are more difficult to discern as the 
contrast drops. The point at which grating detection is lost for a given 
spatial frequency is known as the contrast threshold and it is the reciprocal 
of this value that identifies the contrast sensitivity (CS). Plotting CS against 
spatial frequency gives an inverted “bell shaped curve” called the contrast 
sensitivity function – allowing us to define the point of transition from the 
“visible” to the “invisible” world. The experimental use of sinusoidal 
gratings in this fashion has been key to the development of our 
33
understanding of retinal function both at the level of the retinal ganglion 
cell response to contrast (Enroth-Cugell and Robson, 1966) and in 
generating a working hypothesis for the role of dopamine in the retina and 
the subsequent changes seen in PD.
Figure 4. (A) Note the letter “E” falling on the retina and subtending a 
visual arc measured in degrees and minutes (60 min = 1 deg). (B) 
Below, the conversion from Snellen nomenclature (i.e. 6/6) to spatial 
frequency in cycles per degree (cpd). At 6/6 acuity, the visual 
stimulus (letter, grating) must subtend a visual angle of 5 minutes, 
with each component of the stimulus taking up 1 minute. A full 
“cycle” from black-white-black therefore takes 2 minutes of arc and 
30 cycles could therefore fit in 1 full degree. (C) narrower bars with 
tighter spacing have increased spatial frequency. (D) the Campbell-
Robson grating demonstrates our ability to discern gratings at mid-
spatial frequency better than those of low- or high-spatial frequency.
A
B
C
D
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In addition to using static gratings with different spatial frequencies, one 
can also employ gratings which drift or flicker, introducing a temporal 
frequency modulation, another important concept in visual science. 
Variations in temporal frequency are described in reversals per sec (rev/
sec) or complete cycles per second (Hz). As gratings are made up of 
alternating high and low contrast components, one completed cycle per 
second, from high-low-high contrast, requires two reversals per second. 
As temporal frequency increases, contrast becomes more difficult to 
perceive, resulting in flicker fusion, the point at which the stimulus appears 
not to change at all. 
Given the layout of the retina, with specific rod and cone distributions and 
different populations of bipolar and RGCs it will be obvious that the spatial 
and temporal qualities of the retina are not uniform but rather depend on 
which parts are stimulated and under what conditions. Hence, at least 
from a retinal perspective, VA and CS will depend not just on “optical” 
factors such as refractive error and pupil size but also on “neural” factors 
such as photoreceptor density, stimulus contrast and luminance and the 
region of the retina being stimulated (Altpeter et al., 2000, Dacey and 
Petersen, 1992, Perry and Cowey, 1985, Silva et al., 2008, Thibos et al., 
1987).
2.6 Retinal involvement in Parkinson’s disease
There can be little doubt that dopamine plays an important role in retinal 
function but precisely how dopaminergic deficiency, as seen in PD, might 
affect the retina, is less clear. The hypothesis that the retina is a site of 
functional and structural change in PD raises a number of questions. 
Firstly, given that PD prevalence increases with age, if there is evidence of 
retinal dysfunction in PD, the proportion due to Parkinson’s disease-
specific as opposed to age-related change needs to be clarified. If there is 
a disease-specific effect, could this be due to dopaminergic deficiency at a 
retinal level, to central deficits in the LGN or visual cortex, or to both? If 
there is a local dopaminergic deficiency in the PD retina, does this 
interfere with signal transmission and hence cause functional limitations in 
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vision? And finally, to what extent does dysfunction of the retina contribute 
to the generation of the more striking visual symptoms seen in PD such as 
visual hallucinations? Work over the past 40 years has addressed many of 
these issues and, where answers are available, these will be highlighted in 
the course of the discussion.
2.6.1 The ageing retina
Visual function changes as we age, in part due to age-related diseases of 
the eye such as cataract, age-related macular degeneration, diabetic 
retinopathy and glaucoma (Johnson, 2001, Klein et al., 1992, Mangione et 
al., 1994, Owsley et al., 2000, Owsley et al., 2001). Even in the absence of 
such overt pathology, however, visual function declines with age. Such 
changes include reduction in the accommodative power of the lens, 
leading to presbyopia, and a reduction in pupil size often referred to as 
“senile miosis”. The former limits the focusing ability of the eye and the 
latter, in extreme situations, may reduce retinal illumination.  Retinal 
degeneration also occurs, leading to reductions in rod and cone numbers 
and the loss of RGCs (Curcio, 2001, Pitts, 1982, Weale, 1987). These 
changes will ultimately define and limit the “neural” function of the ageing 
retina. Age-related ophthalmological disease, often in combination with 
such factors, contributes to the deterioration in visual acuity, contrast 
sensitivity, colour vision and dark adaptation evident as we age. In 
addition, “central” dysfunction due to visual cortex pathology and co-
existing cognitive decline may confound studies of vision in the ageing 
population. 
Snellen charts provide a measure of VA under conditions not routinely 
encountered in the “real-world”. In essence, Snellen acuity measures the 
ability to read a chart under static, high-contrast conditions. In reality, 
visual stimuli fall on the retina with highly variable levels of contrast and 
luminance. In addition, both stimulus and recipient are frequently in 
motion, requiring constant corrective eye movements and attentional 
selection of relevant stimulus components if the image is to be maintained 
on the optimal part of the retina. 
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In that regard, there is also a marked effect of ageing on visual processing 
of moving objects. Early studies examining so-called dynamic visual acuity 
(DVA) have demonstrated specific dynamic impairments in the elderly. 
DVA is required for important “real-world” tasks such as walking and 
driving and is a better marker of driving ability in the elderly than static 
visual acuity (SVA) (Brown, 1972a, Brown, 1972b, Burg and Hulbert, 
1961). This is because, whilst SVA sets the maximum achievable DVA, 
there is a fall off in dynamic acuity caused by “retinal slip” of the image as 
eye tracking becomes more inaccurate at higher target velocities. 
Measurement of DVA is more difficult and time-consuming than assessing 
SVA and there exists no standardized technique in routine clinical practice, 
perhaps explaining the lack of recent clinical data in the field.  More 
recently, it has been demonstrated that older subjects show greater 
impairment on sinusoidal grating and dot cinematogram tests of motion 
perception (Billino et al., 2008, Conlon and Herkes, 2008, Willis and 
Anderson, 2000). Such tasks assess motion perception processing in 
retinal, subcortical and cortical visual areas although the relative 
contribution that low-level, retinal deficits make to such changes remains 
unclear.
In addition, contrast sensitivity declines as we age, particularly at 
intermediate and high spatial frequencies.  This CS loss is caused, in part, 
by “optical” factors such as lens opacity and senile miosis, in combination 
with retinal “neural” factors such as photoreceptor and ganglion cell 
degeneration (Burton et al., 1993, Owsley and Sloane, 1987, Schefrin et 
al., 1999, Sloane et al., 1988a, Sloane et al., 1988b). Such alterations in 
the spatial and temporal qualities of the retina could potentially confound 
studies of vision in PD unless control groups appropriately matched for 
age are also assessed.
Colour vision relies on the cone photoreceptor population and is therefore 
largely confined to the central retina. Because there is a segregation of 
colour-specific information at the retinal level into blue-yellow (BY) and 
red-green (RG) pathways, it is possible to use colour discrimination tasks 
to assess cone and RGC subpopulations. Colour vision is affected by the 
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ageing process particularly along the BY (tritan) axis, possibly due to cone 
dysfunction and opacified lens absorption of short wavelength light 
(Knoblauch et al., 1987, Nguyen-Tri et al., 2003). However, scotopic vision 
is more vulnerable to the ageing affect and rod photoreceptors are 
particularly at risk (Curcio et al., 1993, Jackson and Owsley, 2000, 
Jackson et al., 2002). This has implications for dark adaptation in the 
elderly eye, a potential additional problem in the dopamine-deficient retina.
2.6.2 Retinal dopamine in Parkinson’s disease
Neurochemical evidence for dopaminergic deficiency in the human retina 
was first advanced with reports of reduced tyrosine hydroxylase 
immunoreactivity of dopaminergic cells in 5 patients with PD (Nguyen-
Legros, 1988). Tyrosine hydroxylase (TH) is the rate-limiting enzyme in the 
synthesis of dopamine and hence identifies DA-containing cells in the 
retina. Harnois and Di Paolo, examining parkinsonian patients at post-
mortem, found that subjects not receiving L-DOPA therapy at the time of 
death had significantly lower retinal dopamine concentrations than controls 
or those whose death occurred less than fifteen hours after their last dose 
(Harnois and Di Paolo, 1990). Such post-mortem studies in human tissue 
are rare, with small numbers of patients involved and, as such, one must 
interpret these findings with a degree of caution. Treatment of monkeys 
with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a neurotoxin 
which destroys dopaminergic cells, causes a dose-dependent, but 
reversible, reduction in TH immunoreactivity in amacrine cells (Tatton et 
al., 1990). Dopaminergic depletion of the cat retina leads to enhancement 
of intra-retinal scotopic electrophysiological responses, an effect reversed 
by the addition of dopamine and consistent with dopaminergic modulation 
of amacrine function (Naarendorp et al., 1993). These studies, despite 
their limitations, provided a tantalizing link between previously 
documented electrophysiological and psychophysical evidence of retinal 
dysfunction in PD and the hypothesis that it was dopaminergic deficiency 
itself that mediated these changes.
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2.7 Evidence of visual dysfunction in Parkinson’s disease 
2.7.1 Visual acuity
Reports of impaired visual acuity in PD patients first emerged in the early 
1990s in a small cross-sectional study (Jones et al., 1992). Small absolute 
changes in Snellen and computer-generated tests of acuity were found in 
PD. Surprisingly, given the broad range of visual complaints reported, few 
studies have looked specifically at VA in the PD population. The clinical 
significance of diminished VA is highlighted by the finding of visual loss as 
a risk factor for visual hallucinations in PD (Holroyd et al., 2001, Matsui et 
al., 2006) and in Alzheimer’s disease (Chapman et al., 1999, McShane et 
al., 1995). A potential confounder is the impact cognitive impairment has 
on the ability of patients to perform tests of vision. However, Matsui et al. 
studied PD patients with and without VH, and despite a reduction in visual 
acuity in the VH group, no significant difference in mini-mental state 
examination (MMSE) scores between groups was reported (Matsui et al., 
2006).
2.7.2 Contrast sensitivity (CS)
The first clinical reports of abnormal contrast sensitivity in PD came from 
Regan and Neima (1984) when they investigated the vision of ten patients 
using letter charts similar to Snellen cards, but with varying contrast levels 
(Regan and Neima, 1984a). Half of the PD patients demonstrated 
abnormalities on low contrast letter tests despite many having normal 
Snellen acuities. Further studies using vertical gratings with a sinusoidal 
luminance profile have consistently shown CS loss at a variety of spatial 
frequencies (Bulens et al., 1986, Delalande et al., 1996, Harris et al., 
1992, Langheinrich et al., 2000). Bodis-Wollner and Yahr reported that the 
spatial frequency loss in PD was most marked at 4.8 cpd, the normal peak 
CS region in controls (Bodis-Wollner et al., 1987). Such modification of the 
CS curve in PD was exaggerated when temporal variation was introduced 
at the 4-8 Hz range (Bodis-Wollner et al., 1987, Regan and Maxner, 1987). 
In addition, spatiotemporal CS to moving gratings was diminished in PD in 
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a different pattern to the reductions seen in age-matched controls, 
suggesting a disease-specific “motion blur” in contrast perception (Masson 
et al., 1993, Mestre et al., 1990). 
That these alterations are driven by dopaminergic deficiency is supported 
by the findings that CS improves after the administration of levodopa 
(Bulens et al., 1987, Hutton et al., 1993) and that similar alterations occur 
in drug-induced parkinsonism (Bulens et al., 1989). In addition, PD 
patients with marked motor fluctuations between their “on” and “off” state, 
show a mid-spatial frequency decrease in CS similar to that observed in 
stable parkinsonian patients. When tested in an “on” condition, the CS 
curves more closely resembled age-matched controls (Bodis-Wollner and 
Onofrj, 1987). These psychophysical tests of presumed retinal function 
are, however, relatively complex tasks drawing on attentional and 
cognitive abilities and contrast is processed in retinal, subcortical and 
cortical regions (Crucian and Okun, 2003, Geldmacher, 2003). Given that 
few studies have controlled for these potential confounders, it is difficult to 
know how much of the CS change can be truly attributed to retinal 
dysfunction. CS losses have been identified as orientation-specific in 
some cases (Bulens et al., 1988, Regan and Maxner, 1987) arguing for a 
degree of cortical influence, as orientation specificity is not determined at a 
retinal level (Hubel and Wiesel, 1977, Hubel et al., 1977, Hubel et al., 
1978, Regan and Maxner, 1987). 
Static measures of CS are attractive due to their ease of application in a 
clinical setting but they cover a relatively narrow range of spatial 
frequencies and have been criticised for their lack of test-retest reliability 
(Reeves et al., 1991). Contrast charts vary from study-to-study but include 
static gratings as well as contrast charts with letter optotypes of 
diminishing contrast. Several studies, using static charts, have 
demonstrated disturbances of CS (Buttner et al., 1996, Pieri et al., 2000, 
Price et al., 1992, Uc et al., 2005) with evident progression in one 
longitudinal follow-up study over 20 months (Diederich et al., 1998, 
Diederich et al., 2002).
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Contrast sensitivity is vital for a range of day-to-day activities and 
diminished CS has been implicated in falls, difficulties in reading and 
driving performance, as well as with activities of daily living in elderly 
patients (de Boer et al., 2004, Ivers et al., 1998, Kooijman and 
Cornelissen, 2005, Lord, 2006, Owsley and Sloane, 1987, West et al., 
2002, Worringham et al., 2006). The functional significance of CS changes 
in PD specifically is less clear. A similar change in CS is seen when the 
retina makes the transition from high- to low-luminance levels (Wink and 
Harris, 2000). It is tempting to infer from this that dopamine is, at least in 
part, responsible for preparing the retina for photopic vision and that a 
deficiency state leads to an inappropriately dark-adapted retina. In 
addition, despite equivalent cognitive scores on MMSE, Diederich showed 
that PD patients with visual hallucinations had significantly worse CS than 
those without hallucinations, suggesting a putative role for retinal 
dysfunction in the development of visual complications in PD (Diederich et 
al., 1998).
2.7.3 Colour vision
Deficits in colour vision in PD are also well documented and suggest 
involvement of different colour-opponent pathways in the disease process. 
In general, colour vision is cone-mediated via specific, segregated visual 
pathways - parvocellular, mediated by small RGCs (P-cells) and 
terminating in the parvocellular layers of the LGN, and koniocellular, 
mediated by bistratified RGCs and synapsing in the interlaminar layers of 
the LGN. In contrast, achromatic information is transmitted by large RGCs 
(M-cells) in the magnocellular pathway. Clinical, psychophysical and 
electrophysiological tests of colour vision have all been applied to the PD 
population, although each has potential drawbacks. The Farnsworth-
Munsell 100 Hue test (FM) and the D-15 Lanthony test (D-15) are the 
most widely used clinical tests, requiring participants to arrange coloured 
discs into a smoothly graduated colour sequence. Even allowing for the 
limited quantification power and the variability in test-retest scores (Birch 
et al., 1998), PD patients demonstrate significantly higher error rates on 
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the FM test than age-matched controls (Pieri et al., 2000, Price et al., 
1992). Less dramatic, but statistically significant, deficits are also seen in 
colour discrimination tasks devoid of the “motor” requirements of the FM 
and D-15 tasks (Haug et al., 1995, Haug et al., 1994, Regan et al., 1998). 
Silva et al. (2005) probed chromatic and achromatic contrast sensitivity 
changes in PD using complex psychophysical measures designed to 
isolate parvocellular, koniocellular and magnocellular pathways (Silva et 
al., 2005). Significant impairment in all three pathways was found, more 
marked along the protan/deutan (RG) axis than the tritan (BY). This 
pattern contrasts with that typically seen in ageing - a predominant tritan 
axis deficiency - or in retinal disease states such as glaucoma in which all 
colour axes are involved with particular emphasis on the tritan axis 
(Castelo-Branco et al., 2004). Such comparisons suggest a disease-
specific pattern of retinal impairment in PD distinct from “normal ageing” or 
the commoner age-related ophthalmological diseases. Evidence that 
these abnormalities have a retinal component comes from the finding of 
amplitude reductions in chromatic and achromatic pattern 
electroretinogram (PERG) responses in PD when compared to controls 
and subjects with Multiple System Atrophy (MSA) (Sartucci et al., 2006b).
2.7.4 Motion perception
In addition to changes in VA and CS, perception of motion is also affected 
in PD and PD dementia (Mosimann et al., 2004b, Trick et al., 1994). Uc et 
al. (2005) studied visual attention and motion perception in PD patients 
and age-matched controls using the useful field of vision (UFOV) test and 
random dot cinematograms (Uc et al., 2005). The UFOV test assesses 
speed of visual processing and selective and divided visual attention when 
visual stimuli (car silhouettes) are presented individually and 
simultaneously in the central and peripheral visual field. Random dot 
cinematograms present a motion signal amid spatially random background 
noise. PD patients demonstrated impairments of visual attention, spatial 
and motion detection compared to controls. These group differences 
became non-significant when CS and VA were controlled for – suggesting 
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a retinal contribution to this impaired motion perception. However, group 
differences persisted for measures of visual speed of processing and 
alternative measures of visual attention, supporting a cortical contribution 
to such perceptual disturbances as well. The correlation between impaired 
visual perception and cognition backs up this hypothesis, arguing in favour 
of both “bottom-up” (retinal) and “top-down” (cortical) components to the 
breakdown in visual perception in PD.
One recent approach that sheds further light on this area involves the use 
of a range of hierarchical stimuli designed to bias responses from low-level 
(magnocellular), intermediate-level and higher-level (dorsal stream) visual 
pathways to study their inter-dependence (Castelo-Branco et al., 2008). 
PD patients, screened for ophthalmological disorders and matched for 
cognition by MMSE, demonstrate preferential impairment in motion 
discrimination tasks requiring perceptual integration of moving surfaces. 
Despite abnormalities of low-level magnocellular pathways, there was no 
correlation between these and motion integration impairments in the PD 
group. This recent work, demonstrating a dissociation between low- and 
high-level visual processing in PD, suggests that motion perception in the 
higher visual centres of the cortex is affected in PD and that not all such 
perceptual impairments can be explained by abnormalities in the early 
magnocellular pathway from retina to subcortical, striate and extra-striate 
regions. The studies by Castelo-Branco et al. and Uc et al. also highlight 
the link between impairments of motion perception and motor function, 
with impaired performance on simple and complex finger-tapping tasks 
correlating with motion perception measures in the former, and severity of 
postural instability and gait disorders correlating with impairments in visual 
speed of processing in the latter.
2.7.5 Structural changes in the retina
These changes in visual function might suggest structural alterations at a 
microscopic or macroscopic level in the retina. In light of the increasing 
evidence that cortical and subcortical visual pathology also plays a role in 
these abnormalities, development of tools to probe the retina in isolation 
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become increasingly important. One solution to these methodological 
issues is to focus on retinal structure in PD and other Lewy body 
disorders. One post-mortem study has suggested swelling of 
photoreceptors and RGCs as well as pale intracellular inclusions in the 
outer plexiform layer in the retina in patients with dementia with Lewy 
bodies (DLB). All sixteen patients studied at post-mortem suffered visual 
hallucinations and demonstrated ante-mortem abnormalities on flash-ERG 
(Devos et al., 2005). It is difficult to generalise from this small study in DLB 
to the PD population, however, and further studies are required. 
Optical Coherence Tomography (OCT) is a technique for obtaining cross-
sectional images of the retina in a non-invasive fashion with a resolution of 
10 microns. “Time-domain” methods function effectively as ‘optical 
ultrasound’, projecting a near-infrared light beam onto the retina and 
comparing the echo time delays of light reflected from the retina with that 
returned from a reference mirror. More recently, “frequency-domain” OCT 
has become available, permitting faster signal acquisition, a better signal-
to-noise ratio and 3-dimensional image reconstruction with an axial spatial 
resolution of 3-5 microns. OCT is capable of assessing the thickness of 
retinal nerve fibre layers (RNFL) around the optic nerve head, thus 
providing a measure of the integrity of the retinal ganglion cell axons as 
they exit the retina, as well as providing information of macular 
morphology in the central retina.
OCT is accurate and reproducible in the assessment of glaucoma and 
ageing (Blumenthal et al., 2000, Budenz et al., 2005, Paunescu et al., 
2004) provided signal strength, an automated measure of signal-to-noise 
ratio and signal uniformity, is adequate (Cheung et al., 2008). Factors such 
as age, ethnicity, axial length and optic disc size all influence RNFL 
thickness as measured by OCT and should be taken into account when 
interpreting results (Budenz et al., 2007). OCT demonstrates 
morphological changes in retinal structure in multiple sclerosis, 
Alzheimer’s disease and glaucoma (Iseri et al., 2006, Kanamori et al., 
2003, Parisi et al., 1999). RNFL thinning has been found in PD, albeit in 
relatively small numbers of patients (Altintas et al., 2007, Inzelberg et al., 
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2004, Moschos et al., 2010) and macular thickness has also been 
reported to be reduced (Altintas et al., 2007, Cubo et al., 2010, Hajee et 
al., 2009). One possible hypothesis to explain morphological changes in 
the PD retina is that dopaminergic deficiency deprives the retina of key 
trophic factors vital to maintaining structural integrity. To date, the 
functional implications of these reported morphological changes are 
unclear.
2.7.6 VEP & ERG
Retinal responses to visual stimuli generate clinically measurable electrical 
activity in the eye, as does the transmission of these responses to the 
primary visual cortex. Measurement of the amplitude and latency of such 
electrical responses provides information on the functional integrity of the 
visual pathway and both electroretinograms (ERG) and visual-evoked 
potentials (VEP) have been extensively studied in PD. Early work from 
Bodis-Wollner and Yahr demonstrated a delay in the VEP latency to 
sinusoidal gratings at a mid-spatial frequency (Bodis-Wollner and Yahr, 
1978) and these findings have been replicated in a number of subsequent 
studies using a variety of spatial and temporal stimulus parameters (Ikeda 
et al., 1994, Marx et al., 1986, Nightingale et al., 1986, Regan and Neima, 
1984b, Tartaglione et al., 1987).  Such VEP latency changes can be 
reversed with the administration of levodopa therapy and, in the healthy 
retina, treatment with dopaminergic blockers, such as haloperidol, results 
in an increment of VEP latency at identical spatial frequencies to those 
used in the PD patient group (Onofrj et al., 1986). It is possible to obtain 
both normal and abnormal results in the same patients depending on the 
characteristics of the pattern stimulus and this helps to explain the often 
contradictory neurophysiological findings in early work (Tartaglione et al., 
1987).
The PERG, by stimulating the retina at an even mean luminance, 
measures the electrical contribution from cells of the inner retina – 
predominantly the retinal ganglion cells (Maffei et al., 1985). As with other 
measures, the response is highly dependent on the spatial, temporal and 
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contrast characteristics of the gratings or checkerboards used. Studies 
have consistently shown alterations in both PERG latencies and 
amplitudes in PD (Gottlob et al., 1987, Langheinrich et al., 2000, 
Nightingale et al., 1986, Peppe et al., 1998, Peppe et al., 1992, Sartucci et 
al., 2006, Stanzione et al., 1990). In contrast to the “global” reduction in 
amplitude of PERG response in age-matched controls compared to young 
controls, PD patients show a specific medium-frequency deficit to a variety 
of sinusoidal grating spatial frequencies (Tagliati et al., 1996).  These 
changes respond to administration of levodopa (Peppe et al., 1998, Peppe 
et al., 1995) and may be progressive (Ikeda et al., 1994). Administration of 
the selective D2 receptor antagonist l-sulpiride to normal controls mimics 
the mid-spatial frequency abnormalities seen in PD (Stanzione et al., 
1995), unlike the PERG response to haloperidol, a dopamine receptor 
antagonist with affinity for both D1 and D2 receptors (Stanzione et al., 
1999). Identical changes in the PERG response are also seen in the 
monkey retina using l-sulpiride (Tagliati et al., 1994) and these important 
findings in the human and primate suggest a pivotal role for the D2 
receptor-dependent action of dopamine in “tuning” the PERG response to 
stimuli of different spatial frequencies. 
Animal studies, particularly in the primate, have also proven extremely 
useful in advancing a coherent hypothesis for dopaminergic actions at a 
retinal level. Ghilardi et al. (1989) administered MPTP systemically to 
monkeys, inducing a parkinsonian syndrome in all cases. Such measures 
have been shown to reduce primate retinal dopamine levels at post-
mortem assessment (Ghilardi et al., 1988b). Subsequent measurement of 
pattern VEP and ERG demonstrated reductions in amplitude and 
prolongation of latency compared to pre-administration results. Treatment 
with levodopa produced transient recovery both in parkinsonian signs and 
pattern VEP and PERG measurements (Ghilardi et al., 1988a). 
Administering 6-hydroxydopamine (6-OHDA) intraocularly to locally 
destroy dopaminergic function in monkeys also results in spatial 
frequency-dependent losses in PERG amplitude, which improve after 
levodopa administration (Bodis-Wollner and Tzelepi, 1998, Ghilardi et al., 
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1989). In addition, by measuring ERG response to flash and pattern 
stimuli after administration of a variety dopaminergic antagonists (l-
sulpiride, haloperidol) and a D1 receptor agonist, Bodis-Wollner and 
Tzelepi (1998) postulated that dopamine, acting via both D1 and D2 
receptors pre- and post-synaptically modulates the balance of centre-
surround receptive fields of retinal ganglion cells, tuning the overall retinal 
response to spatial frequency in a “push-pull” manner (Bodis-Wollner and 
Tzelepi, 1998).
2.7.7 Summary – PD and the “subcortical” visual system
What are the functional implications of these findings? That dopamine is 
vital to retinal function is now beyond doubt but the precise nature of its 
actions in the human retina is only now becoming clearer. The complexity 
of the connections of dopaminergic amacrine cells suggests multiple roles, 
not least in suppressing the transmission of rod-driven visual information 
from the peripheral retina in low-light, but not fully dark, conditions 
(mesopic). The use of alternating sinusoidal gratings both to stimulate 
individual ganglion cells, such as in the seminal work of Enroth-Cugell and 
Robson (1966), and in exciting a massed central retinal ganglion cell 
response, such as in the PERG, has provided the link necessary to better 
define the role of dopamine in normal retinal function. This bridge between 
cellular retinal structure and individual and summative RGC function 
implicates dopamine heavily in organising the receptive field of these 
output cells of the retina. Thus the spatiotemporal contrast sensitivity 
abnormalities in PD, particularly at the point where the normal peak of CS 
occurs, are a measure of dopaminergic influences on the “centre-
surround” receptive fields of RGCs. The striking similarity between the CS 
function curves of dark-adapted normal retina and light-adapted PD retina 
implicate DA in the transition from scotopic to photopic vision (Harris et al., 
1992, Wink and Harris, 2000). The finding of a diurnal variation in 
dopamine concentration, dependent on melatonin release, would support 
the dopaminergic mediation of dark-light transitions. In other words, 
dopamine activity favours cone-mediated, high-contrast vision and the 
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parkinsonian retina may therefore exist in an inappropriately dark-adapted 
state. This, in turn, may lead to larger RGC receptive fields and lower 
spatial and temporal resolving potential with an ultimate impact on visual 
acuity, contrast sensitivity and colour and motion perception. 
ERG and VEP data consistently demonstrate functional disruption of the 
transfer of visual information out of the retina, particularly the 
magnocellular and parvocellular pathways. Magnocellular neurons are 
vital for integrating rod-driven signals and this pathway, from retina to 
visual cortex via LGN, is particularly sensitive to motion and low luminance 
contrast detection. The reliance on information from the rod system also 
means that the magnocellular pathway dominates in the peripheral retina. 
The cone contribution to this pathway is reflected in its important diurnal 
pattern of activity. Disruption of this M-pathway may deprive particularly 
the dorsal visual stream of vital cues for accurate motion perception. 
Parvocellular pathways, relaying colour and acuity data also breakdown in 
PD, possibly contributing to ventral stream failure of object-form 
perception. 
In addition to this “bottom up” disruption of information processing, there 
are also likely to be both subcortical and cortical components to visual 
symptomatology in PD and PD dementia. Visuocognitive and 
visuoperceptual impairments are most striking in PDD, where visual 
hallucinations are particularly prominent (Mosimann et al., 2004b). 
Cognitive impairment is common in PD, even in incident cohorts with mild 
or early disease and simple screening tools for cognitive dysfunction such 
as the MMSE will miss many PD patients with mild cognitive impairment – 
a potential confounder in tests of visual function (Foltynie et al., 2004). 
New clinical diagnostic criteria for identifying patients with PDD, in 
conjunction with a better appreciation of mild cognitive impairment as a 
precursor to more marked decline (Janvin et al., 2006b, Williams-Gray et 
al., 2007), should allow separation of these patients from cognitively intact 
PD patients – a vital step if we are to integrate both “bottom up” and “top 
down” approaches to vision research in PD and PDD (Emre et al., 2007).
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“De-afferentation” of the visual cortex from accurate retinal input can be 
seen in Charles Bonnet Syndrome as a potent risk factor for visual 
hallucinations. Hallucinations as a cortical release phenomenon have long 
been postulated in CBS and a similar pathogenic mechanism may occur in 
PD and PDD. Impaired visual acuity and contrast sensitivity are risk 
factors for hallucinations in PD but it seems unlikely that the subtle 
changes seen in PD are the entire explanation. Further work is needed to 
explore the interactions between dysfunction of the retina and the “central” 
breakdown of visual processing both at the primary visual cortex and 
beyond. It seems likely that retinal changes contribute to the multitude of 
other visual symptoms encountered in PD (blurred vision, difficulty 
reading) although data is currently lacking to support this notion. 
Visuomotor problems such as gait disorders, freezing, postural instability 
and falls are a huge source of anxiety and morbidity in patients with PD. 
Evidence is now emerging that visual dysfunction directly contributes to 
these more traditional “motor” complications, although the relative 
contributions of retina and visual cortex to the vast array of motor 
symptoms remain unclear (Castelo-Branco et al., 2008, Uc et al., 2005). 
Structural degeneration of the retina has been reported in PD, but how this  
changes with disease progression and whether it contributes to symptoms 
such as visual hallucinations is currently unknown. With the emergence of 
better non-invasive techniques for studying retinal function we now have 
the opportunity not only to confirm these findings in larger cross-sectional 
cohorts but also to embark on longitudinal studies to address the role of 
OCT as a potential biomarker of neurodegeneration in PD. Combining this 
approach with post-mortem retinal work may also help to clarify the 
potential trophic role of dopamine in maintaining retinal structure and 
function. The counterphase balance between dopamine and melatonin 
may also be important, not just in pupillary function and retinal dark-light 
adaptation, but in the development of alterations in sleep-wake cycle or 
even REM-sleep behaviour disorder, prominent non-motor features of PD.
The inclusion of appropriate age-matched controls in many studies has 
highlighted the marked difference between normal ageing and Parkinson’s 
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disease in terms of retinal function. However, we do not have an answer to 
the question of how PD may interact with age-related ophthalmological 
diseases such as cataract and AMD as almost all studies to date have 
excluded patients with significantly diminished visual acuity or identifiable 
ocular pathology. Whilst this has helped to clarify the role of dopamine in 
retinal function and disease-specific disruption of visual processing in PD, 
it is not the “real world” that we inhabit as clinicians. A better appreciation 
of how structural disease of the eye contributes to disability in PD is 
overdue, particularly as effective treatments exist for many of the 
concomitant ocular disorders that may contribute to visual symptoms in 
PD. Successful intervention therefore offers the prospect of improvements 
in the quality of life of PD patients and their carers. It also seems likely that 
we need to move beyond traditional static methods of assessing visual 
adequacy as detailed assessment of some of the more subtle changes in 
visual function may allow earlier identification of those patients at risk of 
developing visual, motor and cognitive complications of PD. In addition, 
understanding neurodegeneration within the retina, both at a microscopic 
and macroscopic level, may provide a clearer window through which to 
view the disease process itself and its influence, not just on the eye, but 
also on visuoperceptual, visuocognitive and visuomotor performance as 
well.
2.8 Visual cortex: structure and function
So far, we have focused on the hierarchical organisation of the visual 
system up to the point that visual information converges on the primary 
(striate) visual cortex. We now begin to see considerable divergence 
through the so-called extra-striate or visual association areas. In addition 
to this forward flow of visual information, there is also a process of 
feedback, modulating responses at various cortical and subcortical levels. 
Our understanding of the visual system in humans has traditionally been 
based on experimental data from non-human primates and patients with 
discrete lesions in the visual pathways. More recently, work utilising tools 
such as fMRI and transcranial magnetic stimulation (TMS) has 
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transformed the field, demonstrating for the first time how cortical visual 
processing occurs both in normal subjects and those with 
neurodegenerative disorders.
Primary visual cortex, also known as area V1, is the region of visually-
responsive cortex that receives the bulk of the retino-geniculate input. 
Located in the calcarine sulcus of the occipital lobe it contains a retinotopic 
representation of the contralateral visual field. From here, visual 
information is passed to area V2, the first extra-striate visual region, where 
further analysis and sorting of “raw” data is achieved. Neurons in V1 and 
V2 have relatively simple response properties to stimulation in appropriate 
parts of their receptive field. Cells in this region selectively respond to 
stimuli of, for example, a specific spatial frequency, orientation, colour or 
direction of motion (Hubel and Wiesel, 1959, Zeki, 1978, Tootell et al., 
1988, Burkhalter and Bernardo, 1989). 
Area V3 is located adjacent to V2 and can be subdivided into a dorsal and 
ventral component. In addition to this, further subdivisions such as areas 
V3A and V3B have been proposed in humans. Dorsal V3, V3A and V3B 
seem to receive input from both V1 and V2 and are, in part, responsible 
for processing information on motion. The properties of ventral area V3 
are less completely understood, at least in humans, but cells in this area 
seem to project to visual association areas in the temporal lobe (Tootell et 
al., 1997).
Area V4, located on the ventral surface of the brain, is involved both in 
object recognition (Gallant et al., 2000), motion- (Tootell and Hadjikhani, 
2001) and colour-perception (Zeki et al., 1991, Howard et al., 1998). 
Responses in V4 are optimal to geometric shapes and contours rather 
than complex figures such as animals, objects or faces (Desimone et al., 
1985, Kastner et al., 2000). The flow of visual information from V1 and V2, 
through ventral V3, to V4 marks the anatomical beginning of what is often 
referred to as the “ventral stream” of visual processing.
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Visual information is also directed in a more dorsal direction, passing from 
V1 and V2, through the dorsal divisions of V3 and also into area V5/MT, 
located at the junction between the lateral occipital and medial temporal 
cortex (Ungerleider and Desimone, 1986, Tootell and Taylor, 1995). This 
extensively studied area also receives input from subcortical visual 
structures such as the pulvinar nucleus of the thalamus and the LGN 
(Kaas and Lyon, 2007). Output from V5/MT flows both to the ventral 
stream via area V4, and also in a more dorsal direction, to regions such as 
the posterior parietal cortex (PPC), intraparietal sulcus (IPS) and the 
parietal and frontal eye fields. V5/MT is primarily involved in integrating 
simple information on visual motion into a more complete representation of 
the coherent movement of complex objects (Tootell et al., 1995, Smith et 
al., 1998, Welchman et al., 2005). 
This division of the visual pathways into a dorsal and ventral stream was 
first hypothesised by Ungleleider and Mishkin in 1982 based on work in 
primates (Ungerleider and Mishkin, 1982). In their seminal article, it was 
suggested that the ventral stream was specialized for object-form 
identification – the “what” pathway - with the dorsal stream subserving 
spatial assessment – the “where” pathway (Figure 5). Although now 
thought to be an oversimplification, the concept of two parallel and 
complementary streams of visual information processing remains valid. 
More recently, the hypothesis has been revised by Goodale and Milner to 
highlight the role of the dorsal (visuomotor) stream in integrating visual 
information for use in motor tasks, whereas the ventral (visuoperceptual) 
stream interprets visual information, assembling a conscious percept that 
can be allied with other cognitive constructs to aid recognition and 
identification (Goodale and Milner, 1992, Goodale and Westwood, 2004).
2.8.1 Ventral stream
The ventral stream terminates in ventral and medial temporal lobe cortex 
in defined regions such as the lateral occipital complex (LOC), fusiform 
face area and parahippocampal place area. Such regions demonstrate 
attribute-based, category-specific activation to objects for the LOC (Eger 
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et al., 2008, Vinberg and Grill-Spector, 2008), novel and famous faces for 
the fusiform face area (Clark et al., 1998, Grill-Spector et al., 2004, 
Kanwisher et al., 1997, Chao et al., 1999), and scene recognition for the 
parahippocampal place area (Epstein et al., 1999, Park and Chun, 2009). 
In addition to ventral stream activity during face perception and picture 
encoding tasks, there is also activation evident in hippocampal and 
parahippocampal regions, suggesting that these repositories of semantic 
and episodic memory are accessed concurrently with object perception to 
allow integration of visual perception with prior experience (Ricci et al., 
1999, Stern et al., 1996). 
Figure 5. Schematic representation of dorsal and ventral stream 
pathways as they flow from occipital to parietal and temporal lobes 
respectively.
Complementing this “bottom up” driven process of building a complex 
visual percept, there appears to be “top down” modulation mediated by 
activation in frontal and parietal regions. For example, visual imagery 
activates identical areas of the temporal lobe to those used for visual 
perception, albeit to a less marked extent. This is associated with attribute-
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“where” or “vision 
for action”
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“what” or “vision for 
perception”
dependent activation of the prefrontal cortex, and content-unrelated 
activity in the posterior parietal cortex, suggesting that these areas have a 
role in retrieval and maintenance of visual memories from storage   
(Figure 6) (Ishai et al., 2002, Ishai et al., 2000, Mechelli et al., 2004).
Figure 6. Schematic of the principal cortical regions involved in 
dorsal and ventral stream processing. Note the communication 
between V5/MT and V4, thereby ensuring that motion perception is 
also served by the ventral stream. Note also the close association 
between dorsal stream, cingulate gyrus and parietal and frontal eye 
fields and between ventral stream, hippocampus and prefrontal 
cortex.
2.8.2 Dorsal stream
The dorsal stream terminates in the posterior regions of the parietal lobe 
(PPC), where integration occurs between visuospatial input and motor 
planning. In particular, regions such as the PPC seem to be vital in the 
planning, initiation and adjustment of visually-guided limb and eye 
movements (Milner and Goodale, 1995). In Perenin and Vighetto’s study 
of 10 patients with unilateral lesions of the posterior parietal lobe, deficits 
in coordination and accuracy of visually-elicited hand movements (so-
called “optic ataxia”) were noted despite an absence of limb weakness or 
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visual space misrepresentation (Perenin and Vighetto, 1988). In addition, 
lesions in the human PPC also impact on the ability to make “online” 
corrections to movements once they have begun, suggesting a role for the 
PPC in integrating visual feedback in the adjustment on ongoing motoric 
output (Pisella et al., 2000). In support of this lesion data is evidence from 
functional imaging studies, demonstrating increased activity in the PPC 
during visually-guided reaching (Clower et al., 1996, Desmurget et al., 
2001) and disruption to the accuracy of these reaching movements when 
TMS is applied to the contralateral PPC (Desmurget et al., 1999).
Distinct from this “vision for action” role of the PPC, fronto-parietal 
networks are also involved in the deployment of visuospatial attention 
(Corbetta et al., 1993). Posner et al. (1984) demonstrated that parietal 
stroke patients, as compared to stroke controls with other patterns of 
cortical injury, struggle to disengage attention from one stimulus and re-
engage with a second (Posner et al., 1984). Furthermore, there are 
decrements in vigilance in PPC-lesioned patients when sustained attention 
is required for spatial compared to verbal tasks (Malhotra et al., 2009). 
Tests of working memory, “visual detection versus identification” and 
visuospatial ability invoke changes in fMRI PPC activity, suggesting roles 
for this region in directing spatial attention, non-spatial tasks and overall 
attentional vigilance (Coull and Frith, 1998, Newman et al., 2003, 
Vandenberghe et al., 1996). In addition, PPC provides “top down” 
modulation of visual cortex excitability for attended stimuli (Silvanto et al., 
2009, Slotnick et al., 2003) and contributes to attentional selection of 
pertinent visual stimuli among distractors (Kastner et al., 1999, Battelli et 
al., 2009).
2.8.3 Prefrontal cortex
The frontal lobe, and specifically the prefrontal cortex (PFC), plays an 
important part both in attention and memory and hence influences the 
processing of visual information in both dorsal and ventral streams. For 
example, visual perception and imagery both activate the PFC in a 
category-selective fashion (Mechelli et al., 2004, Haxby et al., 2000) and 
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TMS of different PFC regions leads to specific deficits in both spatial and 
non-spatial tasks (Mottaghy et al., 2002). In addition, visual and spatial 
working memory is a key component of PFC function and, due to its 
connectivity to medial temporal, hippocampal and parahippocampal 
regions, the PFC is also vital to the integration of working memory with 
semantic and episodic memory (Courtney et al., 1998, Ranganath, 2006).
Several models have been proposed in an attempt to integrate this fronto-
parietal contribution to visuospatial and visuoperceptual processing with 
Ungerleider and Mishkin’s (1982) and Goodale and Milner’s (1995) original 
hypotheses. One such model divides the parietal lobe anatomically and 
functionally into a superior parietal lobe (SPL) devoted to visuomotor 
integration and online correction of ongoing movements and an inferior 
parietal lobe (IPL) more involved with action understanding and spatial 
perception (Rizzolatti and Matelli, 2003). Regions of the IPL are also active 
in non-spatial tasks, arguing for a crucial role in sustaining intensity of 
attention and attentional selectivity (Figure 7) (Husain and Nachev, 2007).
Corbetta and Shulman’s influential model focuses more on the role of 
fronto-parietal networks in visuospatial attention (Corbetta and Shulman, 
2002). As such, the SPL and inferior parietal sulcus are implicated in 
deploying attention and selecting suitable responses from a range of 
potential competing stimuli in a goal-directed fashion. In contrast, inferior 
regions of the PPC, ventral PFC and the temporoparietal junction (TPJ), 
act as a “ventral attentional network”, allowing attention to be switched 
from one part of the visual field to another in response to a novel or highly 
salient event. This “circuit-breaker” pathway is strongly lateralized to the 
right hemisphere and implies a “bottom up” contribution to selective 
attention, rather than the more conventional “top down” control suggested 
by earlier models (Rees and Lavie, 2001). This rightward bias for the 
attention system may help explain why hemispatial neglect and visual 
inattention is most marked after lesions to the right hemisphere.
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The neuropsychological deficits in attention, frontal executive, visuospatial 
and visuoperceptual abilities characteristic of PD and PDD argue strongly 
for dysfunction in a variety of cortical regions such as PFC, PPC and the 
dorsal (occipito-parietal) and ventral (occipito-temporal) streams as an 
explanation for some of the visual and cognitive symptoms encountered in 
the disorder. If so, imaging and post-mortem studies should provide 
evidence to support this notion.
Figure 7. Depiction of the key networks involved in the control of 
visual attention. Although distinctions are made between parietal, 
temporal and frontal regions, in essence they function as an 
interconnected and interdependent functional network.
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(from V1)
2.9 Cortical impact of PD and PDD
A variety of neuroimaging approaches have been used to highlight the 
structural and functional consequences of the neurodegeneration evident 
in PD and PDD. Bruck at al (2004) demonstrated hippocampal and PFC 
atrophy in non-demented PD patients compared to HC, the former being 
associated with memory deficits and the latter with attentional impairments 
on cognitive testing (Bruck et al., 2004). More diffuse, but subtle, atrophy 
has also been detected in superior parietal, occipital, fusiform and 
parahippocampal regions of non-demented PD patients, correlating with 
visuospatial and visuoperceptual impairments (Pereira et al., 2009). 
Greater reductions in grey matter density in limbic, paralimbic and 
neocortical regions are evident in PD hallucinators compared to non-
hallucinators suggesting a link not just with cognitive profile but also visual 
symptomatology (Ramirez-Ruiz et al., 2007, Ibarretxe-Bilbao et al., 2009).
As one might expect, atrophy is much more dramatic in studies focusing 
on PDD or the closely related DLB. Hippocampal, parahippocampal, 
frontal, parietal and occipital regions are all affected (Burton et al., 2005) 
although those cortical areas involved in dorsal and ventral stream 
processing seem particularly vulnerable (Beyer et al., 2007, Ramirez-Ruiz 
et al., 2005). Diffusion tensor imaging, which provides a surrogate 
measure of the integrity of neural connectivity, suggests that 
communication between precuneus, posterior cingulate and posterior 
parietal regions is damaged in PDD and DLB (Firbank et al., 2007, Matsui 
et al., 2007). A pictorial representation of the referenced studies on PD, 
PDD and DLB, and the brain regions affected, is provided in Figures 8 & 
9.
Single photon emission computed tomography (SPECT) studies, 
measuring regional cerebral blood flow, provide a functional rather than 
structural measure of cortical integrity. SPECT studies in DLB and PDD 
have demonstrated reductions in blood flow in occipital and posterior 
parietal areas (Abe et al., 2003, Mito et al., 2006) and these changes are 
associated with both cognitive and behavioural features such as 
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attentional deficits and hallucinations (O'Brien et al., 2005). In addition to 
this occipito-parietal change, hypoperfusion is also evident in inferior 
temporal and fusiform regions in hallucinators compared to non-
hallucinators (Matsui et al., 2006, Oishi et al., 2005). Subtle perfusion 
changes are even demonstrable in parieto-occipital regions in PD patients 
with MCI compared to a cognitively normal PD cohort (Nobili et al., 2009). 
MR spectroscopy and positron emission tomography also highlight 
reductions in metabolic activity in occipital (Summerfield et al., 2002), 
temporal and frontal areas (Perneczky et al., 2008).
Figure 8. Imaging studies in PD. In this depiction, the lobes of the 
brain have been flattened out to allow a better appreciation of the 
principal regions affected in PD. Note the bias toward involvement of 
medial temporal, occipito-parietal and prefrontal regions even early 
in the disease course.
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Bruck (2004) - hippocampal and pre-frontal 
cortex atrophy in PD vs HC. Former assoc. 
with memory deficits and latter with 
attentional problems
Pereira (2009) - sup parietal, sup occipital, middle 
occipital, fusiform & parahippocampal atrophy in 
PD. Correlated with visuospatial and 
visuoperceptual impairments
Structural imaging - PD
Ramirez-Ruiz (2007) - reduction in grey 
matter density in superior parietal and left 
lingual regions in PD hallucinators vs non-
hallucinators
Ibarretxe-Bilbao (2009) - atrophy in limbic, 
paralimbic and neocortical (frontal, parietal) 
areas in PD hallucinators vs non-hallucinators 
and controls.  Atrophy progressive in 
hallucinators and correlated with cognitive 
deficits
Figure 9a. Imaging studies in PDD and DLB. Here we see a similar, 
but more marked, pattern of involvement to that in non-demented PD 
patients. In particular, the occipito-parietal and temporal regions are 
targets for the degenerative process.
Structural imaging - PDD & DLB
Burton (2004) - diffuse atrophy inc. 
hippocampal and parahippocampal, occipital, 
right frontal & left parietal in PDD & DLB
Ramirez-Ruiz (2005) - neocortical atrophy inc. 
right fusiform and right temporo-occipital 
regions in PDD
Beyer (2007) - diffuse atrophy in occipital, 
temporal and parietal regions in PDD & DLB
Matsui (2007), Firbank (2007) - diffusion tensor 
imaging suggests reductions in connectivity 
between precuneus, posterior cingulate and 
posterior parietal regions in PDD & DLB
Perfusion imaging - PD, PDD & DLB 
Abe (2003) - reduced regional cortical blood 
flow (rCBF) in occipital and PPC (PD vs HC)
Oishi (2005) - hypoperfusion in right fusiform 
region and hyper-perfusion in sup. and middle 
temporal gyri in PD hallucinators
O’Brien (2005) - cognitive and behavioural 
features associated with perfusion changes in 
post. cingulate, thalamus and inferior occipital 
regions (PDD & DLB)
Matusi (2006) - PD and PDD hallucinators and 
non-hallucinators. Reduced perfusion in inferior 
parietal lobe, inferior temporal gyrus, precuneus 
and occipital lobe
Nobili (2009) - PD-MCI vs PD demonstrates 
reduced perfusion in posterior parietal cortex, 
right occipital region and precuneus
Mito (2006) - reduced perfusion in anterior 
cingulate and occipital cortex, more marked in 
PIGD vs TD phenotype
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Figure 9b. In addition to the occipital and temporal changes we see 
reduced activation in temporal and primary visual cortex and 
aberrant frontal and subcortical activation in hallucinators compared 
to non-hallucinators.
Another powerful imaging tool employed to study the neuroanatomical 
substrate of cognitive impairment and associated symptomatology in PD is  
fMRI. During stroboscopic and kinematic stimulation of the visual pathway, 
PD hallucinators show an altered pattern of activation in the visual 
pathways, with reduced activity in occipital and parietal, and increased 
activation in frontal, subcortical and visual association areas compared to 
non-hallucinators (Stebbins et al., 2004, Holroyd and Wooten, 2006). DLB 
patients demonstrate reduced activation in ventral occipito-temporal 
regions for face perception tasks and reduced activation of lateral occipito-
temporal for visual motion tasks (Sauer et al., 2006). Results from face 
recognition and visual pop-out tasks in PD hallucinators and non-
hallucinators highlight the role of pre-frontal, cingulate and temporal 
regions in this task, with hallucinators showing reductions in activation in 
these key areas (Ramirez-Ruiz et al., 2008, Meppelink et al., 2009).
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Functional MRI - PD, PDD and DLB
Sauer (2006) - fMRI during face perception and 
visual motion tasks. Reduced activation in DLB 
(cf. AD) in ventral occipital-temporal regions 
for former and lateral occipital-temporal 
regions for latter
Ramirez-Ruiz (2008) - face recognition task in 
PD hallucinators and non-hallucinators. 
Reduced activation of right pre-frontal areas 
and anterior cingulate and increased activation 
of right inferior frontal gyrus in hallucinators
Stebbins (2004) - stroboscopic and kinematic 
stimuli in PD hallucinators and non-
hallucinators. Altered pattern of activation with 
posterior activation in non-hallucinators and 
frontal/sub-cortical activation in hallucinators 
Holroyd (2006) - PD hallucinators and non-
hallucinators. Increased activation in association 
visual cortex and reduced activation in primary 
visual cortex
Meppelink (2009) - Visual pop-out task 
demonstrates reductions in occipital and ventral 
stream activation in PD hallucinators. Also subtle 
parietal and frontal hypoactivation.
We have already touched upon the extensive neuropathological changes 
seen in PD and PDD as α-synuclein and tau burden increase with disease 
progression. Two studies have examined the neuropathology of Lewy 
body dementias (PDD and DLB) specifically with CVH in mind. Consistent 
to both is a putative link between α-synuclein burden in the medial 
temporal lobe (particularly the amygdala) and visual hallucinations in life 
(Harding et al., 2002, Kalaitzakis et al., 2009).
2.9.1 Summary - Cortical visual processing in PD
In essence, visual perception appears to be dependent on two main 
factors - the characteristics of the visual input to both dorsal and ventral 
streams in terms of object colour, motion and form, which can activate 
visual centres directly or “capture” attentional networks to facilitate 
perceptual awareness in a “bottom up” fashion. The second key 
component is the ongoing monitoring of visual information by the fronto-
parietal attentional networks to allow selection and suppression of visual 
stimuli dependent upon the prevailing requirements of the moment in a 
goal-directed, “top down” fashion (Kimchi, 2009). Evidence from 
neuropsychological, neuropathological and imaging studies would support 
the notion that PD interferes with these ventral (“vision for perception”) and 
dorsal (“vision for action”) streams as well as damaging the brain’s abilities 
to modulate visual attention and effectively respond in a goal-directed 
fashion and that it is these changes that contribute to the development of 
CVH in PD and PDD.
2.10 Control of eye movements
In order to make sense of the visual environment humans must direct the 
fovea, the area of highest visual acuity, to appropriate parts of a given 
scene. The eye movements required for this task must be rapid, accurate 
and proceed in an order that will allow us to build an internal 
representation of what we are viewing as quickly as possible. Such 
movements are known as saccades and are a controlled by a complex 
network of cortical and subcortical structures.
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The brainstem saccade generator, a network of functionally interconnected 
excitatory and inhibitory premotor burst neurons (PBNs), is required to 
generate a saccade. PBNs show an intense discharge before each 
saccade and project monosynaptically to ocular motoneurons (Scudder et 
al., 2002). These form the final common pathway innervating the 
extraocular muscles to effect rapid saccadic eye movements. PBNs are 
only active during a saccade and are inhibited tonically by omnipause 
neurons in the pons to allow fixation on a particular target until another 
saccade is required (Horn et al., 1994). It is not enough, however, merely 
to generate a saccade - the movement must be made at the right time, in 
the right direction and be brought to an end without overshooting the 
target. Control of saccadic accuracy is achieved by the superior colliculus 
(SC) and the dorsal vermis and caudal part of the fastigial nucleus of the 
cerebellum (Robinson and Fuchs, 2001). Direct electrical stimulation of the 
SC is capable of producing saccades in primates (Robinson and Fuchs, 
2001) and further work suggests that not only does the SC play an 
important role in the initiation of saccades but that it is also involved in 
specifying direction and amplitude (Scudder et al., 2002). 
Higher centres also influence the SC, which is tasked with integrating 
spatial cues from cortical and subcortical areas, driving the brainstem to 
generate spatially accurate and temporally appropriate saccades. 
Important cortical areas that contribute to saccade generation include: the 
frontal eye field (FEF) which lies in the precentral gyrus and sulcus; the 
supplementary eye field (SEF), just anterior to the supplementary motor 
area of the paracentral sulcus; and the parietal eye field (PEF), lying in the 
IPS. In addition, the dorsolateral prefrontal cortex (DLPFC) and PPC are 
also vital in the cortical programming of appropriate spatial saccades 
(Pierrot-Deseilligny et al., 1995, Pierrot-Deseilligny et al., 2005). These 
areas project to the SC as well as to areas of the thalamus and 
subthalamic nuclei, caudate, globus pallidus and substantia nigra. In turn, 
these thalamic and basal ganglia regions project to the SC, providing 
cortical regions and the basal ganglia with direct and indirect access to the 
SC and lower brainstem structures concerned with saccadic eye 
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movements (Figure 10). It seems likely that the basal ganglia in general, 
and the SN in particular, exert a tonic inhibitory effect on the brainstem 
saccade generator whereas the direct cortical input to SC and brainstem is 
principally excitatory (Hikosaka et al., 2000). 
Figure 10. Network of cortical, subcortical and brainstem regions 
responsible for saccadic control. Note the complex interaction 
between frontal, parietal and subcortical structures that directly and 
indirectly influence the superior colliculus and brainstem saccadic 
generator.
When viewing a natural visual environment, numerous saccades, 
interspersed with periods of foveal fixation, are deployed in a structured 
fashion to make sense of the surroundings. In this way, complex scenes 
can be explored efficiently, selecting areas of particular relevance whilst 
ignoring others (Noton and Stark, 1971, Rayner and Pollatsek, 1992, 
Henderson and Hollingworth, 1999). Foveal fixation is integral to visual 
perception, as visual information processing is suppressed during a 
saccade, and one can therefore view saccadic output as the “means to an 
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end” for building up a representation of the external world. This process of 
selection is coordinated by “top down” control, and visual exploration 
proceeds in a goal-directed fashion, using endogenously-cued saccades, 
guided by cognitive processes such as spatial attention, working and 
explicit memory (Henderson, 2003). 
“Bottom up” factors such as the visual properties of the scene being 
viewed (novel versus familiar shapes, colour, contrast, motion) are also 
important in determining visual exploration (Krieger et al., 2000, Parkhurst 
and Niebur, 2003, Frey et al., 2007). This latter property is referred to as 
“visual saliency” and computational models, based on “saliency maps” 
within the visual system are, to some extent, capable of predicting 
subsequent human fixations (Itti and Koch, 2001). Saccades cued 
primarily by the characteristics of the visual environment have a greater 
reflexive bias.
Such distinctions between “reflexive” and “voluntary” saccades are 
artificial in the sense that cognitive control is exerted, to a greater or lesser 
extent, on most of the saccades we make. Endogenously-triggered 
saccades have longer latencies compared to exogenously-cued saccades, 
reflecting the degree of cognitive control exerted over them (Walker et al., 
2000). However, even “reflexive” saccades, with typical latencies in the 
region of 150-200 ms, take longer to execute than one might expect from 
a circuit involving solely brainstem and cerebellar regions (Carpenter, 
1981, Hutton, 2008). In addition, they also show considerable variability in 
latency. This is necessitated by our limited resources for processing the 
wealth of potential visual input confronting us, meaning even reflexive 
saccades must be cognitively biased in favour of stimuli worthy of further 
attention (Carpenter, 2001). 
In a laboratory setting, saccades are typically subdivided into four main 
types: 
• prosaccades – made in response to, and in the direction of, a 
sudden-onset visual stimulus (reflex-biased, exogenously triggered)
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• antisaccades - volitional saccades made in the opposite direction to 
a brief visual stimulus (cognitively-biased, exogenously triggered)
• memory-guided saccades - generated to a remembered location 
after removal of a visual stimulus (cognitively-biased, endogenously 
triggered) and
• predictive saccades - made prior to a regularly recurring visual 
stimulus at a predictable location (cognitively-biased, endogenously 
triggered)
As previously discussed, several cortical regions are involved in the 
control of saccadic eye movements and both lesional, TMS and fMRI work 
has unveiled the anatomical substrates of eye movement control. 
Prosaccades are largely under the control of the PEF located within the 
PPC. Lesions in the PEF in humans lead to increased latency and 
reduced accuracy of these saccades (Pierrot-Deseilligny et al., 1991b). In 
addition, TMS applied to the PPC region early during the preparation for a 
memory-guided saccade, i.e. prior to the movement beginning, causes 
errors in amplitude of the subsequent saccade (Muri et al., 1996). The 
PEF therefore would appear to be involved both in early saccade 
programming and integration between incoming visual information and 
subsequent eye movements. Understanding of the role of the SEF is much 
less complete, however, a key role in facilitating switching between 
competing voluntary saccadic responses has been hypothesised based on 
lesional and fMRI studies (Parton et al., 2007, Nachev et al., 2005). 
The FEF has an important role in generating voluntary saccades to visual 
stimuli. Lesions lead to increased latency of antisaccades, suggesting that 
the FEF facilitates disengagement of fixation from one visual stimulus to 
allow a saccade to begin to another (Rivaud et al., 1994, Pierrot-
Deseilligny et al., 1995). In contrast, lesions in the DLPFC lead to an 
increase in unwanted reflexive saccades during an antisaccade task, 
presumably by removing inhibitory influences on other cortical and 
subcortical areas. In addition, the DLPFC is key to the generation of 
accurate memory-guided and predictive saccades (Pierrot-Deseilligny et 
al., 1991a, Pierrot-Deseilligny et al., 1995). TMS applied to the DLPFC 
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prior to memory-guided saccades causes an increase in amplitude errors 
during subsequent movements. This effect is seen late in the preparation 
phase for the saccade, suggesting an additional role for the DLPFC 
related to processing spatial memory for eye movements (Muri et al., 
1996).
Given the anatomical overlap between the regions involved in 
programming saccades and those controlling attention, working memory, 
spatial and visual perception, one can begin to see how measurements of 
eye movements might provide a window onto the integrity of these 
cognitive domains themselves. That an important relationship exists, for 
example, between spatial attention and saccadic output is not in doubt. 
Numerous experiments utilising both prosaccade and antisaccade tasks 
have demonstrated the intimate links between attention, saccadic 
characteristics and object recognition (Deubel and Schneider, 1996, 
Kristjansson, 2007, Rizzolatti et al., 1987). Despite a variety of models 
having been proposed to characterize the relationship, however, the 
precise nature of the interaction remains a matter for debate (Clark, 1999, 
Klein, 1980, Rizzolatti et al., 1994, Henderson, 2003). 
Likewise, performance on saccade tasks can provide an insight into 
working memory. For example, error rates on antisaccade tasks increase 
with rising demands on tests of working memory load (Mitchell et al., 
2002). In addition, when participants in an antisaccade study were 
dichotomised into groups with high- and low-span working memories, 
those falling into the lower-span group made more errors on an 
antisaccade task and had longer saccadic latencies when the correct 
response was selected (Unsworth et al., 2004).
2.11 Eye movements, neurodegeneration and dementia
Eye movement abnormalities are well recognised in patients with PD, both 
in terms of deficient smooth pursuit, restricted vergence, reduced range of 
eye movements and alterations in saccadic output (Corin et al., 1972, 
White et al., 1983, Rascol et al., 1989, Repka et al., 1996, Bares et al., 
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2003). Evidence for disease-specific disruption of exogenously-cued, 
reflexive saccades in PD is contradictory. Whereas some studies have 
demonstrated increases in saccadic latency and reductions in amplitude 
(Rascol et al., 1989, MacAskill et al., 2002), others have not replicated 
these findings (Vidailhet et al., 1994, Briand et al., 1999, Briand et al., 
2001, Mosimann et al., 2005). Both the properties of the stimulus used 
and medication effects are important determinants of saccadic metrics and 
may help explain some of the inconsistencies in the reported literature 
(Chambers and Prescott, 2010, Michell et al., 2006, Hood et al., 2007).
There is some evidence to support the notion that endogenously-cued 
saccades are sensitive to the effects of PD both in terms of saccadic 
latency, amplitude and error rates (Kennard and Lueck, 1989, Briand et 
al., 1999, Hood et al., 2007, MacAskill et al., 2002, van Stockum et al., 
2008) although, again, results are inconsistent (Lueck et al., 1990, 
Vidailhet et al., 1999, Mosimann et al., 2005). Cognitive impairment is an 
important determinant both of error rates, saccade latency and gain in PD 
and PDD  (Hodgson et al., 1999, Mosimann et al., 2005) and the cognitive 
heterogeneity of PD subjects in previous studies remains an important 
potential confounder when interpreting these results.
In support of this assertion is the finding that patients with Huntington’s 
disease (HD), a condition characterised by cortical and subcortical 
dementia and parkinsonism, show prolonged saccadic latencies and 
increased error rates on voluntary saccades compared to pre-symptomatic 
gene carriers for HD or controls (Blekher et al., 2006, Golding et al., 2006). 
In addition, patients with AD, PDD and DLB show longer fixation durations, 
increased saccadic latencies and increased saccadic errors (Lueck et al., 
2000, Ogrocki et al., 2000, Abel et al., 2002, Mosimann et al., 2005) with 
oculomotor reaction times increasing in line with dementia severity 
(Pirozzolo and Hansch, 1981). It seems likely, therefore, that both reflex-
biased, exogenously-cued and cognitively-biased, endogenously-cued 
saccades are affected by the neurodegeneration of cortical and subcortical 
structures seen in PD, but that saccades requiring greater cognitive 
modulation and preparation prior to triggering are most susceptible.
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Eye movement recording during more “everyday” tasks such as facial 
emotion recognition, text- and clock-reading can provide valuable insight 
into not just the visual exploration strategies used in reaching a decision, 
but also the cognitive processes required to do so.  For example, PD 
patients demonstrate less structured visual strategies for solving the Tower 
of London task than HC and these strategies correlate closely with deficits 
in visual working memory and/or attention (Figure 11) (Hodgson et al., 
2002). Consistent with the view that visual exploration strategies can 
provide a window onto cognitive decline, subjects with AD employ a less 
structured approach to clock reading than HC, with fewer fixations within 
specified regions of interest and greater delay in time to first fixation within 
these regions of interest (Mosimann et al., 2004). Similar strategy deficits 
are also evident during reading and face emotion recognition tasks (Lueck 
et al., 2000, Ogrocki et al., 2000) and visual search strategies in HD 
become less systematic and structured as the disease progresses 
(Blekher et al., 2009). 
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Figure 11. Example of visual exploration strategies during Tower of 
London task in PD and HC. Note the distribution of fixations and 
saccades in favour of the workspace in the HC group. In contrast, PD 
patients have a more even distribution suggesting deficits in visual 
working memory and/or visual attention (Hodgson et al., 2002).
T.L. Hodgson et al. / Neuropsychologia 40 (2002) 411–422412
solutions internally is enhanced still further. In this
variant of the task, subjects are required to inspect the
problems visually and then make a single motor re-
sponse to indicate how many moves would be required
to reach an ideal solution. In this way, the one-touch
task isolates the cognitive planning component of the
test by demanding the internal plan ing of solutions
without actually executing the appropriate moves. Ear-
lier studies have established formally identical patterns
of impairme t on the on -touch task and classical TOL
tasks in patients with frontal-lobe damage and in pa-
tients with Parkinson’s disease [45,47,49] even when the
same patients are performing the two tasks [42].
Our studies in control subjects have shown that
during the solution of relatively simple 3 move prob-
lems several discrete phases are observed in ocular
scanning during the one-touch TOL task. These corre-
spond to an initial problem assessment during which
gaze is equally distributed between the Goalspace and
Workspace, followed by a solution elaboration phase
when subjects bias their gaze towards the Workspace
region. As problem complexity increases, the total time
spent fixatin the Workspace reg on increases strongly
with the total number of moves required for problem
solution. Fixations on the Workspace are also dis-
tributed in a problem dependent manner, such that
Fig. 1. Example X–Y plots for different subjects planning solutions to the same five move Tower of London problem. Half the subjects were
instructed to solve problems in the ‘Downstairs’ manner by rearranging the balls in the lower visual field to match the upper. The other group
of subjects solved problems in the converse ‘Upstairs’ manner. Although all subjects were presented with an identical set of problem pictures, the
eye movements made by the control subjects differed systematically dependent upon instruction set, with gaze being strongly biased towards the
Workspace during solution planning. In contrast, Parkinson’s disease patients failed to show this pattern regardless of whether a correct or
incorrect response was given. Fixations were classified offline according to where they landed in a 3×2 analysis grid (shown top-left panel)
superimposed over each problem picture.
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2.12 Summary – Eye movements in PD and insights into cognition
Saccadic characteristics and hence visual exploration strategies are 
influenced by a variety of factors - FEF and PEF activity, input from ventral 
and dorsal streams and fronto-parietal attentional and executive networks. 
Indeed, many of these visual, cognitive and oculomotor functions co-
localize to neuroanatomically linked cortical regions and convergent 
evidence supports the notion that the cognitive deficits seen in conditions 
such as AD, DLB and PDD interfere with “top-down” control of 
endogenous saccades. It follows that measurements of visual exploration 
behaviour might therefore provide novel insights into the contribution 
various cognitive domains make to the neuropsychological deficits evident 
in PD and PDD, and may even act as a surrogate biomarker for those at 
risk of cognitive impairment. In addition, given that visuomotor control of 
saccades is closely linked with areas vital for visuospatial and motoric 
output integration, and contributes to effective visual perception by 
foveation of salient areas of the visual environment, disruption of efficient 
visual exploration strategies in PD may promote the development of 
visuoperceptual impairment and CVH as well as contributing to motor 
complications such as visually-induced gait freezing.
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3. Methods
3.1 Case ascertainment and diagnostic procedures
The study was approved by the NHS Local Research Ethics Committee 
and all participants gave written informed consent prior to study inclusion. 
The study design was cross-sectional with Parkinson’s disease (PD) 
participants over the age of 49 years consecutively recruited from the 
Newcastle upon Tyne NHS Trust Movement Disorder service over a two 
year period (June 2008 - June 2010). In addition, patients with Parkinson’s  
disease dementia (PDD) were approached from PD nurse-specialist 
clinics making the recruitment of this cohort non-consecutive. We chose 
an age restriction in order to allow potentially closer age-matching of the 
PD and PDD groups. 
A total of 154 PD patients were approached, with 63 declining to 
participate. Non-participants were older than those agreeing to take part in 
the study (74.2 vs. 70.2 years, p = <0.001) but there was no difference in 
gender distribution. One PD participant was considered to have atypical 
clinical features and subsequent investigation revealed a normal 
DATSCAN, with evidence suggesting a diagnosis of dystonic tremor. The 
healthy, age-matched control (HC) cohort comprised spouses/partners of 
study participants and was supplemented from an existing research 
database held at the Institute for Ageing and Health, Newcastle University, 
UK. These HC participants had expressed an interest in taking part in 
clinical research projects if they fulfilled inclusion criteria and were 
approached consecutively. 
Inclusion criteria for the study were:
• diagnosis of PD or PDD
• ability to give informed consent
• suitable caregiver to provide additional information
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Exclusion criteria:
• severe dementia (MMSE <10)
• poor sitting stability − making clinical evaluations difficult for the 
patient 
• absence of a regular caregiver to provide support
• active medical psychiatric illness which could interfere with 
assessment 
• alcohol abuse, head injury, stroke, epilepsy or other major physical 
illness 
• severe visual loss
No restriction was made on medications and stable doses of 
cholinesterase inhibitors and antipsychotic medications were permitted. All 
participants fulfilled UK Brain Bank Criteria for a diagnosis of PD (Hughes 
et al., 1992) and PDD participants met MDS consensus criteria for 
dementia in Parkinson’s disease (Emre et al., 2007). These require a 
diagnosis of PD according to UK Brain Bank criteria, a dementia syndrome 
of insidious onset and slow progression, with cognitive deficits severe 
enough to impair daily life, independent of impairment ascribable to motor 
or autonomic symptoms (Tables 1 & 2). These criteria have been 
operationalised and are the current “gold standard” for the clinical 
diagnosis of PDD (Dubois et al., 2007).
Demographic data was collected via separate participant and spouse/
partner interviews in the home setting by the principal investigator (NA). 
Activities of daily living (ADL) were recorded using the Unified PD Rating 
Scale (UPDRS) part II and Bristol ADL (Bucks et al., 1996, Fahn and 
Elton, 1987). Both measures are well validated in PD and dementia, with 
higher scores reflecting greater deficits. Extrapyramidal motor features 
were assessed with the UPDRS part III and gait disturbance using the 
Freezing of Gait Questionnaire (FOG), the latter six-part questionnaire 
providing general information on gait control and functional independence 
(parts 1 & 2) and gait freezing (parts 3-6) (Giladi et al., 2000). Quality of 
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life data was collected using the Parkinson’s Disease Quality of Life 
Questionnaire (PDQ-8) (Peto et al., 1998), depressive symptoms with the 
Beck Depression Inventory (BDI) (Levin et al., 1988) and behavioural 
symptoms with the caregiver questionnaire form of the Neuropsychiatric 
Inventory (NPI-Q) (Kaufer et al., 2000). Sleep symptoms were screened 
using an abbreviated form of the Mayo Sleep Questionnaire (MSQ) 
(Boeve et al., 2002) and excessive daytime somnolence (EDS) with the 
Epworth Sleepiness Score (ESS) (Razmy et al., 2004). ESS scores were 
dichotomised around a cutoff of 9 to define a group with EDS in the study 
cohort (Brodsky et al., 2003). A positive response to two questions from 
the MSQ: “Have you ever seen the patient appear to act out his/her 
dreams while sleeping?” and “Has the patient told you about dreams of 
being chased, attacked, or that involve defending himself or herself?” has 
a sensitivity and specificity for REM sleep behaviour disorder (RBD) of 
85% and 100% respectively (Boeve et al., 2002). 
Medications were documented individually and converted to levodopa 
equivalent doses (LED) using recently published criteria to allow 
comparison between PD groups of total exposure to dopaminergic 
treatments (Tomlinson et al., 2010).
Details of visual symptoms and hallucinations were qualitatively and 
quantitatively assessed using the North East Visual Hallucination 
Inventory (NEVHI), which provides information on visual symptoms 
ranging from floaters, feelings of presence and passage, perceptual 
disturbances and complex visual hallucinations. The NEVHI also 
examines the impact that these symptoms have on patients and the 
thoughts and emotions accompanying them (Mosimann et al., 2008). 
Screening questions include:
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1. Do you feel like your eyes ever play tricks on you? Have you ever 
seen something (or things) that other people could not see? 
2. Have you ever looked at an object or pattern and something else 
suddenly appeared or disappeared? 
3. Have you ever had the feeling of the presence of somebody or 
something in the corner of your eye? 
4. Have you ever seen somebody or something, like a shadow, in the 
corner of your eye? 
5. Have you ever had any other visual experiences?
6. Have you experienced seeing dots, flashes, patterns of light or 
similar that were not there? 
Additional visual symptoms were elicited using a semi-structured interview 
with questions derived from the 25-item National Eye Institute Visual 
Function Questionnaire (Mangione et al., 2001) in combination with 
questions on spatial and motor symptoms used in an earlier study of visual 
symptoms in PD (Davidsdottir et al., 2005).
3.2 Neuropsychological assessment
Global cognition was assessed using the Folstein Mini-Mental State 
Examination (MMSE) (Folstein et al., 1975) and the Mattis Dementia 
Rating Scale (DRS-2) (Brown et al., 1999). The DRS-2 is a widely used 
assessment tool taking around 20-25 minutes to complete and consists of 
five subscales, providing information on cognitive domains such as 
attention (ATT), initiation/perseveration (IP), construction (CONST), 
conceptualization (CONCEPT) and memory (MEM). The scores of the five 
sub-scales contribute to a total DRS-2 score and normative data is 
available such that scores can be adjusted for age and, in the case of total 
DRS-2 score, education (Age and education adjusted MOANS sub-scale 
score (AEMSS)). The CONST sub-scale score of the DRS 2 has a 
relatively low ceiling effect and has been shown to be insensitive to subtle 
changes of visuo-constructional impairment in PD. Additional tests have 
been recommended when using the DRS 2 to screen this cognitive 
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domain for problems in PD and, for this reason, clock drawing was 
included as part of the cognitive assessment (Brown et al., 1999). Clock 
drawing was scored “out of 5” using the Shulman method (5=perfect; 
4=minor visuospatial errors; 3= inaccurate representation of time when 
visuospatial organisation is only slightly impaired; 2= moderate 
visuospatial disorganisation such that time depiction is impossible; 1= 
severe level of disorganisation; 0= no reasonable representation of a 
clock) (Brodaty and Moore, 1997, Shulman, 2000, Cahn-Weiner et al., 
2003).
In order to address the potential impact of cognitive heterogeneity on the 
eye-tracking measures of the non-demented PD cohort, we defined two 
sub-groups: cognitively normal (PD-CNL) and possible mild cognitive 
impairment (PD-pMCI). In the absence of published criteria for MCI in PD, 
we used both a global cognitive score (AEMSS) and domain sub-scale 
scores (ATT, I/P, CONST, CONCEPT, MEM, CDT) to identify possible MCI. 
An AEMSS score 1.5 SD below the HC group mean or 2 or more domain 
sub-scale scores 1.5 SD below HC group mean values was taken as 
evidence of PD-pMCI. This approach split the PD group into 37 PD-CNL 
patients (58%) and 27 with possible PD-MCI (42%). 
3.3 Ophthalmological assessment
Ophthalmological assessment included measurement of logMAR visual 
acuity (VA) and contrast sensitivity (CS – Mars letter CS chart, Mars 
Perceptrix™). The former presents rows containing 5 letter optotypes, 
each assigned an individual logarithmic value according to the angle of 
resolution at the retinal level. This allows conversion of a geometric letter 
sequence to a linear scale, providing a more robust measure of VA than 
that afforded by a Snellen chart. Lower logMAR scores reflect better VA, 
with a logMAR score of 0.0 equivalent to 6/6. Testing distance was 4 
metres and both uncorrected (UCVA) and “best at presentation” (BAPVA) 
visual acuity was documented.
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The Mars CS chart consists of rows of letters with sequentially reducing 
contrast presented under standarised lighting conditions. Viewing distance 
was 40 centimetres with the head stabilised and normal near refractive 
correction utilised. CS threshold is reached when letters can no longer be 
resolved from the background. Higher scores on CS testing reflect better 
performance. 
Intraocular pressure (IOP) was recorded with an IcareTM automated 
tonometer. Cataract severity was graded by two independent assessors 
(NA - neurologist, MC - ophthalmologist) on a pragmatic scale for cortical, 
nuclear and posterior capsular lens opacity (0 = absent; 1+ = mild; 2+ = 
moderate; 3+ = marked; 4+ = severe) with consensus sought between both 
assessors in the event of discrepancy.  Slit lamp examination was used to 
document structural corneal, retinal or optic nerve pathology. Visual fields 
were examined by confrontation. Saccadic, pursuit and vergence eye 
movements were assessed clinically and cover testing performed to detect 
ocular misalignments.
3.4 OCT
A consecutively selected proportion of study participants were approached 
to participate in a sub-study examining retinal morphology in PD using 
Optical Coherence Tomography (OCT) - a technique for obtaining cross-
sectional images of the retina in a non-invasive fashion. “Time-domain” 
methods function effectively as ‘optical ultrasound’, projecting a near-
infrared light beam onto the retina and comparing the echo time delays of 
light reflected from the retina with that returned from a reference mirror. 
This reflectivity profile, called an axial depth scan (A-scan), contains 
information about the spatial dimensions and location of structures within 
the item of interest. A cross-sectional tomograph (B-scan) is then created 
by combining a series of these A-scans, providing a composite image with 
an axial resolution of 10 microns. More recently, “frequency-domain” OCT 
has become available, permitting faster signal acquisition, a better signal-
to-noise ratio and 3-dimensional image reconstruction with an axial spatial 
resolution of 3-5 microns. OCT is capable of assessing the thickness of 
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retinal nerve fibre layers (RNFL) around the optic nerve head, thus 
providing a measure of the integrity of the retinal ganglion cell axons as 
they exit the retina, as well as providing information of macular 
morphology in the central retina.
Measures of peri-papillary RNFL, macular thickness and volume were 
made using a commercially available Ocular Coherence Tomography 
(OCT) device (Zeiss Stratus 3000TM) following pupillary dilation. 
Throughout scanning, participants kept the eye constantly fixed on an 
internal target provided by the OCT machine. Scan quality was assessed 
by examining the signal strength and confidence limits generated by the 
automated software analysis. OCT scans with a signal strength < 5/10 or 
with a macular protocol confidence limit >20 microns were reviewed for 
“best fit” automated contour lines. Scans with poor fit contour lines or 
missing data were excluded from analysis (Figure 12). 
The fast RNFL scan protocol consisted of a single 360° circular scan with 
a diameter of 3.4 mm centered on the optic disc, containing 256 A-scans 
taken in a single session of 1.92 seconds. Peri-papillary RNFL thickness 
parameters were automatically calculated by OCT 3000 unit software and 
included: average thickness (360° measurement), temporal quadrant 
thickness (226–315°), superior quadrant thickness (316–45°), nasal 
quadrant thickness (46–135°), and inferior quadrant thickness (136–225°). 
The fast macula scan protocol consisted of 6 mm radial line scans 
centered on the macula, each containing 128 A-scans taken in a single 
session of 1.92 seconds. Six sets of intersecting and equally spaced 
scans were obtained each crossing the central fovea. The automated 
analysis program presents both mean foveal thickness and total macular 
volume in a 6.00 mm macular map. 
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Figure 12. Example of macular and RNFL OCT scans. Scan quality 
was judged by three parameters: 1) signal strength 2) automated 
foveal thickness confidence limit and 3) “best fit” contour lines.
3.5 Neurophysiological assessment
A consecutively selected proportion of study participants were approached 
to participate in a sub-study examining the retinal and early visual cortical 
responses to visual stimuli in PD. The stimulus used was an alternating 
checkerboard pattern, which reverses its local luminance while keeping 
average luminance constant. Luminance signals cancel out, leaving non-
linearities that have been shown to originate mainly in the retinal ganglion 
cell (RGC) layers of the retina. This massed RGC response forms the 
electrical basis of the pattern electroretinogram (PERG).
PERG and visual-evoked potential (VEP) recordings were made to stimuli 
designed to bias responses from two separate retino-geniculo-striate 
!
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pathways – the magnocellular (M) and parvocellular (P) systems. Larger 
RGCs, more prominent in the peripheral retina, and known as 
magnocellular RGCs respond optimally to stimuli with high temporal and 
low spatial frequencies, particularly when contrast levels are low. 
Parvocellular RGCs, most prominent in the central retina, respond most 
strongly to stimuli with low temporal and high spatial frequencies, 
particularly when contrast is high (Ferrera et al., 1992, Ferrera et al., 1994, 
Malpeli et al., 1996, Maunsell et al., 1990, Merigan and Maunsell, 1990, 
Skottun, 2000). As such, M-pathways are specialised for motion 
perception at low contrast and P-pathways for fine feature and colour 
perception in the central retina. This segregation of information is 
maintained in early visual cortex but, beyond V1, M- and P-pathways 
intermingle such that, for example, motion information is also delivered 
into the ventral stream (Ferrera et al., 1994, Nealey and Maunsell, 1994, 
Merigan et al., 1991).
3.5.1 Stimuli
The stimulus set-up for electrophysiological testing is presented 
schematically in Figure 13. A variety of achromatic and chromatic stimuli 
have previously been employed in an attempt to probe M- and P- 
pathways in healthy controls (Tobimatsu et al., 1995) and disease 
populations such as schizophrenia (Butler et al., 2005) and PD (Silva et 
al., 2005). It has been argued that by varying the spatial frequency and 
contrast of achromatic stimuli (checks or gratings) it is possible to bias 
responses from the M- and P-pathways. Using such methods, a 
predominant magnocellular pathway deficit has been postulated in 
schizophrenia, although the functional implications of this in terms of visual 
and cognitive impairment remain unclear (Butler et al., 2007, Slaghuis and 
Bishop, 2001). Problems have arisen in interpreting findings from many of 
the studies in schizophrenia however, as stimuli may have cross-activated 
both pathways due to shared spatio-temporal and contrast properties 
(Blakemore and Vital-Durand, 1986, Levitt et al., 2001, Skottun and 
Skoyles, 2007a, Skottun and Skoyles, 2007b). 
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Figure 13. PERG/VEP stimuli and experimental set-up. Small check 
size, high contrast stimulus to bias parvocellular response from the 
central retina and large check size, low contrast stimulus to bias 
magnocellular response from peripheral retina. Below is the typical 
set-up for gathering the experimental data.
3.5.2 PERG
The PERG is a retinal bio-potential evoked by an alternating pattern - in 
our case a checkerboard - and reflects the massed response of the RGCs 
to an isoluminant stimulus. Transient PERG responses are complete 
before the next pattern reversal occurs, at least for low temporal 
frequencies, and allow separation of the PERG components into troughs 
(N35, N95) and a single, positive peak (P50) (Figure 14). For the purpose 
of this study, we have measured the amplitude (µV) of the P50 and N95 
components as well as their respective implicit times (msecs). Higher 
temporal frequencies lead to an overlapping of successive waveforms and 
the generation of a “steady-state” PERG. The steady-state PERG 
(ssPERG) waveform is roughly sinusoidal and interpretation requires 
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Fourier analysis of the second harmonic, giving an amplitude and phase 
shift measurement relative to the stimulus (Figure 14).
Typically, PERG responses are small in comparison to flash-evoked 
potentials and are critically dependent on stimulus characteristics. PERGs 
are difficult to record with low stimulus luminance and cannot be elicited 
from very low contrast stimuli. The PERG P50 amplitude increases with 
luminance contrast between the black and white checks and a maximal 
contrast as close as possible to 100% is desired. For the transient PERG, 
recordings require a temporal frequency of 6 rev/sec (3Hz) or less 
whereas for the ssPERG, a reversal rate of 15 rev/sec (7.5Hz) 
demonstrates the best correlation to check size. In addition, higher 
stimulus temporal frequencies are not recommended when recording the 
PERG due to a decreasing signal:noise ratio when reversal rates become 
higher than 18 rev/s (8Hz) (Holder et al., 2007).
3.5.3 VEP
Visual-evoked potentials (VEP) are visually evoked electrophysiological 
signals extracted from the electroencephalographic activity in the visual 
cortex. As such, they reflect a composite response of subcortical 
structures (retina, optic nerve, LGN, optic radiation) and the visual cortex 
itself. VEPs can be elicited by flashes of light as well as alternating 
patterns and it is the pattern-reversal VEP (PVEP) that we have utilised in 
this study.
As previously mentioned for PERG recordings, the waveform of a VEP 
depends on the temporal frequency of the stimulus. At low frequencies, a 
transient PVEP is recorded and as temporal frequency rises, the 
waveform becomes sinusoidal and is termed “steady state”. The transient 
pVEP waveform consists of two negative troughs (N75 and N135) and a 
single positive peak (P100). For the purpose of our study, we measured 
both the right, left and midline occipital P100 amplitude (µV) and latency 
(msec) (Figure 14).
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Whilst the responses of both PERG and PVEP increase with increasing 
stimulus field size, the amplitude of the PVEP is more macular-dependent. 
Whereas pattern contrast is crucial in driving a measurable PERG 
response, contrast has little effect on the PVEP response for contrasts 
above 50%.
Figure 14. Stylised PERG and VEP waveforms. a) Typical transient 
PERG waveform allowing measurement of P50 and N95 amplitude 
and implicit time; b) typical transient pVEP response – the amplitude 
of the waveform is considerably greater than that generated by the 
PERG; c) steady-state PERG – Fourier analysis of the waveform 
allows dissection of the significant second harmonic from 
background noise. 
!"#"
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Figure 15. PERG and VEP recordings. Examples of the transient and 
steady-state data collection. Note the automated Fourier analysis of 
the steady-state recording (below).
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3.5.4 Stimulus characteristics
The visual stimuli were created on a Cambridge Research System, Visage 
graphics module and presented on a high-resolution widescreen plasma 
display. Check size, contrast and frequency of temporal modulation were 
varied to bias responses from M- and P-pathways. 
Examining ERG and VEP responses in PD poses some practical 
problems, which necessarily had a bearing on the choice of the stimuli 
chosen. Both PD and HC participants were elderly with a range of co-
morbid ocular and retinal disease (e.g. cataract, macular degeneration). In 
addition, to minimize the impact of tremor artifact, mobility problems and 
fatigue during assessment, the study protocol was designed to last no 
more than 30 minutes and require only one hospital visit. This 
necessitated the simultaneous recording of ERG and VEP responses, 
impacting on the spatio-temporal frequency, contrast and luminance of 
checkerboard stimuli in the study. We chose wide-screen stimulus 
presentation to minimize the effect of loss of central fixation on data 
acquisition and monitored attention to the task using a video camera. In 
addition, the larger stimulus field provided more reliable peripheral retinal 
stimulation and increased the overall amplitude of data recordings. 
Medications were not withheld on the day of assessment.
The properties of both stimuli used in the protocol are summarized below:
 M-pathway – check size: 30o; temporal frequency: 7.5 Hz (15 
reversals/sec); luminance: 40 cd-s/m2/sec; contrast: 40%
 P-pathway – check size: 0.8o; temporal frequency: 2Hz (4 revs/
sec); luminance: 80 cd-s/m2/sec; contrast: 98%
Although M-biased pathways should ideally be driven with very high 
temporal frequencies at very low contrasts, the requirement for 
simultaneous recording of the PERG and PVEP led to higher contrast and 
lower frequencies being employed in the M-pathway condition.
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What evidence, therefore, do we have that our M- and P-biased 
protocols achieved some separation of the two key pathways under 
investigation?
In the study, HC were tested with additional protocols to examine macular 
and peripheral retinal contributions to the PERG. We reasoned that if the 
M-pathway is largely dependent on a peripheral retinal contribution, then, 
under M-biased conditions, patching the central 15o of the stimulus screen 
would make little difference to the measured responses, whereas patching 
all but the central 15o of the screen would effectively abolish the PERG 
response. Similarly, in the P-biased condition, patching the central 15o of 
the field should substantially reduce the PERG response whereas 
patching of all but the central 15o of the screen should have little impact on 
PERG response. 
Under M-biased conditions, in almost all cases, there was no reduction in 
P50 amplitude when the central 15o patch was used. When the stimulus 
field size was reduced to 15o, the PERG was virtually non-detectable 
above the background noise. We can therefore infer that no contributions 
from the central 15o of retina contributed to the pattern ERG obtained from 
the M-biased protocol i.e. the response was derived from peripheral retina 
beyond the central 15o either side of fixation. In contrast, repeating these 
protocols for the P-biased stimuli, P50 amplitudes in both full-field and 
central 15o only conditions were similar, demonstrating that the bulk of the 
P-biased response derived from the central 15o of the retina.
3.5.5 Electrophysiological recordings
The PERG was recorded in each eye by placing thin gold-plated foil 
electrodes into the conjunctival sac near the lower limbus. Reference 
electrodes were attached to the temples and the earlobes were grounded. 
VEPs were recorded from the scalp at right, midline and left occipital 
regions. Electrode impedance was measured and was not allowed to 
exceed 5kΩ and balanced. Signals were recorded using a Roland 
electrodiagnostic acquisition system with external triggers.
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Participants fixated a central LED and binocularly viewed the patterns, 
with natural pupils, while ERGs and VEPs were simultaneously recorded. 
The viewing distance was constant at 50 cm. Normal refractive correction 
was worn where required, but participants were not formally refracted prior 
to ERG and VEP recording. Stimuli were presented for bursts of 15 
seconds with 15 second pauses until a minimum of 150 repetitions had 
been achieved per condition. This was to minimise blink artifact and 
ensure attention was effectively directed to the central fixation point of the 
plasma display.
3.6 Eye tracking assessment
Participants viewed a range of visual stimuli (angle matching, clock 
matching, inverted clock matching, shape position and overlapping figure 
tasks) as part of an eye tracking battery (Figure 16). Overlapping figures, 
first described by Ghent and Poppelreuter (Ghent, 1956, Poppelreuter, 
1917) and formalized by De Renzi et al. (1969) have been used in 
previous studies of PDD and DLB (Mori et al., 2000, Mosimann et al., 
2004b) to provide information on impairment of object-form perception. 
Given that the overlapping figures and comparator images are identifiable 
and complex objects, we hypothesised that impairment on this task would 
reflect “ventral” stream dysfunction. In our experimental paradigm, 
participants were required to study a central composite image of animals, 
clothing, utensils or fruit and choose which one of four individual 
comparators underneath was present centrally. In order to compare visual 
exploration across different tasks within the battery we standarised the 
screen layout for all conditions to present a central stimulus and four 
comparator images.
Impairment in the judgment of line orientation has been demonstrated in 
patients with right parietal lobe damage (Benton et al., 1978) and is also 
impaired in PD and PDD (Montse et al., 2001, Mosimann et al., 2004b). 
Due to screen layout constraints we modified Benton’s original task, 
requiring participants to match a centrally presented angle to one of four 
comparator angles underneath. We hypothesised that this task would 
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have a greater spatial than perceptual bias, with performance linked to the 
integrity of the “dorsal” stream. 
We also introduced a clock-matching task to the eye tracking battery. 
Clock reading is an over-learned perceptual task that is impaired both in 
AD, DLB and patients with parietal lobe lesions (Schmidtke and Olbrich, 
2007). fMRI studies in AD suggest that the lingual and superior temporal 
lobe, cuneus and precuneus are involved in clock reading (Leyhe et al., 
2009, Saur et al., 2010). Visual exploration of clock faces is impaired in AD 
with patients making fewer fixations at the ends of the clock hands and 
taking longer to explore the clock face (Mosimann et al., 2004a). Although 
clock drawing is frequently impaired in PDD (Cahn-Weiner et al., 2003), 
clock reading has not been studied in PD and PDD. For this reason, we 
included a clock task requiring participants to perform both clock reading 
and clock matching. An inverted clock task was also included in the test 
battery, introducing a greater spatial component to the clock task by 
requiring participants to mentally rotate the comparators by 180o prior to 
giving their response (Amick et al., 2006).
Finally, we included a shape position in the battery. This task incorporated 
elements of the position discrimination task of Warrington and James 
(Warrington and James, 1988) and the spatial location task of MacQuarrie 
(MacQuarrie, 1953) previously found to be impaired in PDD and DLB (Mori 
et al., 2000, Mosimann et al., 2004b). In addition to having a visuospatial 
bias, this task also depends upon the recognition of individual elements of 
the pattern (triangles, squares) as well as the relationship of the 
component parts to each other.
Stimuli were presented on a 20” TFT computer monitor enabled with an 
EyeLink 1000 remote eye tracker with a temporal resolution of 1000 Hz, 
spatial resolution of 0.05o and average accuracy of 0.5o (SR Research 
Ltd., Mississauga, Ontario, Canada). Participants were positioned 80 cm 
from the stimulus monitor and wore normal refractive correction. In the 
event of spectacle lenses precluding acquisition of data, participants were 
auto-refracted and wore an appropriate pair of eye tracker-compatible 
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goggles incorporating a near correction instead. All participants were able 
to resolve the stimuli presented during the training phase of the 
experiment. Viewing was binocular, unless diplopia was encountered 
during testing (when one eye was patched). All recordings were 
monocular. A chin rest and forehead bar maintained the participant’s head 
position and distance from the computer monitor. Measurements of eye 
movements were conducted in a dimly lit room and online viewing of data 
collection was undertaken behind a blackout curtain.
The eye tracker was calibrated for each participant before the experiment 
began. Calibration consisted of having the participant fixate on nine 
calibration points (3 points each across the top, middle and bottom of the 
screen), one at a time. Re-calibration after each image in the eye tracking 
battery was achieved by virtue of required fixation on a central target 
before the next stimulus could be presented. Stimuli were presented in 
blocks - angle-clock-inverted clock; shape position; overlapping figure – in 
a pseudorandom fashion. Each block began with a previously viewed 
practice image followed by 16 trial images presented in one of six 
randomised orders. A total of 80 images were viewed for each participant 
and the battery took 10-15 minutes to complete. Participants were 
encouraged to take a break if required. Screen layout was identical for 
each stimulus with a central stimulus and four comparators arrayed 
beneath. All comparators appeared equally for each category to ensure no 
bias emerged for any particular choice option. Participants gave a verbal 
response (“1”,”2”,”3” or “4”) at which point the investigator (NA) activated a 
game pad keypress and the stimulus moved on to a central fixation point 
prior to the next stimulus presentation.
The EyeLink 1000 system incorporates a unique on-line parsing system 
which analyzes eye position data into meaningful events and states 
(saccades, fixations, and blinks). For each data sample, the parser 
computes instantaneous velocity and acceleration and compares these to 
the velocity and acceleration thresholds. These thresholds are 30o per 
second for velocity and 8000o per sec2 for acceleration. If either is above 
threshold, a saccade signal is generated. The parser will check that the 
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saccade signal is on or off for a critical time before deciding that a saccade 
has begun or ended. This check does not affect the recorded time of the 
saccade start or end, but adds some delay to the real-time events sent 
through the link. Fixations are defined as anything that is not a saccade or 
a blink.
In addition to general characteristics of response, such as response time 
and average duration of fixations, the screen was sub-divided into interest 
areas (IA) such as the central stimulus, four comparator stimuli and 
correct/incorrect IAs. Analysis of the distribution of fixations in correct and 
incorrect IAs, the first IA explored and the number of times a given IA is re-
visited during exploration reveal the strategy employed by participants to 
solve the visual task presented to them. We chose three measures to 
define visual exploration strategy:
1) Time to first fixation in the correct IA
2) Run count (RC) into the central stimulus
3) RC ratio
The RC ratio is generated from the mean RC into the 3 incorrect IAs vs. 
the RC into the correct IA. As such, low RC ratios are likely to reflect a 
strategy where the correct IA is explored in preference to incorrect regions 
and a RC ratio of 0.5 reflects a strategy where exploration of the correct 
IA is twice as frequent as that of the incorrect IAs. High RC ratios suggest 
either a less structured strategy, where incorrect IAs are re-visited 
repeatedly, or a cautious approach aimed at minimising errors.
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Figure 16. Battery of tests employed in the eye tracking experiment. 
Angle, clock and inverted clock tasks were always presented as a 
hierarchical block, mixed randomly with shape position and 
overlapping figure blocks. Participants were randomised to one of 6 
protocols with a different external “block” order (i.e. shape position – 
[angle-clock-inverted clock] – overlapping figure). Each block began 
with a practice image to ensure participants understood the task, 
followed by 16 trial images presented in a pseudo-random order. 
Visual perception battery. Stimuli were presented in blocks - angle-clock-inverted 
clock; shape position; overlapping figure – in a pseudorandom fashion. Each 
block began with a previously viewed practice image followed by 16 trial images 
presented in one of six randomized orders.
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Figure 17. Example of fixation/saccade map for a single study 
participant. Interest area analysis provides insight into the visual 
exploration strategy employed for each image viewed.
Eye tracking outcome variables
1. Overall response time (msec)
2. Average fixation duration (msec)
3. Time to first correct fixation - time (msec) from stimulus onset to first fixation in the 
correct interest area (IA) 
4. Central run count (RC) - Number of times the central stimulus is entered during a 
single image trial
5. RC ratio - ratio of RC into incorrect IA : RC into correct IA; reflects the requirement 
to check correct and incorrect comparators against each other
correct 
interest 
area
incorrect 
interest 
area
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3.7 Statistics
Data were analysed using the JMP 8 statistical package (SAS Institute 
Inc). The distribution of data was examined for normality (Shapiro-Wilk 
test). Means and standard deviations (SD) were calculated. Normally 
distributed data were analysed with parametric tests (Independent sample 
t-tests, ANOVA) and non-normally distributed data with non-parametric 
tests (Wilcoxon Rank Sum, Kruskal-Wallis). For comparison between more 
than two groups, post-hoc tests were employed only if the omnibus 
statistical test result was significant. Pearson chi-square test was 
employed for comparison of frequencies and Fisher’s exact-Test utilised 
when expected frequency in either group was < 5. All reported p values 
are two-tailed for parametric tests. Wilcoxon Rank Sum test results are 
presented using normal approximation and a p value of <0.05 was 
considered significant. Significance values are reported to 3 decimal 
places and values less than 0.001 abbreviated to p = <0.001. Non-
significant results are highlighted with the suffix ‘ns’. Statistical techniques 
specific to various chapters will be included in the appropriate sections. 
Error bars on graphs reflect 95% confidence intervals.
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4. Visual symptoms in Parkinson’s disease and PD 
dementia
4.1 Background
Visual symptoms are common in Parkinson’s disease (PD) and include 
difficulty reading and diplopia (Biousse et al., 2004, Chaudhuri et al., 
2006), illusory misperception, feelings of presence and passage and CVH 
(Fenelon et al., 2000). Although presence, passage and illusions are often 
classified as hallucinations, similar experiences are reported in the general 
population (Ohayon, 2000), in patients with brainstem disorders (Benke, 
2006), and in narcolepsy (Manford and Andermann, 1998). Such 
similarities may help explain the putative link between sleep disorders, 
brainstem dysfunction and hallucinations in PD (Pacchetti et al., 2005) and 
why minor hallucinatory experiences do not have the same predictive 
value in terms of the development of PDD (Llebaria et al., 2010). The 
cause of diplopia in PD is unclear and no studies have addressed this 
symptom explicitly.
Visual acuity (VA) (Matsui et al., 2006), contrast sensitivity (CS) (Bodis-
Wollner et al., 1987, Uc et al., 2005), colour perception (Price et al., 1992) 
and motion perception (Castelo-Branco et al., 2008) are all impaired in 
PD, with VA and CS identified as risk factors for CVH (Diederich et al., 
1998, Matsui et al., 2006). A potential criticism of some studies of visual 
function in PD is a failure to take into account the cognitive requirements 
for completing tests of VA and CS accurately. Whilst CVH have been 
closely studied in the context of cognitive decline in PD, the association 
between cognition and other visual phenomena such as illusions, 
presence and passage has not been specifically addressed.
With this in mind, we set out to characterise the range of visual symptoms 
seen in PD and PDD and assess their correlations with ocular pathology 
and cognition exploring the following hypotheses: First, that visual 
symptoms are more common in PD than healthy controls and will be more 
common still in PDD. Second, that cognitive impairment may contribute to 
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reduced VA and CS in PD. Finally, we hypothesized that CVH, presence, 
passage and illusions may not share a common aetiology and, as such, 
should be analysed individually in studies of visual symptoms in PD.
4.2 Specific Methods
To compare informant-to-patient rater reliability on the NEVHI, we used the 
Kappa measure of agreement and the McNemar test for significance (here 
the null hypothesis proposes that both patient and informant ratings are 
equivalent and we sought a p value > 0.05).
Cortical and nuclear lens opacities were graded on a scale from 0-4, with 
grades 2-3 denoting moderate/marked cataract. None of the cohort had 
severe cataract (grade 4). Results were dichotomised into a group with 
“none or mild” and a group with “moderate or marked” cataract.
To explore factors predictive of VA and CS in the whole PD cohort (n = 90), 
stepwise linear regression was conducted using a standard least squares 
approach with backward elimination. The following variables were 
submitted into the model:  Age, PD duration, UPDRS III, AEMSS, MMSE, 
retinal abnormality, cortical and nuclear cataract severity. Stepwise logistic 
regression with backward elimination was utilised to identify predictors for 
diplopia. We entered basic demographic factors (age, disease duration, 
UPDRS III, LED), presence of cognitive decline (diagnosis of dementia, 
AEMSS, MMSE), severity of somnolence (ESS) and oculomotor 
abnormalities (abnormal ocular alignment, hypometric saccades and 
reduced convergence amplitude) into our model. 
We also conducted stepwise logistic regression after having dichotomised 
the PD group into those with CVH and those without (CVH+/CVH-). 
Variables entered into the model included basic demographic factors (age, 
disease duration, UPDRS III, LED, agonist use), neuropsychiatric features 
(BDI score, NPI symptom score), presence of sleep disorders, 
somnolence (RBD, EDS) or visual impairment (BAPVA, CS) and presence 
of cognitive decline (diagnosis of dementia, AEMSS, MMSE). In addition, 
we also separated the PD group into those with and without illusory 
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misperceptions (illusion+/illusion-), feelings of presence (presence+/
presence-) and sensations of passage (passage+/passage-), performing 
regression analyses in a similar manner to that outlined above.
4.3 Results
4.3.1 Demographic characteristics
Total recruitment figures were: PD n = 64; PDD n = 26; HC n = 32 and 
basic group demographics are shown in Table 3. All three groups were 
well matched for age (ANOVA (df 2, n = 122) = 0.66, p = 0.517; ns) and 
education (Kruskal-Wallis (df 2, n = 122) = 2.06, p = 0.357; ns). Males 
were over represented in the PDD group compared to HC (Fisher’s exact 
(df 1, n = 58) = 8.85, p = 0.003) and although there was a similar trend in 
gender difference between PD and PDD groups this did not reach 
significance (Fisher’s exact (df 1, n = 90) = 3.2, p = 0.080, ns). As 
expected, PD duration was longer for PDD than PD patients (t-Test (df 88, 
n = 90) = 2.33, p = 0.022) and estimated dementia duration was 1.8 years 
(range 0-3 years, where 0 = newly diagnosed at study entry). The disease 
groups differed in their total dopaminergic medication dosage (expressed 
as LED), with the PD group taking the lowest daily dose (t-Test (df 88, n = 
90) = 2.23, p = 0.028). PD patients were more likely to be using alternative 
dopaminergic agents such as monoamine oxidase inhibitors (Fisher’s 
exact (df 1, n = 90) = 9.06, p = 0.003), and dopamine agonists (Fisher’s 
exact (df 1, n = 90) = 13.2, p = <0.001) whereas PDD patients were 
predominantly treated with levodopa monotherapy. As expected PDD 
participants were taking more anti-psychotic and cholinesterase inhibitor 
medications than other groups.
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Table 3. Basic group demographics of the visual symptoms study.
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HC
n=32
PD
n=64
PDD
n=26 p value
Age (years) 72.2 (7.7) 70.2 (8.1) 71.2 (6.5) ‡0.517(ns)
Education (years) 11.6 (2.6) 12.2 (3.2) 11.3 (3.0) *0.357 (ns)
Gender (%Male) 47 66 84
** 0.122a (ns), 0.003b, 
0.080c (ns)
PD duration (years) n/a 8.4 (5.7) 11.5 (5.8) §0.022
Estimated dementia 
duration (years)
n/a n/a 1.8 (0.9)
Total LED n/a 668 (432) 893 (436) †0.028
Agonist use (%) n/a 48 8 **<0.001
MAOI use (%) n/a 34 4 **0.003
COMT-I use (%) n/a 31 36 **0.623 (ns)
ChE inhibitor use (%) n/a 2 42 **<0.001 
Antipsychotic use (%) n/a 2 23 **<0.001
UPDRS II n/a 13.2 (6.1) 22.0 (5.9) §<0.001
UPDRS III n/a 23.1 (10.0) 35.4 (14.7) §<0.001
FOG n/a 6.0 (5.0) 11.0 (6.9) §0.003
BADLS n/a 4.1 (5.5) 18.4 (9.6) §<0.001
PDQ-8 n/a 25.6 (18.6) 42.3 (17.9) §<0.001
NPI Q (symptom scale) n/a 2.9 (3.8) 9.4 (4.6) §<0.001
NPI Q (carers distress) n/a 2.3 (3.1) 10.8 (7.4) §<0.001
BDI 4.4 (4.6) 10.7 (8.3) 15.6 (6.5) §<0.001a,b, <0.001c
ESS 3.9 (2.7) 9.0 (5.6) 11.8 (4.5) §<0.001a,b, 0.038c
EDS (%) 3 46 77 **<0.001a,b, 0.010c
RBD (%) 4 36 58 **<0.001a,b, 0.094c (ns)
Values expressed as means (+/- SD) (unless otherwise stated)
Statistical tests: ‡ANOVA; † t Test; *Kruskal-Wallis; §Wilcoxon rank sum; **Pearson χ2 +/- Fisherʼs exact 
test where groups frequency < 5  
(ns = non-significant)
a = HC vs PD; b = HC vs PDD; c = PD vs PDD
LED - Levodopa equivalent dose; MAOI - Monoamine oxidase inhibitor; COMT-I - Catechol-O-
methyl transferase inhibitor; ChE - Cholinesterase UPDRS - Unified Parkinsonʼs Disease Rating 
Scale; FOG - Freezing of Gait; BADLS - Bristol Activities of Daily Living Scale; PDQ-8 = Parkinsonʼs 
Disease Quality of Life 8; NPI-Q; Neuropsychiatric Inventory- Questionnaire form; BDI - Beck 
Depression Inventory; ESS - Epworth Sleepiness Scale; EDS - Excessive Daytime Somnolence; 
Mayo RBD-Q - abbreviated version of Mayo REM sleep Behaviour Disorder Questionnaire.
There were differences between HC and both disease groups in measures 
of depression (BDI : Wilcoxon rank sum HC = 32, PD = 63, Z = 4.00, p = 
<0.001; HC = 32, PDD = 26, Z = 5.62, p = <0.001), excessive daytime 
somnolence (EDS: HC vs. PD Fisher’s exact (df 1, n = 93) = 17.9, p = 
<0.001; HC vs. PDD (df 1, n = 58) = 33.8, p = <0.001) and REM sleep 
behaviour disorder (RBD: HC vs. PD Fisher’s exact (df 1, n = 84) = 11.0, p 
= <0.001; HC vs. PDD (df 1, n = 55) = 19.6, p = <0.001). Comparison 
between PD and PDD groups revealed significant differences in motor 
function (UPDRS III: Wilcoxon rank sum PD = 64, PDD = 25, Z = 3.59, p = 
<0.001; FOG: PD = 64, PDD = 26, Z = 3.01, p = 0.003), activities of daily 
living (UPDRS II: Wilcoxon rank sum PD = 64, PDD = 26, Z = 5.08, p = 
<0.001; BADLS: PD = 59, PDD = 25, Z = 6.08, p = <0.001), quality of life 
(PDQ-8: Wilcoxon rank sum PD = 63, PDD = 26, Z = 3.76, p = <0.001) 
and neuropsychiatric burden (NPI Q symptom: Wilcoxon rank sum PD = 
60, PDD = 25, Z = 5.59, p = <0.001; Carer distress scale: PD = 64, PDD = 
25, Z = 5.81, p = <0.001; BDI : PD = 63, PDD = 26, Z = 3.49, p = <0.001). 
PDD patients scored higher than PD patients on the ESS (Wilcoxon rank 
sum PD = 61, PDD = 26, Z = 2.07, p = 0.038) and when this variable was 
dichotomised such that an ESS score > 9 reflected excessive daytime 
somnolence (EDS), 46% of PD and 77% of PDD patients fulfilled criteria 
for EDS (Fisher’s exact (df 1, n = 87) = 7.1, p = 0.010). There was no 
significant difference between disease groups for frequency of RBD 
(Fisher’s exact (df 1, n = 81) = 3.3, p = 0.094, ns).
4.3.2 Cognitive features
As expected, PDD patients scored significantly lower than PD or HC 
patients on both tests of global cognitive function (MMSE, AEMSS) and all 
cognitive domain sub-scale scores (Table 4). Mean MMSE scores were 
29.5 and 28.9 for the HC and PD groups, respectively, demonstrating a 
small but significant difference (Wilcoxon rank sum HC 32, PD = 64, Z = 
2.34, p = 0.019). The AEMSS revealed more striking differences between 
HC and PD groups (Wilcoxon rank sum HC 32, PD = 64, Z = 3.05, p = 
0.002). PD and HC group comparisons on DRS 2 sub-scale scores 
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revealed differences in measures of IP (Wilcoxon rank sum HC 32, PD = 
64, Z = 2.84, p = 0.005) and CONCEPT (Wilcoxon rank sum HC 32, PD = 
64, Z = 2.42, p = 0.016) but not in measures of ATT, CONST or MEM (ATT: 
Wilcoxon rank sum HC 32, PD = 64, Z = 1.87, p = 0.061, ns; CONST: HC 
32, PD = 64, Z = 0.99, p = 0.322, ns; MEM: HC 32, PD = 64, Z = 0.40, p = 
0.693, ns). Both PD and PDD group scores were lower than HC scores for 
the Shulman CDT (Wilcoxon rank sum HC 32, PD = 63, Z = 3.42, p = 
0.001; HC = 32, PDD = 25, Z = 6.15, p = < 0.001).
Table 4. Cognitive features of visual symptoms study group.
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HC
n=32
PD
n=64
PDD
n=26 p value
Global cognition
MMSE
29.5 (0.8) 
(range 27-30)
28.9 (1.2) 
(range 25-30)
23.6 (3.8) 
(range 13-28)
§0.019a, <0.001b, <0.001c
AEMSS
12.5 (3.0) 
(range 8-18)
10.2 (3.3) 
(range 3-17)
3.8 (1.8) 
(range 1-7)
§0.002a, <0.001b,c
Cognitive sub-scale scores
ATT 12.3 (1.3) 11.6 (1.6) 9.8 (2.4) §0.061a (ns), <0.001b,c
I/P 11.1 (1.3) 9.2 (2.9) 4.0 (2.0) §0.004a, <0.001b,c
CONST 10.0 (0.0) 9.9 (0.5) 8.1 (2.8) §0.322a (ns), <0.001b,c
CONCEPT 11.3 (1.6) 10.1 (2.3) 7.7 (3.4) §0.016a, <0.001b, 0.001c
MEM 9.7 (3.3) 9.5 (2.8) 4.6 (2.4) §0.693a (ns), <0.001b,c
CDT 4.9 (0.3) 4.5 (0.8) 2.7 (1.5) §0.001a, <0.001b,c
MMSE - Mini-mental state examination; CDT - Clock drawing test (Shulman scoring 
method); AEMSS - Age and education-adjusted MOANS scaled score (from DRS); ATT - 
Attention; I/P - Initiation/perseveration; CONST - Construction; CONCEPT - 
Conceptualization; MEM - Memory.
Values expressed as means (+/- SD)
Statistical tests: §Wilcoxon rank sum
(ns = non-significant)
a = HC vs PD; b = HC vs PDD; c = PD vs PDD
4.3.3 Visual symptoms
Visual symptoms are shown in Table 5. Those reported significantly more 
commonly in the PD and PDD groups included diplopia (HC vs. PD 
Fisher’s exact (df 1, n = 96) = 6.9, p = 0.009; HC vs. PDD (df 1, n = 58) = 
18.3, p = <0.001; PD vs. PDD (df 1, n = 90) = 6.2, p = 0.017), difficulty 
reading despite appropriate refractive correction (Fisher’s exact (df 1, n = 
96) = 4.3, p = 0.047; HC vs. PDD (df 1, n = 58) = 10.7, p = 0.001; PD vs. 
PDD (df 1, n = 90) = 3.2, p = 0.122, ns), misjudging objects when walking 
(HC vs. PD Fisher’s exact (df 1, n = 96) = 8.9, p = 0.001; HC vs. PDD (df 
1, n = 58) = 14.9, p = 0.001; PD vs. PDD (df 1, n = 90) = 2.1, p = 0.195, 
ns) and freezing in narrow spaces (Fisher’s exact (df 1, n = 96) = 8.9, p = 
0.002; HC vs. PDD (df 1, n = 58) = 18.6, p = <0.001; PD vs. PDD (df 1, n = 
90) = 4.5, p = 0.044). 
PD subjects were more likely to report CVH and passage than their HC 
counterparts (Fisher’s exact (df 1, n = 96) = 6.2, p = 0.014), but there was 
no difference in the frequency of either illusions or presence (illusions: 
Fisher’s exact (df 1, n = 96) = 0.0, p = 1.000, ns; presence:  (df 1, n = 96) 
= 1.7, p = 0.230, ns). In contrast, PDD subjects were more likely to report 
all four visual symptoms (CVH: Fisher’s exact (df 1, n = 58) = 47.0, p = 
<0.001; illusions: (df 1, n = 58) = 9.5, p = 0.003; presence: (df 1, n = 58) = 
11.2, p = 0.001; passage: (df 1, n = 58) = 22.3, p = <0.001). CVH, illusions 
and presence were more common in the dementia group than non-
demented PD subjects (CVH: Fisher’s exact (df 1, n = 90) = 40.0, p = 
<0.001; illusions: (df 1, n = 90) = 13.0, p = 0.006; presence:  (df 1, n = 90) 
= 7.1, p = 0.010), but the comparison between these groups for passage 
did not reach significance (Fisher’s exact (df 1, n = 90) = 3.2, p = 0.102, 
ns). There were no differences between the three groups in the frequency 
of floaters, simple visual hallucinations (phosphenes, brief flashes of 
lights) or migrainous aura. 
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Table 5. Visual symptoms of the study group.
If responses were restricted to the preceding month only, the pattern of 
visual symptoms changed significantly. Within this time frame, CVH rates 
between HC and PD subjects were equivalent (CVH: Fisher’s exact (df 1, 
n = 96) = 2.09, p = 0.298) while illusions, presence and passage 
experiences were significantly more common in the PD group (illusions: 
Fisher’s exact (df 1, n = 96) = 6.86, p = 0.007; presence:  (df 1, n = 96) = 
8.20, p = 0.004; passage:  (df 1, n = 96) = 13.09, p = 0.001). Again, 
although there was a trend to a higher frequency of passage in PDD (vs. 
PD), the difference was not significant (Fisher’s exact (df 1, n = 90) = 4.33, 
p = 0.060, ns). 
For CVH, informant reports closely matched those of patients in both the 
PD and PDD cohorts (PD 17% vs. PD informant 14%, κ 0.76, p = 0.317; 
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Values expressed as %
Statistical tests: **Fisherʼs exact test, *Pearson Chi square (omnibus test) (ns = non-
significant)
a = HC vs PD; b = HC vs PDD; c = PD vs PDD
%
HC
n=32
PD
n=64
PDD
n=26
p
Diplopia 6 30 58 **0.009a, <0.001b, 0.017c
Difficulty reading 6 23 42 **0.047a, 0.001b, 0.122c (ns)
Misjudge objects 0 23 39 **0.001a, 0.001b, 0.195c (ns)
Freeze in narrow spaces 0 23 46 **0.002
a, <0.001b,0.044c
CVH 0 17 89 **0.014a, <0.001b, <0.001c
preceding month 0 6 54 **0.298a (ns), <0.001b, <0.001c
Illusion 25 25 65 **1.000a (ns), 0.003b, 0.006c
preceding month 0 19 58 **0.007a, <0.001b, 0.007c
Presence 19 31 62 **0.230a (ns), 0.001b, 0.010c
preceding month 0 22 50 **0.004a, <0.001b, 0.008c
Passage 9 48 69 **0.009a, <0.001b, 0.102c (ns)
preceding month 3 38 62 **<0.001a, <0.001b, 0.060c (ns)
Floater 13 11 8 *0.836 (ns)
SImple visual hallucinations 0 3 0 *0.398 (ns)
MIgrainous aura 16 3 4 *0.054 (ns)
PDD 89% vs. PDD informant 85%, κ 0.84, p = 0.317). There was poor 
agreement between HC, PD and PDD patients and informants for 
experiences of illusions (HC κ 0.33, p = 0.014; PD κ 0.33, p = <0.001; 
PDD κ 0.27, p = <0.001), presence (HC κ 0.45, p = 0.045; PD κ 0.53, p = 
<0.001; PDD κ 0.42, p = 0.034) and passage (HC n/a; PD κ 0.36, p = 
<0.001; PDD κ 0.24, p = <0.001). This suggests that CVH are not under-
reported by PD subjects but that other visual symptoms (illusions, 
presence, passage) are not discussed openly with relatives or caregivers.
4.3.4 Ocular features
The three study groups were well matched for frequencies of diabetes 
mellitus, hypertension, glaucoma and previous cataract removal. No 
participants were known to have age-related macular degeneration (AMD), 
although branch retinal vein occlusions and posterior vitreous detachment 
had occurred in one each of the HC and PD cohort. In addition, one PD 
participant had known background diabetic retinopathy (see Table 6). 
Frequency of lens opacity in all three groups was equivalent (right lens: 
HC 66%, PD 73%, PDD 68%; Pearson χ2 (df 2, n = 120) = 0.61, p = 
0.736; ns; left lens: HC 59%, PD 75%, PDD 60%; Pearson χ2 (df 2, n = 
120) = 0.61, p = 0.217; ns). For cortical lens opacities there was no 
significant difference between groups in frequencies of moderate/marked 
cataract in either the right (Pearson χ2 (df 2, n = 114) = 2.2, p = 0.332; ns) 
or left eye (Pearson χ2 (df 2, n = 113) = 1.89, p = 0.388; ns). PDD patients 
differed from PD and HC patients in the frequency of moderate/marked 
nuclear cataract both in the right (HC vs. PDD Fisher’s exact (df 1, n = 54) 
= 6.1, p = 0.013; PD vs. PDD (df 1, n = 82) = 4.6, p = 0.047) and left eye 
(HC vs. PDD Fisher’s exact (df 1, n = 53) = 6.6, p = 0.010; PD vs. PDD (df 
1, n = 81) = 9.4, p = 0.005). 
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Table 6. Ocular features of the visual symptoms study group.
Right and left intraocular pressures (IOP) were within normal ranges for all 
participants, even in those participants with treated glaucoma. There was 
no significant difference between group means (Right IOP: ANOVA (df 2, n 
= 117) = 2.51, p = 0.086; ns; Left IOP: ANOVA (df 2, n = 117) = 2.05, p = 
HC
n=32
PD
n=64
PDD
n=26 p
DM (%) 9 8 4 **0.735 (ns)
HT (%) 34 27 12 **0.153 (ns)
Glaucoma (%) 6 2 4 **0.469 (ns)
Cataract removal (%) 9 13 12 **0.901 (ns)
AMD (%) 9 9 4 **0.685 (ns)
Cortical lens opacity - moderate/marked (%)
Right 19 13 27 **0.332 (ns)
Left 19 15 29 **0.388 (ns)
Nuclear lens opacity - moderate/marked (%)
RIght 6 12 32 **0.488a (ns), 0.013b, 0.047c
Left 6 7 33 **1.000a (ns), 0.010b, 0.005c
RIOP 14.5 (3.3) 13.0 (2.5) 14.3 (4.9) ‡0.086 (ns)
LIOP 14.7 (2.9) 13.3 (2.7) 14.5 (5.8) ‡0.133 (ns)
Retinal health
Right normal (%) 69 79 79 **0.484 (ns)
Left normal (%) 69 78 79 **0.565 (ns)
Disc cupping 6 6 4 **0.490 (ns)
Peri-papillary atrophy 9 2 4 **0.481 (ns)
RIght AMD 9 8 4 **0.758 (ns)
Left AMD 9 8 4 **0.836 (ns)
Right macular sparing change 9 5 8 **0.598 (ns)
Left macular sparing change 13 5 8 **0.372 (ns)
Visual function
Binocular UCVA 0.25 (0.28) 0.33 (0.28) 0.46 (0.28) †0.259a (ns), 0.010b, 0.085c (ns)
Binocular BAPVA 0.00 (0.11) 0.06 (0.14) 0.12 (0.15) †0.035a, 0.001b, 0.068c (ns)
Binocular CS 1.68 (0.10) 1.63 (0.10) 1.49 (0.20) †0.038a, <0.001b, <0.001c
DM - Diabetes mellitus; HT - Hypertension; AMD - Age-related macular degeneration; RIOP - Right 
intraocular pressure; LIOP - left intraocular pressure; UCVA - Uncorrected visual acuity; BAPVA - 
“Best at presentation” visual acuity; CS - Contrast sensitivity
Values expressed as means (+/- SD) (unless otherwise stated)
Statistical tests: ‡ANOVA; † t Test; **Pearson χ2 +/- Fisherʼs exact test where groups frequency < 5  
(ns = non-significant)
a = HC vs PD; b = HC vs PDD; c = PD vs PDD
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0.133; ns). Retinal examination was normal in the majority of cases, with 
no significant group differences (Right retina normal: Pearson χ2 (df 2, n = 
119) = 1.5, p = 0.484; ns; Left retina normal: Pearson χ2 (df 2, n = 119) = 
1.1, p = 0.565; ns). We also specifically rated the appearance of the optic 
disc and documented the presence of macular sparing retinal change and 
AMD in all study participants. The commonest disc findings were - normal, 
disc cupping or peri-papillary atrophic change. There was no difference 
between groups in any of these findings (Right: Pearson χ2 (df 4, n = 120) 
= 3.4, p = 0.490; ns; Left: Pearson χ2 (df 4, n = 120) = 3.4, p = 0.481; ns). 
Disc cupping was seen in 6% of HC and PD and 4% of PDD patients. 
Peri-papillary atrophy was noted in 9% of HC, 2% of PD and 4% of PDD 
patients. Similar frequencies of right AMD (Pearson χ2 (df 2, n = 118) = 
0.6, p = 0.758; ns), left AMD (Pearson χ2 (df 2, n = 117) = 0.6, p = 0.836; 
ns), right (Pearson χ2 (df 2, n = 118) = 1.0, p = 0.598; ns) and left macular-
sparing drusen (Pearson χ2 (df 2, n = 98) = 2.0, p 0.372; ns) were seen in 
all groups. 
Binocular uncorrected (UCVA) and “best at presentation” VA (BAPVA) was  
significantly better for the HC group than the PDD group. UCVA (mean ± 
SD) for the three study groups was as follows: HC 0.25 ± 0.28, PD 0.33 ± 
0.28, PDD 0.46 ± 0.28, with only the HC vs PDD comparison reaching 
statistical significance (t-Test (df 49, n = 51) = 2.70, p = 0.010). In contrast, 
when normal refractive correction was worn, both PD and PDD groups 
demonstrated worse binocular BAPVA than controls (HC vs. PD t-Test (df 
87, n = 89) = 2.14, p = 0.035; HC vs. PDD (df 51, n = 53) = 3.53, p = 
0.001). For both binocular UCVA and BAPVA, there was a trend to better 
acuity in PD compared to PDD but neither comparison reached 
significance (UCVA t-Test (df 77, n = 79) = 1.75, p = 0.085; ns; BAPVA (df 
80, n = 82) = 1.85, p = 0.068; ns). Binocular CS in the HC group was 
greater than in PD or PDD groups. These differences reached significance 
for all comparisons (HC vs. PD t-Test (df 87, n = 89) = 2.11, p = 0.038; HC 
vs. PDD (df 52, n = 54) = 5.73, p = <0.001; PD vs. PDD (df 81, n = 83) = 
4.48, p = <0.001).
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Three independent factors predictive of impaired acuity were identified – 
age, disease severity (UPDRS III) and presence of moderate or marked 
nuclear cataract. The model containing all three predictors was significant 
(df 3, n = 74) = 19.4, p = < 0.001, explaining 45% of the variance in 
BAPVA scores, with UPDRS III emerging as the strongest individual 
contributor to the model (Table 7). Two independent factors predictive of 
impaired CS were identified – age and UPDRS III. The model containing 
both predictors was statistically significant (df 2, n = 78) = 27.0, p = < 
0.001, explaining 42% of the variance in CS scores, with disease severity 
again emerging as the strongest individual predictor. Global cognition 
(AEMSS) did not influence either VA or CS, despite the trend to poorer 
acuity in the PDD group.
Table 7. Predictors of key visual symptoms in PD. 
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BAPVA = Best at presentation visual acuity; CS = Contrast sensitivity; CVH = Complex visual 
hallucinations; UPDRS III - Unified Parkinsonʼs Disease Rating Scale (part III); ESS - Epworth 
Sleepiness Scale; BDI - Beck depression inventory ; RBD - Rapid Eye Movement Sleep Behaviour 
Disorder
Regression models Beta Std error Chi sq df p
BAPVA (high scores = worse acuity)
Standard - full model (df 3, n = 74) = 19.4, p = < 0.001, R2 0.45
UPDRS III .45 0.00 0.001
Age .31 0.00 <0.001
Moderate/marked nuclear cataract .24 0.03 0.011
CS (high scores = better CS)
Standard - full model (df 2, n = 78) = 27.0, p = < 0.001, R2 0.42
UPDRS III -.56 0.00 <0.001
Age -.36 0.00 <0.001
Diplopia
Logistic - full model (df 4, n = 86) = 26.5, p = < 0.001, R2 0.23
PD duration .12 0.05 7.46 1 0.003
ESS .10 0.05 3.63 1 0.049
Abnormal ocular alignment 1.11 0.52 4.53 1 0.020
Hypometric saccades .61 0.28 4.61 1 0.026
CVH
Logistic - full model (df 3, n = 81) = 57.9, p = < 0.001, R2 0.54
Dementia 1.84 0.44 17.39 1 <0.001
BDI .14 0.05 7.18 1 0.001
BAPVA 9.17 3.42 9.50 1 0.001
Illusions
Logistic - full model (df 2, n = 86) = 18.0, p = < 0.001, R2 0.16
ESS .15 0.05 8.40 1 0.004
UPDRS III .05 0.02 5.57 1 0.018
Presence
Logistic - full model (df 2, n = 81) = 33.5, p = < 0.001, R2 0.31
RBD 1.19 0.30 15.85 1 <0.001
ESS .20 0.06 10.07 1 0.002
4.3.5 Risk factors for visual symptoms
Diplopia was a feature of 34 of the total PD and PDD cohort (38%) and 
stepwise logistic regression identified PD duration, ESS scores, abnormal 
ocular alignment and hypometric saccades as independent factors 
predictive of diplopia, with the full model (df 4, n = 86) = 26.5, p = < 0.001) 
accounting for 23% of the variance in reports of diplopia (Table 7).  The 
CVH+ group consisted of 34 patients (38% of the total PD group). Three 
independent factors predictive of CVH+ were identified – diagnosis of 
dementia, BDI , and BAPVA. The model containing all 3 predictors was 
statistically significant (df 3, n = 81) = 57.9, p = < 0.001, and predicted 
54% of the variance in the documentation of CVH, with a diagnosis of 
dementia proving the strongest individual predictor. For other visual 
symptoms, the PD group breakdown was as follows: illusion+ 33 patients 
(37% of combined PD/PDD group), presence+ 36 patients (40%) and 
passage+ 49 patients (54%). Independent factors for illusion+ 
categorization were ESS and UPDRS III scores, although the combined 
model predicted only 16% of the variance between groups (df 2, n = 86) = 
18.0, p = < 0.001). With respect to sensation of presence, only RBD and 
ESS scores were independent predictors of presence+ status, the 
combined model explaining 31% of the variance in presence+/presence- 
status (df 2, n = 81) = 33.5, p = < 0.001). None of the variables outlined 
above contributed to a model predictive of sensations of passage.
4.4 Discussion
To the best of our knowledge this is the first time the full range of visual 
symptoms in PD have been combined in a single study utilising 
ophthalmological, neurological and cognitive assessment.  Our study 
builds upon previous work that has either focused on the ophthalmic 
features of PD in isolation (Biousse et al., 2004, Repka et al., 1996), 
provided detailed phenomenological classification of a subset of visual 
symptomatology in PD (Fenelon et al., 2000), or examined the relationship 
between visual, cognitive and motor dysfunction in PD in the absence of 
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comprehensive ophthalmological assessment (Davidsdottir et al., 2005, 
Uc et al., 2005). In addition, this is the first study to describe the range of 
visual problems across cognitive sub-groups in PD.
Difficulty reading and diplopia were frequently reported visual symptoms. 
With respect to diplopia, we found a higher rate than previously reported in 
the PD literature, perhaps reflecting our larger sample size and case mix 
of cognitively normal and cognitively impaired subjects. Disease duration 
was an important factor in predicting diplopia, as was ocular misalignment 
and ocular motility, although only 20% of patients exhibited the latter 
findings. In addition, daytime somnolence was associated with diplopia 
suggesting that drowsiness may interfere with compensatory fusion of 
ocular misalignment in PD. There is scope for further work examining the 
prevalence of diplopia in PD and which disease-specific and oculomotor 
features contribute to the development of this troublesome symptom. 
One of the a priori hypotheses of our study was that cognitive impairment 
impacts on tests of basic visual function, providing a possible explanation 
for the reductions in VA and CS previously reported in PD. We observed 
significant reductions in VA and CS in both PD and PDD, but neither 
AEMSS nor MMSE scores emerged as predictors in the regression 
analysis. Ocular health was similar between HC and PD groups, although 
there was a higher frequency of moderate/marked nuclear cataract in the 
PDD group. Despite this contributing to the model of VA predictors, it 
cannot account for reduced VA in the non-demented PD group, who were 
well matched with HC subjects for lens opacities. UPDRS III emerged as 
the most consistent independent predictor for VA and CS within the PD 
group, arguing in favour of a disease-specific impact on retinal, subcortical 
or central visual function in PD.
Fenelon et al. (2000) reported minor hallucinations (presence, passage, 
illusions) in 25% of PD patients and our results confirm this finding with 
respect to illusions and presence.  Interestingly, our HC group also 
experienced a high rate of illusions and presence.  Hallucinatory 
experiences are not uncommon in the general population (Ohayon, 2000) 
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and, in the clinical context, our results suggest that recently experienced 
symptoms are more informative than lifetime occurrence. The higher rates 
of recent illusions and presence symptoms in PDD are likely to reflect the 
impact of cognitive decline.  In contrast, passage was uncommon in the 
HC group and common in both PD and PDD groups, suggesting a 
disease-specific contribution from PD, independent of the cognitive status 
of patients.
The overall rate of 38% for CVH in our combined PD and PDD cohort is 
higher than previous studies, which have yielded figures of 20-25% 
(Fenelon et al., 2000, Graham et al., 1997, de Maindreville et al., 2005). 
The most likely explanation was the “enrichment” of our cohort with PDD 
patients, whose CVH rate was almost 90%. CVH rate in the non-demented 
PD group alone was 17%, and thus more in line with previous reports. 
Interestingly, the inter-rater reliability between patients and informants for 
CVH was good, contrary to previous reports suggesting that hallucinations  
are rarely discussed openly by sufferers (Teunisse et al., 1996; McKinlay 
et al., 2008). As noted previously, other visual experiences are not 
routinely volunteered and need to be explicitly sought (Mosimann et al., 
2008).
Several studies have suggested that RBD is an independent risk factor for 
developing visual hallucinations in PD, leading to the intrusion of abnormal 
dream imagery into wakefulness (Onofrj et al., 2002, Pacchetti et al., 
2005). In general, these studies have considered presence, passage and 
illusions collectively as “visual hallucinations”, an approach that implicitly 
assumes a common aetiology for each symptom. Results from our 
regression analyses highlight the well-recognised association between 
cognitive impairment and CVH and also confirm previous reports that 
depressive symptoms and impaired VA are potential contributors. As such, 
both “bottom up” and “top down” disruption may be important in the 
development of CVH in PD and PDD. In contrast, measures of daytime 
somnolence and the presence of RBD contributed to models predictive of 
illusions and presence,  suggesting that these visual experiences may be 
influenced by brainstem regions involved in sleep regulation and arousal 
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and, as such, bear similarities to extracampine and peduncular 
hallucinations. 
There are some limitations to our study. Although we employed 
consecutive recruitment for the PD group, we were not able to use a 
similar approach for the PDD subjects. This was, in part, due to poor 
documentation of a diagnosis of “dementia” in the notes of PD patients 
under review in the Movement Disorder Service. Steps have now been 
taken to ensure that this issue is addressed. In addition, in order to ensure 
close age-matching of the groups, patients under the age of 50 years were 
excluded. As the average age of the PD population in clinic and 
community-based studies is 70-72 years (Lo et al., 2009, Newman et al., 
2009), we feel our results are likely to have considerable external validity 
and that the sample is broadly representative. 
There was significant cognitive heterogeneity in our PD group, and a more 
detailed assessment may have highlighted the contribution of mild 
cognitive impairment to visual symptoms in PD. We did not employ 
specific tests of visual cognition and the study was not designed to assess  
the functional impact of ocular features and visual symptoms. Although we 
used a validated measure of RBD, we did not perform formal 
polysomnographic studies to confirm or refute the presence of RBD. 
Finally, although we have constructed models to examine factors 
predictive of visual symptoms such as CVH, presence, passage and 
illusions, a cross-sectional study such as our own cannot make direct 
causative links between the two. 
Nevertheless, our results raise important issues regarding the 
phenomenological classification of visual symptoms in PD that should be 
borne in mind for future longitudinal studies. Specifically, they caution 
against “lumping” illusions, presence and passage into the same category 
as CVH, particularly when examining the potential link between sleep 
disturbance and “hallucinations”. Furthermore, the high frequency of 
passage hallucinations in both cognitively intact and cognitively impaired 
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PD subjects cautions against necessarily regarding this phenomenon as a 
sinister prognostic indicator of incident dementia.
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5. Retinal morphology in Parkinson’s disease
5.1 Background
Whilst some of the visual symptoms common in PD are likely to stem from 
cortical visual processing deficits, others may be related to lower level 
disturbances of visual function. Visual acuity (VA) (Matsui et al., 2006), 
contrast sensitivity (CS) (Bodis-Wollner et al., 1987, Uc et al., 2005), 
colour perception (Pieri et al., 2000, Price et al., 1992), motion perception 
(Castelo-Branco et al., 2008) and the pattern electroretinogram (PERG) 
response (Langheinrich et al., 2000, Sartucci et al., 2006a) are all 
impaired in PD, with retinal dysfunction advanced as one possible 
explanation for these findings. However, with the exception of PERG data, 
subcortical or central disturbances in visual processing could explain at 
least some of the visual deficits in PD, and tools to probe the retina in 
isolation are therefore important to address the retinal contribution to 
visual dysfunction in PD.
Optical Coherence Tomography (OCT) is a technique for obtaining cross-
sectional images of the retina in a non-invasive fashion, with an axial 
resolution of 10 microns. OCT is capable of assessing the thickness of 
retinal nerve fibre layers (RNFL) around the optic nerve head, thus 
providing a measure of the integrity of the retinal ganglion cell axons as 
they exit the retina, as well as providing information on macular 
morphology. Previous OCT studies have demonstrated morphological 
changes in retinal structure in multiple sclerosis, Alzheimer’s disease and 
glaucoma (Iseri et al., 2006, Kanamori et al., 2003, Parisi et al., 1999). 
RNFL thinning has been found in PD, albeit in relatively small numbers of 
patients (Altintas et al., 2007, Inzelberg et al., 2004, Moschos et al., 2010) 
and macular thickness has also been reported to be reduced (Altintas et 
al., 2007, Cubo et al., 2010, Hajee et al., 2009). One possible explanation 
for these findings is that dopaminergic deficiency deprives the retina of key 
trophic factors vital to maintaining structural integrity (Archibald et al., 
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2009). To date, the functional implications of these reported morphological 
changes are unclear.
The Biomarkers Definitions Working Group define a biomarker as a 
characteristic that is objectively measured and evaluated as an indicator of 
normal biological processes, pathogenic processes or pharmacological 
responses to a therapeutic intervention (Jones, 2010). OCT might prove a 
useful potential biomarker for assessing disease progression in PD and 
fulfills the “objectivity” criterion of this definition. However, to be considered 
as a viable potential biomarker, altered retinal morphology in PD would 
need to be a robust and repeatable finding in larger cohorts, preferably 
with longitudinal follow-up, and be applicable to a typical cohort of elderly 
PD patients with a variety of co-morbidities (i.e. good external validity). 
We therefore compared retinal structure in a PD and healthy age-matched 
control cohort for evidence of RNFL or macular thinning and assessed the 
utility of OCT as a potential biomarker for disease progression in PD. We 
hypothesised that PD patients would demonstrate thinning of the peri-
papillary RNFL and the macula compared to HC, but that the use of OCT 
as a biomarker may be limited by the co-occurrence of retinal disease 
(macular degeneration, glaucoma) and tolerability in a representative PD 
sample. 
5.2 Specific Methods
Measures of peri-papillary RNFL, macular thickness and volume were 
made using a commercially available Ocular Coherence Tomography 
(OCT) device (Zeiss Stratus 3000TM) following pupillary dilation. Scan 
quality was assessed by examining the signal strength and confidence 
limits generated by the automated software analysis. “Best fit” automated 
contour lines were reviewed for OCT scans with a signal strength < 5/10 or 
with a macular protocol confidence limit >20 microns. Scans with poor fit 
contour lines or missing data were excluded from analysis (Figure 12). A 
more detailed discussion of the data acquisition and automated analysis is 
available in the main methods section.
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5.3 Results
Basic group demographics are shown in Table	  8. Both groups (HC = 25, 
PD = 51) were well matched for age (t-Test (df 74, n = 76) = 0.17, p = 
0.864, ns) and gender (Fisher’s exact (df 1, n = 76) = 0.54, p = 0.616, ns). 
Mean PD (± SD) duration was 9.1 ± 6.0 years. All PD patients were on 
pharmacological therapy, with a mean L-DOPA dose of 461 mg/day. Thirty-
seven percent of the PD patients were also taking a dopamine agonist. 
UPDRS II and III mean scores were 14.9 ± 7.1 and 25.7 ± 12.5, 
respectively. Groups were also well matched for a history of hypertension, 
diabetes mellitus, glaucoma and prior cataract removal. There was no 
difference between the cohorts in terms of the frequency of lens opacity, 
age-related macular degeneration and optic atrophy. No participants had 
significant diabetic retinopathy or hypertensive retinal disease. Intraocular 
pressures in both right and left eye were within normal range for all 
participants, including the 2 PD participants with treated glaucoma, 
although both these participants demonstrated optic atrophy on slit lamp 
examination. 
There was no difference in UCVA between the HC and PD groups (Right 
UCVA: Wilcoxon Rank Sum HC = 22, PD = 48, Z = 0.83, p = 0.407; Left 
UCVA: HC = 22, PD = 48, Z = 1.96, p = 0.051; Binocular UCVA: HC = 22, 
PD = 47, Z = 1.08, p = 0.279). Right and binocular BAPVA was 
significantly lower in the PD group, with measures of left BAPVA 
approaching significance (Right BAPVA: Wilcoxon Rank Sum HC = 23, PD 
= 47, Z = 1.98, p = 0.048; Left BAPVA: HC = 23, PD = 47, Z = 1.93, p = 
0.054; Binocular BAPVA: HC = 23, PD = 46, Z = 2.41, p = 0.016). 
Similarly, all measures of CS were lower in the PD group with right and 
binocular CS reaching significance (Right CS: Wilcoxon Rank Sum HC = 
23, PD = 45, Z = 2.34, p = 0.019; Left CS: HC = 23, PD = 44, Z = 1.87, p = 
0.062; Binocular CS: HC = 23, PD = 47, Z = 2.63, p = 0.009). 
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Table 8. Basic demographics of OCT cohort.
UPDRS = Unified Parkinsonʼs disease rating scale; AMD = Age-related macular degeneration; RIOP = Right 
intraocular pressure; LIOP = Left intraocular pressure; UCVA = Uncorrected visual acuity; BAPVA = “Best at 
presentation” visual acuity; CS = Contrast sensitivity
Values expressed as means (+/- SD) (unless otherwise stated)
Statistical tests: † t Test; §Wilcoxon rank sum; **Pearson χ2 +/- Fisherʼs exact test where groups frequency < 5  
HC
n=25
PD
n=51 p
Age (years) 71.6 (7.8) 71.3 (7.7) †0.864 (ns)
Gender (% male) 56 65 **0.616 (ns)
PD duration (years) 9.1 (6.0)
L-dopa dose (mg/day) 461 (389)
Agonist use (%) 37
UPDRS II 14.9 (7.1)
UPDRS III 25.7 (12.5)
% Glaucoma (n) 0 (0) 4 (2) **1.000 (ns)
% Previous cataract surgery (n) 12 (3) 8 (4) **0.678 (ns)
% Diabetes mellitus (n) 8 (2) 6 (3) **1.000 (ns)
% Hypertension (n) 32 (8) 20 (10) **0.260 (ns)
% Right cataract (n) 64 (16) 73 (37) **0.596 (ns)
% Left cataract (n) 60 (15) 73 (37) **0.302 (ns)
% AMD (n) 8 (2) 10 (5) **1.000 (ns)
% Optic atrophy (n) 12 (3) 10 (5) **1.000 (ns)
RIOP (mmHg) 14.5 (3.4) 13.8 (2.7) §0.466 (ns)
LIOP (mmHg) 14.6 (2.7) 14.1 (2.8) §0.465 (ns)
Right UCVA 0.42 (0.37) 0.47 (0.29) §0.407 (ns)
Left UCVA 0.32 (0.26) 0.47 (0.29) §0.051 (ns)
Binocular UCVA 0.24 (0.27) 0.32 (0.26) §0.279 (ns)
Right BAPVA 0.10 (0.24) 0.20 (0.24) §0.048
Left BAPVA 0.10 (0.19) 0.20 (0.23) §0.054 (ns)
Binocular BAPVA -0.01 (0.12) 0.08 (0.15) §0.016
Right CS 1.56 (0.19) 1.48 (0.17) §0.019
Left CS 1.58 (0.14) 1.50 (0.17) §0.062 (ns)
Binocular CS 1.68 (0.09) 1.60 (0.13) §0.009
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In total, 6/25 (24%) HC were excluded from OCT analysis due to the 
presence of macular degeneration or optic atrophy; 10/51 (20%) PD 
subjects were excluded for similar reasons. Two participants with unilateral 
branch retinal vein occlusion were included in the analysis for the 
unaffected eye as were participants with retinal drusen not involving the 
macular region. A further 4 PD patients (8%) were unable to tolerate the 
OCT protocol due to tremor, dyskinesia or anterocollis. This left a 
“restricted group” of 19 HC and 37 PD participants for further analysis 
(Figure 18).
Figure	  18.	  Study	  ﬂow	  chart.	  Note	  the	  restric:on	  of	  group	  size	  based	  upon	  
1)	  ocular	  pathology,	  2)	  scan	  tolerability,	  and	  3)	  data	  quality.
Initial cohort
HC = 25
PD = 51
Ophthalmological assessment & 
OCT analysis
HC
19/25 (86%) without significant 
ocular pathology
6 participants excluded due to 
AMD, optic atrophy
PD
41/51 (80%) without 
significant ocular pathology
10 participants excluded due 
to AMD, optic atrophy
Data quality cutoff
raw OCT profile of scans with signal 
strength < 5 or confidence limit > 20 
microns reviewed for best fit contour lines
HC
RNFL protocol - 17/25 (68%) 
OD and 18/25 (72%) OS 
data available
Macular protocol - 14/25 
(61%) OD and 19/25 (76%) 
OS data available
HC
19/19 (100%) of participants 
tolerated OCT examination
PD
 37/41 (92%) of participants 
tolerated OCT examination
PD
RNFL protocol - 34/51 (67%) 
OD and 32/51 (63%) OS 
data available
Macular protocol - 32/51 
(63%) OD and 31/51 (61%) 
OS data available
n = 31-34n = 14-19
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5.3.1 Restricted group analysis
Basic group demographics are shown in Table 9. Again, both groups were 
well matched for age (t-Test (df 54, n = 56) = 0.77, p = 0.447) and gender 
(Fisher’s exact (df 1, n = 56) = 0.74, p = 0.411). Mean PD duration was 8.9 
± 5.6 years. Disease severity was therefore equivalent to the mean scores 
of the unrestricted cohort (UPDRS II 15.0 ± 7.3; UPDRS III 24.8 ± 11.7).
Table 9. Demographics of the restricted analysis OCT group.
Age
Gender (% male)
PD duration
L-dopa dose
Agonist use (%)
UPDRS II
UPDRS III
Right UCVA
Left UCVA
Binocular UCVA
Right BAPVA
Left BAPVA
Binocular BAPVA
Right CS
Left CS
Binocular CS
HC
n=19
PD
n=37
p
69.4 (6.7) 71.0 (7.8) †0.447 (ns)
47 60 **0.411 (ns)
n/a 8.9 (5.6)
n/a 443.2 (305.3)
n/a 32
n/a 15.0 (7.3)
n/a 24.8 (11.7)
0.35 (0.32) 0.41 (0.27) §0.525 (ns)
0.29 (0.25) 0.44 (0.29) §0.117 (ns)
0.28 (0.20) 0.29 (0.23) §0.280 (ns)
0.05 (0.14) 0.18 (0.22) §0.073 (ns)
0.07 (0.17) 0.19 (0.21) §0.064 (ns)
-0.05 (0.10) 0.05 (0.12) §0.014
1.60 (0.12) 1.49 (0.16) §0.009
1.61 (0.11) 1.44 (0.34) §0.023
1.71 (0.07) 1.61 (0.12) §0.003
Values expressed as means (+/- SD) (unless otherwise stated)
Statistical tests: † t Test; §Wilcoxon rank sum; **Pearson χ2 +/- Fisherʼs exact test where groups frequency < 5  
(ns = non-significant)
UPDRS = Unified Parkinsonʼs disease rating scale; UCVA = Uncorrected visual acuity; BAPVA = “Best at 
presentation” visual acuity; CS = Contrast sensitivity
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There was no difference in UCVA between the HC and PD groups (Right 
UCVA: Wilcoxon Rank Sum HC = 15, PD = 35, Z = 0.64, p = 0.525; Left 
UCVA: HC = 15, PD = 35, Z = 1.57, p = 0.117; Binocular UCVA: HC = 15, 
PD = 35, Z = 1.08, p = 0.280). All measures of BAPVA were lower in the 
PD group with comparisons for binocular acuity reaching significance 
(Right BAPVA: Wilcoxon Rank Sum HC = 15, PD = 34, Z = 1.79, p = 
0.073; Left BAPVA: HC = 15, PD = 35, Z = 1.86, p = 0.064; Binocular 
BAPVA: HC = 15, PD = 34 Z = 2.45, p = 0.014). All measures of CS were 
significantly lower in the PD group (Right CS: Wilcoxon Rank Sum HC = 
15, PD = 34, Z = 2.70, p = 0.007; Left CS: HC = 15, PD = 33, Z = 2.26, p = 
0.024; Binocular CS: HC = 15, PD = 33, Z = 3.00, p = 0.003).
5.3.2 Scan quality
All OCT scans of questionable quality were examined for “best fit” 
automated contour lines, excluding those with missing data or “poor fits” 
from further analysis. For the HC cohort, 5 right macular scans and 3 
RNFL scans (2 right; 1 left) failed quality-control assessment and were 
excluded. For the PD cohort, 5 right and 6 left macular scans along with 3 
right and 5 left RNFL scans also failed to meet inclusion criteria for further 
analysis. We therefore used 14/25 (56%) right and 19/25 (76%) left HC 
macular scans and 32/51 (63%) right and 31/51 (61%) left PD macular 
scans for final analysis. Similarly, we utilised data from 17/25 (68%) right 
and 18/25 (72%) left HC RNFL scans and 34/51 (67%) right and 32/51 
(63%) left PD RNFL scans for final analysis.
5.2.3 OCT results
The OCT results are summarized in Table 10. Average RNFL thickness 
was equivalent between HC and PD groups for both the right (OD) and left 
(OS) eye (OD: Wilcoxon Rank Sum HC = 17, PD = 34, Z = 1.81, p = 
0.071; OS: HC = 18, PD = 32, Z = 0.82, p = 0.413). There were no 
differences in RNFL thickness between HC and PD retina in superior (OD: 
Wilcoxon Rank Sum HC = 17, PD = 34, Z = 1.82, p = 0.069; OS: HC = 18, 
PD = 32, Z = 1.26, p = 0.206), inferior (OD: Wilcoxon Rank Sum HC = 17, 
117
PD = 34, Z = 0.40, p = 0.689; OS: HC = 18, PD = 32, Z = 0.34, p = 0.731), 
temporal (OD: Wilcoxon Rank Sum HC = 17, PD = 34, Z = 0.01, p = 0.992; 
OS: HC = 18, PD = 32, Z = 0.36, p = 0.716) and nasal quadrants (OD: 
Wilcoxon Rank Sum HC = 17, PD = 34, Z = 1.54, p = 0.124; OS HC = 18, 
PD = 32, Z = 1.45, p = 0.148).
Measurements of OD and OS average foveal thickness (OD: Wilcoxon 
Rank Sum HC = 14, PD = 32, Z = 0.01, p = 0.991; OS: HC = 19, PD = 31, 
Z = 0.75, p = 0.453) and macular volume (OD: Wilcoxon Rank Sum HC = 
14, PD = 32, Z = 0.49, p = 0.625; OS: HC = 19, PD = 31, Z = 0.84, p = 
0.401) were also equivalent between HC and PD groups.
Table 10. RNFL and macular thickness measures.
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RNFL thickness (microns) HC PD p
Right n=17 n=34
average 83.47 (9.4) 89.24 (9.4) §0.071 (ns)
superior 90.59 (19.6) 102.79 (19.5) §0.069 (ns)
inferior 116.88 (18.2) 118.03 (17.7) §0.689 (ns)
temporal 62.94 (13.7) 62.65 (12.4) §0.992 (ns)
nasal 63.35 (14.6) 73.47 (20.3) §0.124 (ns)
Left n=18 n=32
average 86.62 (8.4) 88.92 (12.5) §0.413 (ns)
superior 100.28 (12.7) 106.97 (15.2) §0.206 (ns)
inferior 117.11 (17.0) 112.19 (23.7) §0.731 (ns)
temporal 61.67 (9.5) 60.09 (12.4) §0.716 (ns)
nasal 67.61 (17.2) 76.22 (22.9) §0.148 (ns)
Macular thickness HC PD p
Right n=14 n=32
foveal thickness (microns) 179.00 (20.6) 181.34 (29.4) §0.991 (ns)
macular volume (mm3) 6.47 (0.4) 6.54 (0.4) §0.625 (ns)
Left n=19 n=31
foveal thickness (microns) 174.26 (20.1) 171.58 (29.5) §0.453 (ns)
macular volume (mm3) 6.61 (0.5) 6.47 (0.4) §0.401 (ns)
Values expressed as means (+/- SD) (unless otherwise stated)
Statistical tests: §Wilcoxon rank sum
5.4 Discussion
Contrary to our expectations, and previous reports, we found neither 
thinning of the RNFL layer nor a reduction in macular volume or foveal 
thickness in subjects with PD. There are a number of potential reasons for 
this finding. First, the mean age of our PD group was significantly greater 
than in previous studies. Other reports examining the RNFL layer in PD 
have recruited cohorts with mean ages of between 57 – 59 years (Altintas 
et al., 2007, Inzelberg et al., 2004, Moschos et al., 2010) while those 
focusing on macular morphology had mean cohort ages of 64 years (Cubo 
et al., 2010, Hajee et al., 2009). In contrast, the mean age in our study 
was 71 years for both HC and PD groups. Measures of RNFL (Kanamori 
et al., 2003, Alamouti and Funk, 2003) and macular thickness (Kashani et 
al., 2010, Song et al., 2010) are inversely correlated with age, and overall 
measures of RNFL and macular thickness were lower in our study than in 
previously published work. This may have led to a “floor effect”, where 
retinal thickness measures between groups converge with advancing age, 
making detection of subtle differences more difficult. The older age of our 
cohort also makes a direct comparison of other studies with our own 
difficult. However, the mean age in our study more closely matches that of 
the PD population as a whole (Lo et al., 2009, Newman et al., 2009), and 
the inclusion of a well-matched HC group means we feel we are better 
able to generalize our findings accordingly. 
The field of published work on OCT in PD is small. To date, excluding our 
own study, data for only 74 PD patients is available (n = 43 for RNFL data 
and n = 31 for macular studies). In several of these publications, both eyes 
were included in the group analyses, an approach that may not be valid 
due to the interdependence of measurements in right and left eyes. The 
small numbers in previous studies also leaves them open to type I error, 
where significant differences are detected in the absence of a true group 
difference. Standard deviations from published articles, and our own, vary 
from ± 10-20 microns for RNFL measurements, ± 10-30 microns for 
macular thickness and ± 0.3 mm3 for macular volume measurements. 
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Power calculations based on a statistical significance level of 0.05 and a 
predicted power of 0.8 suggest a sample size of between 20-60 would be 
adequate in each group to detect a 10 micron difference in RNFL and 
macular thickness (depending on the SD of measurements). It could 
therefore be argued that several previous studies have been 
underpowered to detect “true” differences between PD and HC groups.  
This criticism could, of course, also be applied to our own data, as, 
although we began with an adequate cohort size (HC 25, PD 51), after 
exclusions, our sample size was considerably reduced. This leaves our 
own study prone to type II error – that is, erroneously accepting that there 
is no difference in HC and PD retinal morphology where one may exist. 
No studies published thus far have reported on the number of participants 
excluded prior to the start of the study; this is potentially important if we 
are to draw conclusions on external validity of findings. Only one study by 
Inzelberg et al. (2004) reported specifically on the number of PD 
participants unable to tolerate the OCT protocol; in this instance 4/16 
(25%) were excluded. In contrast, we found OCT to be well tolerated, with 
only 4/51 (8%) unable to complete the assessment due to tremor, 
dyskinesia or axial dystonia. More problematic was the loss of data due to 
poor quality scans. On average, we lost 4/37 (11%) RNFL and 6/37 (16%) 
macular scans due to data acquisition problems. Most strikingly, 10/51 
(20%) PD participants were excluded from final analysis due to co-morbid 
eye disease (AMD, optic atrophy). In total, therefore, approximately 40% 
of our original cohort was unavailable for final analysis due one of the 
three reasons given above. 
This places limitations both on interpreting the literature published thus far 
on retinal morphology in PD and on assessing the potential utility of OCT 
as a biomarker for disease progression. Results from OCT studies at 
present are contradictory, suggesting that it is too soon to draw firm 
conclusions on whether there is a clinically detectable structural change in 
the retina in PD. One approach likely to resolve the outstanding 
uncertainty would be an appropriately powered, longitudinal study of 
incident PD patients using the newer generation of frequency-domain 
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OCT machines, with better axial resolution (3-5 microns) and shorter data 
acquisition times. Using an incident cohort may reduce the number of 
patients excluded from the analysis due to PD-related disability or 
coincident retinal disease and high-resolution imaging may reduce the 
amount of data lost for technical reasons. Nevertheless, in terms of the 
utility of OCT as a biomarker of disease progression, inter-individual 
variability in measurements and the confounding impact of ocular and 
retinal pathology suggest that this technique may lack both sensitivity and 
specificity to inform on disease progression on a case-to-case basis in PD. 
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6. Visual electrophysiology of Parkinson’s disease
6.1 Background
In order to facilitate the gathering and processing of visual information, the 
retina is laid out in both a laminar and circumferential arrangement. The 
laminar arrangement allows vertical neurotransmission to take place from 
photoreceptor to bipolar cell to retinal ganglion cell (RGC), and it is the 
RGC that acts as the final common pathway in the flow of visual 
information to the optic nerve. There are two main photoreceptors in the 
human retina: rods, present in both the parafoveal and peripheral retina 
and designed for low-light (scotopic) vision, and cones, found 
predominantly in the macula and specialised for bright-light (photopic) 
colour vision (Curcio et al., 1990) (Figure 1). 
In addition, there are cells mediating horizontal retinal neurotransmission 
and these are vital in shaping the temporal and spatial qualities of scotopic 
and photopic vision. Principal players in this horizontal modulation are 
horizontal cells and amacrine cells. One particular amacrine cell 
population (dopaminergic A18 neurons) forms a widespread dendritic 
arborisation throughout the retina (Dacey, 1990, Kolb et al., 1990, 
Pourcho, 1982, Voigt and Wassle, 1987), directly and indirectly interacting 
with rod and cone bipolars, and modulating the flow of rod-driven visual 
information (Bloomfield and Dacheux, 2001, Witkovsky et al., 1993). In 
essence, A18 cells help to coordinate the retinal transition from a dark-
adapted to light-adapted state (Cahill, 1996, Doyle et al., 2002b, Ribelayga 
et al., 2008, Tosini and Menaker, 1996) and, hence, retinal dopaminergic 
deficiency may lead to an inappropriately dark-adapted retina under 
scotopic conditions.
There are also two main types of RGC in the human retina. Those with 
large cell bodies, prominent in the peripheral retina and known as 
magnocellular RGCs (M-cells), carry information on movement and 
contrast. Parvocellular RGCs (P-cells), most prominent in the central 
retina, signal fine feature and colour information to higher visual centres 
122
(Ferrera et al., 1992, Ferrera et al., 1994, Malpeli et al., 1996, Maunsell et 
al., 1990, Nealey and Maunsell, 1994). Given the evidence for a 
dopamine-deficient, rod-primed retina in PD (Harris et al., 1992, Wink and 
Harris, 2000), one explanation for the high prevalence of peripheral visual 
disturbances in the condition is that the retinal balance between M- and P-
cells is tipped in favour of magnocellular “motion” responses, ultimately 
manifesting as fleeting, peripheral sensations of passage. 
The PERG, by stimulating the retina at an even mean luminance, 
measures the electrical contribution from cells of the inner retina – 
predominantly the RGCs (Maffei et al., 1985). The response is highly 
dependent on the spatial, temporal and contrast characteristics of the 
pattern stimulus used and previous studies have demonstrated alterations 
in both PERG latencies and amplitudes in PD (Gottlob et al., 1987, 
Langheinrich et al., 2000, Nightingale et al., 1986, Peppe et al., 1998, 
Peppe et al., 1992, Sartucci et al., 2006, Biomedecine & 
Pharmacotherapy, 60, 476, Stanzione et al., 1990). It is possible to 
manipulate the characteristics of pattern stimuli to bias responses from M- 
and P-cells (Tobimatsu et al., 1995, Butler et al., 2005, Silva et al., 2005) 
and we therefore set out to develop a simultaneous pattern 
electroretinogram and visual evoked potential protocol in an attempt to 
answer the following research questions: 
1) Is there evidence to support a differential disruption of either 
magnocellular or parvocellular pathways in PD? and,
2) Do PD subjects experiencing sensations of passage have different 
electrophysiological responses under magnocellular-biased conditions?
6.2 Specific Methods
See main methods section for full details (3.5). PD subjects were 
dichotomised into two groups depending upon reported experience of 
sensations of passage (passage+/passage-) in the visual periphery. The 
transient PERG responses to magnocellular-biased conditions were 
analysed using passage+/passage- as the grouping variable to assess the 
123
contribution a potential alteration in retinal magnocellular pathways might 
make to the this symptom. The relationship between visual acuity (BAPVA) 
and PERG and PVEP amplitude (P50 PERG and P100 VEP) in both the 
PD and HC groups was investigated using Pearson product-moment 
correlation coefficient in order to clarify the role of the retina in impairment 
of acuity and contrast sensitivity. 
6.3 Results
6.3.1 Demographics
Subjects were well matched for age (t-Test (df 65, n = 67) = 0.68, p = 
0.502, ns) and gender (Fisher’s exact (df 1, n = 67) = 1.20, p = 0.302, ns) 
(Table 11). The PD group scored lower on the AEMSS (Wilcoxon Rank 
Sum HC 22, PD 44, Z = 2.43, p = 0.015) and although performance on the 
MMSE was also impaired, the difference did not reach significance 
(Wilcoxon Rank Sum HC 22, PD 44, Z = 1.90, p = 0.058, ns). Mean (± SD) 
PD duration was 8.3 ± 5.2 years and mean UPDRS II and III scores were 
14.82 ± 6.77 and 24.16 ± 11.38 respectively, making the group 
representative of the overall PD cohort recruited to the study (PD duration 
= 8.4 ± 5.7; UPDRS II = 13.2 ± 6.1; UPDRS III = 23.1 ± 10.0). The overall 
LED was 638 ± 411 mg/day with 44% of PD subjects taking dopamine 
agonists, 28% taking COMT inhibitors and 28% using MAO type-B 
inhibitors.
6.3.2 Visual measures
“Best at presentation” visual acuity (BAPVA) and contrast sensitivity (CS) 
were both significantly lower in the PD group compared to HC (BAPVA: 
Wilcoxon Rank Sum HC 21, PD 41, Z = 2.60, p = 0.009; CS: HC 21, PD 
41, Z = 2.48, p = 0.013) (Table 11). Right and left intraocular pressures 
were normal (RIOP: t-Test (df 64, n = 66) = 1.83, p 0.072, ns; LIOP: (df 64, 
n = 66) = 1.49, p 0.141, ns) and both groups demonstrated equivalent 
frequencies of moderate/marked cortical and nuclear cataract (Cortical: 
Fisher’s exact (df 1, n = 65) = 0.26, p = 0.737, ns; Nuclear: (df 1, n = 65) = 
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2.77, p = 0.158, ns). Retinal examination was normal in 73% of HC and 
71% of PD subjects (Fisher’s exact (df 1, n = 66) = 0.04, p = 1.000, ns) 
with 5 (12%) of PD and 3 (14%) of HC subjects showing evidence of AMD 
and 5 (12%) of PD and 1 (5%) of HC subjects showing optic disc cupping 
on slit lamp examination. 
Table 11. Demographics of ERG/VEP study groups.
6.3.3 Transient PERG responses
The transient PERG responses to parvocellular-biased conditions (0.8o 
check size, high contrast) were equivalent between both groups for right 
and left P50 and N95 amplitude (µV) and implicit time (msec) (Table 12) 
(Right P50 Amp: t-Test (df 58, n = 60) = 0.49, p = 0.626, ns; Left P50 Amp: 
HC
n = 22
PD
n = 44 p
Age 72.4 (7.3) 71.1 (8.0) †0.502 (ns)
Gender (% Male) 52 66 **0.302 (ns)
AEMSS 12.5 (2.8) 10.1 (3.7) §0.015
MMSE 29.5 (0.8) 28.7 (2.0) §0.058 (ns)
PD duration n/a 8.3 (5.2)
UPDRS II n/a 14.8 (6.8)
UPDRS III n/a 24.2 (11.4)
LED mg/day n/a 638 (411)
Agonist use (%) n/a 44
COMT inhibitor (%) n/a 28
MAOI (%) n/a 28
BAPVA -0.01 (0.10) 0.07 (0.13) §0.009
CS 1.69 (0.09) 1.61 (0.14) §0.013
RIOP 14.6 (3.4) 13.2 (2.8) †0.072 (ns)
LIOP 14.9 (2.8) 13.7 (3.0) †0.141 (ns)
Cortical cataract - moderate/
severe (%) 14 19
**0.737 (ns)
Nuclear cataract - moderate/
severe (%) 0 12
**0.158 (ns)
Retina normal (%) 73 71 **1.000 (ns)
Values expressed as means +/- SD (unless otherwise stated)
Statistical tests: † t Test; §Wilcoxon rank sum; **Pearson !2 +/- Fisher’s exact test where groups 
frequency < 5  
(ns = non-significant)
AEMSS - Age- and education-adjusted MOANS scaled score; MMSE - Mini-mental state 
examination; UPDRS - Unified Parkinson’s Disease Rating Scale; LED - Levodopa equivalent dose; 
COMT - Catechol-O-methyl transferase; MAOI - Monoamine oxidase type B inhibitor; BAPVA - 
BInocular “Best at Presentation” visual acuity; CS - Contrast sensitivity; RIOP - Right intraocular 
pressure; LIOP - Left intraocular pressure
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(df 56, n = 58) = 0.09, p = 0.922, ns; Right P50 Imp: (df 56, n = 58) = 1.13, 
p = 0.263, ns; Left P50 Imp: (df 56, n = 58) = 0.72, p = 0.477, ns; Right 
N95 Amp: (df 57, n = 59) = 0.21, p = 0.837, ns; Left N95 Amp: (df 56, n = 
58) = 0.00, p = 0.998, ns; Right N95 Imp: (df 57, n = 59) = 0.93, p = 0.354, 
ns; Left N95 Imp: (df 54, n = 56) = 1.44, p = 0.457, ns). Similarly, the 
transient PERG responses to magnocellular-biased conditions (30o check 
size, low contrast) showed no group differences (Right P50 Amp: t-Test (df 
57, n = 59) = 0.52, p = 0.607, ns; Left P50 Amp: (df 54, n = 56) = 0.03, p = 
0.979, ns; Right P50 Imp: (df 57, n = 59) = 0.91, p = 0.368, ns; Left P50 
Imp: (df 54, n = 56) = 0.84, p = 0.407, ns; Right N95 Amp: (df 57, n = 59) = 
0.53, p = 0.607, ns; Left N95 Amp: (df 54, n = 56) = 0.39, p = 0.697, ns; 
Right N95 Imp: (df 57, n = 59) = 1.06, p = 0.295, ns; Left N95 Imp: (df 54, 
n = 56) = 0.74, p = 0.464, ns).
6.3.4 Transient VEP responses
Under parvocellular-biased conditions, both the amplitude (Right: t-Test (df 
61, n = 63) = 0.02, p 0.984, ns; Left: (df 60, n = 62) = 0.28, p 0.777, ns; 
Midline: (df 60, n = 62) = 0.46, p 0.649, ns) and latency (Right: t-Test (df 
61, n = 63) = 0.67, p 0.503, ns; Left: (df 60, n = 62) = 0.61, p 0.541, ns; 
Midline: (df 61, n = 63) = 0.60, p 0.550, ns) of transient VEP responses 
were equivalent between groups (Table 12). Under magnocellular-biased 
conditions, no difference was detected in the transient VEP response 
(Right Amp: t-Test (df 31, n = 61) = 0.76, p 0.453, ns; Left Amp: (df 59, n = 
61) = 0.85, p 0.397, ns; Midline Amp: (df 30, n = 61) = 1.31, p 0.199, ns; 
Right Imp: (df 59, n = 61) = 0.89, p 0.377, ns; Left Imp: (df 59, n = 61) = 
0.84, p 0.406, ns; Midline Imp: (df 59, n = 61) = 0.82, p 0.418, ns).
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Table 12. Transient PERG and VEP responses.
HC
n = 22
PD
n = 38 p
ERG - parvocellular response
Right P50 Amp 9.93 (5.64) 9.27 (4.67) †0.626 (ns)
Left P50 Amp 10.41 (6.11) 10.56 (5.82) †0.922 (ns)
Right P50 Imp 53.32 (2.08) 52.45 (3.24) †0.263 (ns)
Left P50 Imp 53.14 (2.47) 52.61 (2.84) †0.477 (ns)
Right N95 Amp 11.43 (5.89) 11.13 (5.00) †0.837 (ns)
Left N95 Amp 12.15 (6.38) 12.15 (6.22) †0.998 (ns)
Right N95 Imp 112.09 (8.72) 114.08 (7.41) †0.354 (ns)
Left N95 Imp 112.10 (9.16) 115.31 (7.29) †0.457 (ns)
ERG - magnocellular response
Right P50 Amp 15.37 (5.47) 14.52 (6.31) †0.607 (ns)
Left P50 Amp 15.63 (6.85) 15.68 (7.08) †0.979 (ns)
Right P50 Imp 47.10 (4.02) 46.24 (3.14) †0.368 (ns)
Left P50 Imp 47.05 (3.66) 46.25 (3.30) †0.407 (ns)
Right N95 Amp 18.30 (6.38) 17.29 (7.44) †0.607 (ns)
Left N95 Amp 19.28 (6.92) 18.41 (8.50) †0.697 (ns)
Right N95 Imp 113.38 (9.48) 110.63 (9.60) †0.295 (ns)
Left N95 Imp 113.40 (10.19) 111.33 (9.98) †0.464 (ns)
VEP - parvocellular response
Right Amp 10.79 (5.29) 10.82 (4.89) †0.984 (ns)
Left Amp 10.42 (5.37) 10.07 (4.28) †0.777 (ns)
Midline Amp 12.81 (6.07) 12.11 (5.71) †0.649 (ns)
Right Latency 108.61 (9.92) 110.20 (8.49) †0.503 (ns)
Left Latency 108.70 (10.16) 110.21 (8.84) †0.541 (ns)
Midline Latency 108.30 (9.98) 109.73 (8.46) †0.550 (ns)
VEP - magnocellular response
Right Amp 7.55 (4.39) 6.74 (3.09) †0.453 (ns)
Left Amp 7.88 (4.43) 7.03 (3.27) †0.397 (ns)
Midline Amp 9.26 (5.21) 7.80 (3.57) †0.199 (ns)
Right Latency 113.14 (11.56) 115.83 (10.99) †0.377 (ns)
Left Latency 113.24 (11.40) 115.75 (11.00) †0.406 (ns)
Midline Latency 113.05 (11.42) 115.50 (11.03) †0.418 (ns)
Values expressed as means (± SD)
Statistical tests: † t Test
(ns = non-significant)
ERG = Electroretinogram; VEP = Visual evoked potential; Amp = Amplitude (microV); 
Imp = Implicit time (msec)
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6.3.5 Steady-state PERG & VEP responses
Steady-state parvocellular-biased responses for right and left PERG 
(Right: t-Test (df 55, n = 57) = 1.37, p = 0.176, ns; Left: (df 53, n = 55) = 
0.45, p = 0.658, ns) and right (t-Test (df 62, n = 64) = 0.01, p = 0.990, ns), 
left (t-Test (df 62, n = 64) = 1.34, p = 0.185, ns) and midline VEP (t-Test (df 
62, n = 64) = 1.45, p = 0.152, ns) recording positions were equivalent in 
HC and PD subjects (Table 13). Magnocellular-biased responses 
demonstrated an identical pattern, with no significant differences between 
HC and PD groups (Right PERG: t-Test (df 54, n = 56) = 0.59, p = 0.556, 
ns; Left PERG: (df 53, n = 55) = 0.51, p = 0.612, ns; Right VEP: (df 62, n = 
64) = 0.80, p = 0.429, ns; Left VEP: (df 62, n = 64) = 0.07, p = 0.946, ns; 
Midline VEP: (df 62, n = 64) = 0.70, p = 0.484, ns).
Table 13. Steady-state PERG and VEP responses.
HC
n = 22
PD
n = 38 p
Parvocellular response
Right PERG 0.16 (0.06) 0.13 (0.08) †0.176 (ns)
Left PERG 0.15 (0.02) 0.14 (0.01) †0.658 (ns)
Right VEP 0.29 (0.21) 0.29 (0.21) †0.990 (ns)
Left VEP 0.23 (0.14) 0.28 (0.16) †0.185 (ns)
Midline VEP 0.36 (0.19) 0.29 (0.17) †0.152 (ns)
Magnocellular response
Right PERG 0.31 (0.17) 0.34 (0.17) †0.556 (ns)
Left PERG 0.32 (0.03) 0.34 (0.03) †0.612 (ns)
Right VEP 0.41 (0.32) 0.35 (0.25) †0.429 (ns)
Left VEP 0.39 (0.32) 0.40 (0.30) †0.946 (ns)
Midline VEP 0.44 (0.37) 0.38 (0.27) †0.484 (ns)
Values expressed as means (+/- SD)
Statistical tests: † t Test
(ns = non-significant)
PERG = Pattern Electroretinogram; VEP = Visual evoked potential
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6.3.6 Association between sensations of passage and magnocellular 
pathway parameters
We detected no difference in P50 and N95 amplitude and implicit time 
between passage+ (n = 25) and passage- (n = 19) subjects (Table 14) 
(Right P50 Amp: t-Test (df 36, n = 38) = 0.10, p = 0.919, ns; Left P50 Amp: 
(df 34, n = 36) = 0.13, p = 0.900, ns; Right P50 Imp: (df 36, n = 38) = 0.29, 
p = 0.775, ns; Left P50 Imp: (df 34, n = 36) = 0.58, p = 0.563, ns; Right 
N95 Amp: (df 36, n = 38) = 0.61, p = 0.549, ns; Left N95 Amp: (df 34, n = 
36) = 0.24, p = 0.813, ns; Right N95 Imp: (df 36, n = 38) = 0.23, p = 0.817, 
ns; Left N95 Imp: (df 34, n = 36) = 0.17, p = 0.868, ns). Likewise, the 
steady-state PERG and VEP magnocellular-biased responses were 
equivalent between the two visual symptom groups (Right PERG: t-Test 
(df 31, n = 33) = 0.30, p = 0.765, ns; Left PERG: (df 31, n = 33) = 0.17, p = 
0.865, ns; Right VEP: (df 38, n = 40) = 0.29, p = 0.771, ns; Left VEP: (df 
38, n = 40) = 0.08, p = 0.933, ns; Midline VEP: (df 38, n = 40) = 0.32, p = 
0.753, ns).
Table 14. Association between “sensations of passage” and ERG and 
VEP measures.
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Passage+
n = 22
Passage-
n = 38
p
Transient
Right P50 Amp 14.43 (6.45) 14.64 (6.33) †0.919 (ns)
Left P50 Amp 15.55 (7.87) 15.86 (6.06) †0.900 (ns)
Right P50 Imp 46.36 (3.20) 46.06 (3.15) †0.775 (ns)
Left P50 Imp 46.52 (3.54) 45.87 (3.00) †0.563 (ns)
Right N95 Amp 16.66 (7.68) 18.16 (7.23) †0.549 (ns)
Left N95 Amp 18.70 (8.94) 18.00 (8.14) †0.813 (ns)
Right N95 Imp 110.32 (9.40) 110.06 (10.16) †0.817 (ns)
Left N95 Imp 111.10 (8.67) 111.67 (11.89) †0.868 (ns)
Steady-state
Right PERG 0.33 (0.19) 0.35 (0.15) †0.765 (ns)
Left PERG 0.33 (0.15) 0.34 (0.17) †0.865 (ns)
Right VEP 0.32 (0.22) 0.34 (0.23) †0.771 (ns)
Left VEP 0.37 (0.23) 0.36 (0.19) †0.933 (ns)
Midline VEP 0.37 (0.25) 0.35 (0.20) †0.753 (ns)
Values expressed as means (± SD) 
Statistical tests: † t Test (ns = non-significant)
Amp = Amplitude (microV); Imp = Implicit time (msec); PERG = Pattern electroretinogram; 
VEP = Visual evoked potential
6.3.7 Correlation between visual acuity, contrast sensitivity and ERG/
VEP responses
The PD group had significantly lower visual acuity and contrast sensitivity 
than the HC group. Under parvocellular conditions, despite not detecting 
group differences in terms of PERG P50 or VEP P100 amplitudes, there 
was a strong negative correlation between P50 Amp and BAPVA in the PD 
group (r = -.56, n = 36, p = <0.001) that was not evident in controls (r = -.
26, n = 20, p = 0.253, ns). Controlling for age and disease severity, the 
correlation between VA and parvocellular P50 amplitude remained 
significant (r = -.41). There was also a similar, but non-significant, trend for 
the PERG P50 amplitude under magnocellular conditions in the PD group 
(PD: r = -.31, n = 36, p = 0.069, ns; HC: r = -.17, n = 20, p = 0.467, ns). 
There was no significant correlation between VEP P100 amplitude and 
BAPVA under either parvo- or magnocellular stimulation. Similarly, there 
was a positive correlation between P50 Amp and CS, more striking under 
parvocellular than magnocellular conditions (parvocellular: r = .59, n = 36, 
p = <0.001; magnocellular: r = .37, n = 36, p = 0.019), that was absent in 
controls (parvocellular: r = .27, n = 20, p = 0.266, ns; magnocellular: r = .
33, n = 20, p = 0.132, ns). 
6.4 Discussion
We found no evidence to support the notion that the PD retina and 
subcortical visual system responds differently under magnocellular- and 
parvocellular-biased conditions. Nor did we find a difference in the 
predominantly peripheral retinal response in those PD subjects 
experiencing sensations of passage compared to those without. However, 
the correlation between PERG responses and visual impairment suggests 
that retinal dysfunction might be responsible for the reductions in acuity 
and contrast sensitivity in the PD group. The lack of correlation between 
VEP recordings and both VA and CS would support this notion and, taken 
together, our results provide a tentative link between retinal 
neurophysiological dysfunction and visual symptoms such as blurred 
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vision and difficulty reading, which remain poorly defined and understood 
in PD.
There are a number of possible explanations for some of our “negative” 
results. The first is that the spatial and temporal characteristics of our 
stimuli were in the wrong range to pick up group differences between HC 
and PD subjects. Although previous studies have demonstrated alterations  
in PERG and VEP amplitudes and latencies in PD, the alterations have 
been restricted to mid-spatial frequencies using alternating gratings as 
stimuli. This is very different from our experimental setup, utilising 
checkerboard stimuli with an entirely different range of spatial and 
temporal characteristics. Our principal aim was to develop an experimental 
protocol that enabled simultaneous recording of ERG and VEP responses, 
and this placed limitations on the format of stimuli used. As our primary 
hypothesis was that M-pathway dysfunction contributes to passage 
symptoms in PD, we did not explore the mid-spatial frequency stimuli used 
in previous studies in PD. 
A second potential problem is the possibility that our experimental protocol 
was not sufficiently specific in its activation of M- and P-pathways to detect 
differences between passage+ and passage- subjects. Although similar 
protocols have been studied in schizophrenia, the unique nature of our 
experimental setup makes direct comparisons of the protocols problematic 
(Butler et al., 2007, Butler and Javitt, 2005). Although there is good 
evidence for the existence of two separate pathways within the retina and 
subcortical visual system, due to shared spatio-temporal properties it is 
unlikely to be possible to specifically activate the M- or P-pathways in 
isolation (Blakemore and Vital-Durand, 1986, Levitt et al., 2001, Skottun 
and Skoyles, 2007, Skottun and Skoyles, 2007). Nonetheless, the pilot 
results of patching either the central or peripheral field during recordings 
suggests that we did achieve stimulation of the rod-driven, peripheral 
retina with our M-biased conditions and stimulation of the cone-driven, 
central retina under P-biased conditions (see section 3.5.4).
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Another key confounder of this study is the possible effect of medication in 
the PD group. Due to practicalities of the study, we did not request that 
patients discontinue their medication prior to the recording session and, 
inevitably, patients were tested in a variety of clinical states (medication 
response “on”, “wearing off” etc.). The PD-specific changes in the PERG 
are responsive to treatment with levodopa, an important factor that we 
were unable to control for in our study (Peppe et al., 1998, Peppe et al., 
1995).
We feel our cohort of patients is representative of a typical PD clinic 
population but, as a group, are substantially older than those in other 
studies. In addition, we did not specifically exclude subjects with minor 
ocular disease (cataract, retinal drusen) from the study as these are 
common in elderly populations. This is important if our results are to be 
widely applicable, but introduces potential confounders into the analyses. 
However, the frequency of such ocular features was identical in both 
groups, and we do not feel that the results would have been different if 
these individuals were excluded from the analysis. As with all studies in 
PD, tremor, dyskinesia and somnolence did interfere with some of the 
recording sessions, although most subjects completed the ERG/VEP 
session without any problems.
Finally, the failure to detect differences in peripheral retinal responses 
between passage+ and passage- PD subjects may suggest that this 
symptom either does not have a retinal origin, or simply that the study 
design was inadequate to detect such a change. Although the protocol did 
succeed in isolating the peripheral retinal response, this is not necessarily 
synonymous with activation of the magnocellular pathway. Nonetheless, 
our results suggest that there are no striking differences in a 
representative, treated PD cohort when checkerboard pattern stimuli are 
used to drive central and peripheral retinal responses. Future studies are 
clearly feasible given the tolerability of procedure but modifications would 
be required to our protocol. In particular, the use of a younger cohort, 
assessed on- and off-treatment, at identical times of the day would 
circumvent issues of medication effects. In addition, further work on the 
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design of our pattern stimuli in patients with, for example, specific rod and 
cone dystrophies may provide stronger evidence for our assertion that by 
varying the spatio-temporal characteristics of checkerboard stimuli, it is 
possible to bias responses from M- and P-cells in the human retina.
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7. Visual exploration in Parkinson’s disease and PD 
dementia
7.1 Background
Prominent among the non-motor complications of PD is cognitive 
impairment both in the form of a dementia syndrome (Aarsland et al., 
2003, Hobson and Meara, 2004) and mild cognitive impairment (MCI) 
(Foltynie et al., 2004, Muslimovic et al., 2005). Cognitive impairment in the 
context of PD is characterised by impairments in visuospatial and 
visuoperceptual function, attention (Cormack et al., 2004, Mosimann et al., 
2004b, Uc et al., 2005, Williams-Gray et al., 2007), executive function and 
memory (Muslimovic et al., 2005), a combination that may play an integral 
role in the development of CVH (Collerton et al., 2005, Diederich et al., 
2005, Barnes and Boubert, 2008).
Selection of visual information in a complex scene is achieved by 
deploying sequences of saccades and fixations in a goal-directed fashion 
(Noton and Stark, 1971, Rayner and Pollatsek, 1992, Henderson and 
Hollingworth, 1999). Important cortical areas that contribute to saccade 
generation include the frontal eye field (Rivaud et al., 1994, Pierrot-
Deseilligny et al., 1995, Pierrot-Deseilligny et al., 1991a, Pierrot-
Deseilligny et al., 1995, Muri et al., 1996), the supplementary eye field and 
the parietal eye field (Pierrot-Deseilligny et al., 1991b, Muri et al., 1996). In 
addition, the prefrontal and posterior parietal cortices are also vital in the 
programming of spatially accurate saccades (Pierrot-Deseilligny et al., 
1995, Pierrot-Deseilligny et al., 2005). These areas project, via the 
superior colliculus, thalamus and basal ganglia to lower brainstem 
structures concerned with saccadic eye movements (Hikosaka et al., 
2000). 
Eye movement abnormalities are well recognised in patients with PD, both 
in terms of deficient smooth pursuit, restricted vergence, reduced range of 
eye movements and alterations in saccadic output (Corin et al., 1972, 
White et al., 1983, Rascol et al., 1989, Repka et al., 1996, Bares et al., 
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2003). Evidence for disease-specific disruption of saccades in PD is 
contradictory. Whereas some studies have demonstrated increases in 
saccadic latency, reductions in amplitude and increased error rates 
(Rascol et al., 1989, Kennard and Lueck, 1989, Briand et al., 1999, Hood 
et al., 2007, MacAskill et al., 2002, van Stockum et al., 2008), others have 
not replicated these findings (Vidailhet et al., 1994, Briand et al., 1999, 
Briand et al., 2001, Lueck et al., 1990, Vidailhet et al., 1999, Mosimann et 
al., 2005).
Both the properties of the stimulus used, medication effects and cognitive 
heterogeneity of study cohorts are important determinants of saccadic 
metrics and may help explain some of the inconsistencies in the reported 
literature (Chambers and Prescott, 2010, Michell et al., 2006, Hood et al., 
2007, Hodgson et al., 1999, Mosimann et al., 2005). Indeed, patients with 
AD, PDD and DLB show longer fixation durations, increased saccadic 
latencies and more saccadic errors than controls (Lueck et al., 2000, 
Ogrocki et al., 2000, Abel et al., 2002, Mosimann et al., 2005) suggesting 
cortical neurodegeneration can impair oculomotor function. Aside from the 
absolute metrics of saccades and fixations, visual exploration strategies 
can be used to provide insights into the cognitive processes required for 
more “real-world” tasks such as emotion recognition, text- and clock-
reading (Hodgson et al., 2002, Mosimann et al., 2004a, Lueck et al., 2000, 
Ogrocki et al., 2000).
Saccadic characteristics, and hence visual exploration strategies, are 
therefore influenced by a variety of factors - frontal and parietal eye fields, 
ventral and dorsal visual streams, attentional, executive and basal ganglia 
networks and the effect of medications. Many of these visual, cognitive 
and oculomotor functions co-localize to neuroanatomically linked cortical 
regions targeted by the degenerative process of PD and PDD. It follows 
that measurements of visual exploration behaviour might provide novel 
insights into the contribution various cognitive domains make to the 
neuropsychological deficits evident in PD and PDD, and may even act as 
a surrogate biomarker for those at risk of cognitive impairment. Given that 
cortical saccade programming and integration of visuospatial input with 
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motoric output are achieved in contiguous cortical regions, disruption of 
efficient visual exploration strategies may contribute to motor 
complications such as visually-induced gait freezing. Similarly, there may 
be a similar association between impaired visual exploration, 
visuoperceptual impairment and the development of visual hallucinations.
7.2 Specific methods
For the eye-tracking study, the non-demented PD cohort was subdivided 
into a group with normal cognition (PD-CNL) and a group with possible 
mild cognitive impairment (PD-pMCI) using performance on measures of 
global cognition (MMSE, AEMSS) and the DRS-2 cognitive sub-scale 
scores. This gave four study groups - HC = 32, PD-CNL = 37, PD-pMCI = 
27 and PDD = 26. Not all subjects contributed to the final eye tracking data 
set due to a variety of reasons outlined in the flow chart (Figure 19). 
Reasons for data loss included withdrawal from the study, inability to 
tolerate the test or failure of the eye tracking equipment. The recruitment 
figures for this part of the study were therefore - HC = 29, PD-CNL = 35, 
PD-pMCI = 22 and PDD = 22. In addition, a proportion of participants 
completed only part of the eye tracking battery due to poor 
comprehension, fatigue, drowsiness etc. As expected, the group most 
affected by data loss was the PDD cohort. When comparison was made 
between the demographic features of those PDD subjects completing the 
battery (PDD-c, n = 16) and those failing to do so (PDD-i, n = 10), there 
were no differences in age (Wilcoxon Rank Sum; PDD-c 16, PDD-i 10, z = 
0.40, p = 0.692, ns), education (Wilcoxon Rank Sum; PDD-c 16, PDD-i 10, 
z = 0.08, p = 0.934, ns), UPDRS III (Wilcoxon Rank Sum; PDD-c 16, PDD-
i 10, z = 0.77, p = 0.444, ns) or global cognition (AEMSS: Wilcoxon Rank 
Sum; PDD-c 16, PDD-i 10, z = 0.64, p = 0.507, ns). Subjects failing to 
complete the eye tracking battery did, however, have significantly longer 
PD and dementia durations (PD duration: Wilcoxon Rank Sum; PDD-c 16, 
PDD-i 10, z = 2.27, p = 0.023; dementia duration: Wilcoxon Rank Sum; 
PDD-c 16, PDD-i 10, z = 2.68, p = 0.007).
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Figure 19. Flow chart for eye tracking study.
Figure 3 – Flow chart highlighting degree of data loss
Demographic & basic cognitive assessment 
HC = 32, PD-CNL = 37, PD-pMCI = 27, PDD = 26
Eye tracking cohort
HC = 29, PD-CNL = 35, PD-pMCI = 22, PDD = 22
Withdrew
HC = 2
PD-CNL = 1
PD-pMCI = 1Recording failure
HC = 1, PD-CNL = 1
PD-pMCI = 1, PDD = 1
Unable to tolerate - tremor, 
neck pain, poor comprehension
PD-pMCI = 3
PDD = 3
Angle
Remaining cohort
HC = 29
PD-CNL = 35
PD-pMCI = 21
PDD = 22
Clock
Remaining cohort
HC = 29
PD-CNL = 35
PD-pMCI = 22
PDD = 20
Inverted clock
Remaining cohort
HC = 29
PD-CNL = 34
PD-pMCI = 22
PDD = 16
Shape
Remaining cohort
HC = 29
PD-CNL = 36
PD-pMCI = 22
PDD = 21
Overlapping 
Figure
Remaining cohort
HC = 28
PD-CNL = 35
PD-pMCI = 21
PDD = 22
137
Visual exploration strategies were defined by 1) time to first fixation in the 
correct interest area (IA), 2) Run count (RC) into the central stimulus, and 
3) RC ratio. The RC ratio is generated from the mean RC into the 3 
incorrect IAs vs. the RC into the correct IA. As such, low RC ratios are 
likely to reflect a strategy where the correct IA is explored in preference to 
incorrect regions and a RC ratio of 0.5 reflects a strategy where 
exploration of the correct IA is twice as frequent as that of the incorrect 
IAs. High RC ratios suggest either a less structured strategy, where 
incorrect IAs are re-visited repeatedly, or a cautious approach aimed at 
minimising errors.
In addition to assessing these strategies across the four diagnostic 
groups, we defined subjects as “effective” or “ineffective” explorers based 
on error rates during the eye tracking battery. We reasoned that this would 
provide insight into which factors predicted visual exploration efficiency 
and how deficient visual exploration might impact on visual and motor 
symptoms. We therefore dichotomised our PD subjects (n = 81) into low-
error (LE) and high-error (HE) groups on a task-by-task basis. The median 
error rates were between 0 and 1 for all five eye tracking tasks, and “high-
error” was defined as ≥ 2 errors (out of a possible 16) in a particular task. 
For the simplest task (clock), the HE group was very small (n = 5) whereas 
for the overlapping figure task, the HE group consisted of 29 subjects (of a 
possible 81). This resulted in two relatively heterogeneous groups, with a 
mix of PD-CNL, PD-pMCI and PDD subjects in each.  Over 95% of the 
PD-CNL and PD-pMCI and 85% of the PDD group fell into the LE group 
for clock reading (i.e. “effective explorers”), whereas 17% of the PD-CNL, 
43% of the PD-pMCI and 68% of the PDD group were classified as high-
error makers on the overlapping figures task (i.e. “ineffective explorers”). 
We omitted the clock task from further analysis due to the small numbers 
in the LE group. 
7.2.1 Statistics
Planned group comparisons for the eye tracking analysis were a) HC vs. 
PD-CNL, b) PD-CNL vs. PD-pMCI, c) PD-CNL vs. PDD and d) PD-pMCI 
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vs. PDD. In addition to standard statistical tests, stepwise linear regression 
was conducted using a standard least squares approach with backward 
elimination to identify which cognitive sub-scale scores best predicted RC 
ratio in the overlapping figure task. We entered attention (ATT), initiation/
perseveration (IP), conceptualization (CONCEPT), memory (MEM) and 
clock drawing (CDT) scores into the initial model. We examined the 
potential link between CVH and exploration strategy by performing logistic 
regression, with presence of CVH as the dependent variable and time to 
first fixation in the correct IA, central RC and RC ratio on the overlapping 
figures task as the predictors. We also performed a regression analysis 
using freezing of gait (FOG) as the dependent variable and time to first 
fixation in the correct IA, central RC and RC ratio on the angle task as the 
predictors. The relationship between global cognition (AEMSS), disease 
severity (UPDRS III), levodopa equivalent dose (LED) and fixation 
duration was investigated using Pearson product-moment correlation 
coefficient. Overlapping figures task fixation duration was selected as the 
dependent variable as this was the task with the highest error rates in all 
three PD groups.
7.3 Results
7.3.1 Demographic characteristics
All four groups were well matched for age (ANOVA (df 3, n = 108) = 0.97, 
p = 0.409; ns) and education (Kruskal Wallis (df 3, n = 108) = 3.21, p = 
0.361; ns) (Table 15). Males were over represented in the PDD and PD-
pMCI groups compared to HC (HC vs. PDD: Fisher’s exact (df 1, n = 51) = 
7.95, p = 0.007; HC vs. PD-pMCI: (df 1, n = 54) = 4.41, p = 0.046) and 
there was also a significant gender difference between PD-CNL and PDD 
groups (Fisher’s exact (df 1, n = 57) = 4.49, p = 0.042). PD duration was 
longer for PDD than PD-CNL patients (t-Test (df 55, n = 57) = 2.52, p = 
0.015). Estimated dementia duration was 1.7 years (range 0-3 years, 
where 0 = newly diagnosed at study entry). There was a strong trend to 
higher LED in PD-pMCI and PDD subjects compared to PD-CNL although 
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this only reached significance for comparison between PD-CNL and PDD 
groups (t-Test (df 55, n = 57) = 2.94, p = 0.005). PD-CNL and PD-pMCI 
subjects were well matched for disease severity (UPDRS II: Wilcoxon 
Rank Sum PD-CNL 35, PD-MCI 22, Z = 1.65, p = 0.099, ns; UPDRS III: 
Wilcoxon Rank Sum PD-CNL 35, PD-MCI 22, Z = 1.32, p = 0.187, ns) but 
there were significant differences in UPDRS II and UPDRS III scores 
between PD-CNL/PD-pMCI subjects and those in the PDD cohort 
(UPDRS II: Wilcoxon Rank Sum PD-CNL 35, PDD 22, Z = 4.62, p = 
<0.001; PD-pMCI 22, PDD 22, Z = 3.50, p = < 0.001; UPDRS III: PD-CNL 
35, PDD 22, Z = 3.27, p = <0.001; PD-pMCI 22, PDD 22, Z = 2.28, p = 
0.023).
7.3.2 Cognitive features
When the global cognitive ability of the PD-CNL group was compared to 
HC, both MMSE (Wilcoxon Rank Sum HC 29, PD-CNL 35, Z = 1.23, p = 
0.219, ns) and AEMSS (Wilcoxon Rank Sum HC 29, PD-CNL 35, Z = 0.70, 
p = 0.487, ns) scores were equivalent (Table 15). In contrast, the PD-CNL 
and HC groups differed significantly in these measures when compared to 
the PD-pMCI group (MMSE: Wilcoxon Rank Sum HC 29, PD-pMCI 22, Z = 
3.43, p = <0.001; PD-CNL 35, PD-pMCI 22, Z = 2.95, p = 0.003; AEMSS: 
HC 29, PD-pMCI 22, Z = 4.99, p = <0.001; PD-CNL 35, PD-pMCI 22, Z = 
5.56, p = <0.001). PDD subjects differed from all three groups both for 
MMSE (Wilcoxon Rank Sum HC 29, PDD 22, Z = 6.14, p = <0.001; PD-
CNL 35, PDD 22, Z = 6.39, p = <0.001; PD-pMCI 35, PDD 22, Z = 4.55, p 
= <0.001) and AEMSS scores (Wilcoxon Rank Sum HC 29, PDD 22, Z = 
6.08, p = <0.001; PD-CNL 35, PDD 22, Z = 6.33, p = <0.001; PD-pMCI 35, 
PDD 22, Z = 4.34, p = <0.001). 
PD-CNL subjects matched HC subjects on all cognitive sub-scale scores 
of the DRS-2 (ATT: Wilcoxon Rank Sum HC 29, PD-CNL 35, Z = 0.24, p = 
0.813, ns; IP: HC 29, PD-CNL 35, Z = 0.27, p = 0.785, ns; CONCEPT: HC 
29, PD-CNL 35, Z = 1.44, p = 0.149, ns; MEM: HC 29, PD-CNL 35, Z = 
0.34, p = 0.734, ns; CONST: n/a – identical results) and although there 
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was a strong trend to poorer scores on the CDT, the difference was not 
significant (Wilcoxon Rank Sum: HC 29, PD-CNL 35, Z = 1.96, p = 0.050, 
ns). PD-pMCI subjects scored lower than PD-CNL and HC subjects on all 
cognitive sub-scale scores of the DRS-2 (ATT: Wilcoxon Rank Sum HC 
29, PD-pMCI 22, Z = 2.51, p = 0.012; PD-CNL 35, PD-pMCI 22, Z = 2.52, 
p = 0.012; IP: HC 29, PD-pMCI 22, Z = 5.34, p = <0.001; PD-CNL 35, PD-
pMCI 22, Z = 5.61, p = <0.001; CONCEPT: HC 29, PD-pMCI 22, Z = 3.06, 
p = 0.002; PD-CNL 35, PD-pMCI 22, Z = 2.31, p = 0.021; MEM: HC 29, 
PD-pMCI 22, Z = 2.05, p = 0.040; PD-CNL 35, PD-pMCI 22, Z = 3.16, p = 
0.002; CDT: HC 29, PD-pMCI 22, Z = 3.64, p = <0.001; PD-CNL 35, PD-
pMCI 22, Z = 2.32, p = 0.020) apart from the CONST scale, previously 
noted to discriminate poorly between cognitively normal and cognitively 
impaired individuals (Wilcoxon Rank Sum HC 29, PD-pMCI 22, Z = 1.61, p 
= 0.107, ns; PD-CNL 35, PD-pMCI 22, Z = 1.77, p = 0.072, ns). PDD 
subjects preformed worse on IP (Wilcoxon Rank Sum PD-pMCI 22, PDD 
22, Z = 3.51, p = <0.001), MEM (Wilcoxon Rank Sum PD-pMCI 22, PDD 
22, Z = 3.57, p = <0.001) and CDT (Wilcoxon Rank Sum PD-pMCI 22, 
PDD 22, Z = 3.19, p = 0.001) than the PD-pMCI subjects but there was no 
difference in measures of ATT (Wilcoxon Rank Sum PD-pMCI 22, PDD 22, 
Z = 1.20, p = 0.231, ns), CONCEPT (Wilcoxon Rank Sum PD-pMCI 22, 
PDD 22, Z = 1.11, p = 0.267, ns) and CONST (Wilcoxon Rank Sum PD-
pMCI 22, PDD 22, Z = 1.66, p = 0.097, ns).
141
Table 15. Demographics and cognitive features of eye tracking study 
groups.
HC
n=29
PD-CNL
n=35
PD-pMCI
n=22
PDD
n=22
p value
Age (years) 72.3 (7.8) 69.4 (9.0) 70.8 (7.1) 72.3 (6.0) ‡0.409 (ns)
Education (years) 11.6 (2.7) 12.3 (3.1) 12.0 (3.4) 11.2 (3.0) *0.361 (ns)
Gender (%Male) 48 60 77 86
**0.451a (ns), 0.046b, 
0.007c, 0.025d (ns), 
0.042e, 0.698f (ns)
PD duration (years) n/a 7.6 (5.6) 8.8 (5.4) 11.6 (6.1)
†0.426d (ns ), 0.015e, 
0.118f (ns)
Estimated dementia 
duration (years) n/a n/a n/a 1.7 (0.9)
UPDRS II n/a 11.9 (6.4) 14.9 (5.4) 28.8 (5.8) §0.099d (ns), <0.001e,f
UPDRS III n/a 21.3 (10.5) 25.6 (8.8) 35.4 (14.7)
§0.187d (ns), 0.001e, 
0.023f
LED n/a 579 (406) 774 (479) 917 (450)
†0.105d (ns), 0.005e, 
0.312f (ns)
Global cognition
MMSE 29.6 (0.8) 29.5 (0.7) 28.3 (1.6) 24.5 (2.7)
§0.219a (ns), <0.001b,c,e,f 
0.003d
AEMSS (DRS) 12.8 (2.9) 12.4 (2.1) 7.6 (2.5) 3.9 (1.7) §0.487a (ns), <0.001b,c,d,e,f
Cognitive sub-scale scores (DRS)
ATT 12.2 (1.3) 12.1 (1.2) 10.9 (1.9) 9.9 (2.6)
§0.813a (ns), 0.012b, 
<0.001c, 0.012d, <0.001e, 
0.231f (ns)
I/P 11.0 (1.4) 11.0 (1.3) 6.8 (2.5) 4.1 (2.0) §0.785a (ns), <0.001b,c,d,e,f
CONST 10.0 (0.0) 10.0 (0.0) 9.7 (0.9) 8.7 (2.3)
§n/aa , 0.107b (ns), 
0.003c, 0.072d, 0.001e, 
0.097f (ns)
CDT (Shulman) 4.9 (0.3) 4.7 (0.4) 4.2 (0.9) 2.9 (1.5)
§0.050a (ns), <0.001b,c, 
0.020d, <0.001e, 0.001f
CONCEPT 11.5 (1.5) 10.9 (1.6) 9.2 (2.8) 8.1 (3.2)
§0.149a (ns), 0.002b, 
<0.001c, 0.021d, <0.001e, 
0.267f (ns)
MEM 10.0 (3.2) 10.6 (1.9) 8.1 (3.1) 4.6 (2.5)
§0.734a (ns), 0.040b, 
<0.001c, 0.002d, <0.001e,f
UPDRS - Unified Parkinsonʼs Disease Rating Scale; LED - Levodopa equivalent dose; MMSE - Mini-
mental state examination; CDT - Clock drawing test (Shulman scoring method); AEMSS - Age and 
education-adjusted MOANS scaled score (from DRS); ATT - Attention; I/P - Initiation/perseveration; 
CONST - Construction; CONCEPT - Conceptualization; MEM - Memory.
Values expressed as means (+/- SD) (unless otherwise stated)
Statistical tests: ‡ANOVA; † t Test; *Kruskal-Wallis; §Wilcoxon rank sum; **Pearson χ2 +/- Fisherʼs exact test 
where groups frequency < 5  
(ns = non-significant)
a = HC vs. PD-CNL; b = HC vs. PD-pMCI; c = HC vs. PDD; d = PD-CNL vs. PD-pMCI; e = PD-CNL vs. PDD; 
f = PD-pMCI vs. PDD
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7.3.3 Eye tracking battery performance
Error rates, expressed as a percentage of the total trials, illustrate the 
types of visual task found most challenging by the study subjects (Table 
16 & Figure 20). For all groups, fewest errors were made on the clock 
task, followed by the angle, shape, inverted clock and overlapping figures 
task. Error rate percentage between HC and PD-CNL subjects was 
equivalent across all tasks (Angle: Wilcoxon Rank Sum HC 29, PD-CNL, Z 
= 0.35, p = 0.727; Clock: HC 29, PD-CNL 35, Z = 0.42, p = 0.672, ns; 
Inverted clock: HC 29, PD-CNL 34, Z = 0.32, p = 0.747, ns; Shape: HC 29, 
PD-CNL 35, Z = 0.1.12, p = 0.265, ns; Overlap: HC 28, PD-CNL 35, Z = 
1.09, p = 0.275, ns). Error rate percentages on angle and overlapping 
figures tasks were significantly higher in the PD-pMCI group compared to 
PD-CNL (Angle: Wilcoxon Rank Sum PD-CNL 35, PD-pMCI 22, Z = 2.50, 
p = 0.012; Overlap: PD-CNL 35, PD-pMCI 22, Z = 3.00, p = 0.003) and 
there was a trend toward significance for the inverted clock task (Inverted 
clock: Wilcoxon Rank Sum PD-CNL 34, PD-pMCI 22, Z = 1.76, p = 0.079, 
ns). Both the clock and shape tasks were performed equally well by both 
PD-CNL and PD-pMCI subjects (Clock: PD-CNL 35, PD-pMCI 22, Z = 
0.99, p = 0.324, ns; Shape: PD-CNL 35, PD-pMCI 22, Z = 0.52, p = 0.602, 
ns). Comparison of error rates between PD-CNL and PDD groups reached 
significance for all five tasks (Angle: Wilcoxon Rank Sum PD-CNL 35, 
PDD 22, Z = 5.18, p = <0.001; Clock: PD-CNL 35, PDD 20, Z = 4.01, p = 
<0.001; Inverted clock: PD-CNL 34, PDD 17, Z = 3.12, p = 0.002; Shape: 
PD-CNL 35, PDD 21, Z = 3.18, p = 0.002; Overlap: PD-CNL 35, PDD 22, 
Z = 5.03, p = <0.001). All comparisons between PD-pMCI and PDD 
reached significance (Angle: Wilcoxon Rank Sum PD-pMCI 22, PDD 22, Z 
= 3.15, p = 0.002; Clock: PD-pMCI 22, PDD 20, Z = 2.73, p = 0.006; 
Shape: PD-pMCI 22, PDD 21, Z = 2.59, p = 0.002; Overlap: PD-pMCI 22, 
PDD 22, Z = 2.09, p = 0.037) with the exception of performance on the 
inverted clock task, where PD-pMCI subjects’ performance closely 
resembled that of the PDD group (Inverted clock: PD-pMCI 22, PDD 17, Z 
= 1.09, p = 0.277, ns).
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Table 16. Error rates and response times for the eye tracking battery.
HC
n=29
PD-CNL
n=35
PD-MCI
n=22
PDD
n=22
p value
Error rate (%)
Angle 1.7 (2.8) 1.6 (3.1) 4.9 (6.0) 13.1 (10.0)
§0.727a (ns), 0.012b, 
<0.001c, 0.002d
Clock 0.2 (1.1) 0.5 (2.3) 1.4 (3.2) 5.3 (7.4)
§0.672a (ns), 0.324b (ns), 
<0.001c, 0.006d
Inverted Clock 3.8 (6.3) 3.4 (5.3) 12.2 (19.8) 19.5 (26.0)
§0.747a (ns), 0.079b (ns), 
0.002c, 0.277d (ns)
Shape 2.7 (6.3) 3.6 (5.3) 3.5 (3.7) 16.4 (16.9)
§0.265a (ns), 0.602b (ns), 
0.002c, 0.010d
Overlap 5.0 (6.1) 3.3 (4.4) 10.9 (11.8) 20.2 (16.9)
§0.275a (ns), 0.003b, 
<0.001c, 0.037d
Response time (msec)
Angle 2404 (532) 2523 (593) 3251 (1018) 4719 (1824)
†0.406a (ns), 0.006b, 
<0.001c, 0.002d
Clock 2741 (627) 3114 (826) 3830 (1240) 5054 (1697)
†0.050a (ns), 0.023b, 
<0.001c, 0.010d
Inverted Clock 4419 (933) 4590 (804) 6895 (3052) 8170 (2586)
†0.439a (ns), 0.002b, 
<0.001c, 0.184d (ns)
Shape 3642 (955) 3960 (1126) 4616 (1631) 7672 (4084)
†0.234a (ns), 0.106b (ns), 
<0.001c, 0.004d
Overlap 4886 (1409) 5221 (1232) 7121 (2365) 9921 (4031)
†0.319a (ns), 0.002b, 
<0.001c, 0.009d
Values expressed as means (± SD)
Statistical tests: † t Test; *Kruskal-Wallis; §Wilcoxon rank sum
(ns = non-significant)
a = HC vs. PD-CNL; b = PD-CNL vs. PD-pMCI; c = PD-CNL vs. PDD; d = PD-pMCI vs. PDD
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Figure 20. Error rates for the eye tracking battery.
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Figure 21. Response time for the eye tracking battery.
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7.3.4 Response times
Response times (RT) for the eye tracking battery were shortest for the 
angle task, followed by clock, shape position, inverted clock and 
overlapping figures tasks respectively (Table 16 & Figure 21). HC 
subjects had the shortest RT across all tasks with a trend to progressively 
longer RT moving from PD-CNL, through PD-pMCI to PDD groups. The 
RT comparison between HC and PD-CNL subjects failed to reach 
significance for any of the tasks, although there was a strong trend to 
significance for clock matching (Angle: t-Test (df 62, n = 64) = 0.84, p = 
0.406, ns; Clock: (df 62, n = 64) = 2.00, p = 0.050, ns; Inverted clock: (df 
61, n = 63) = 0.78, p = 0.439, ns; Shape: (df 63, n = 65) = 1.20, p = 0.234, 
ns; Overlap: (df 61, n = 63) = 1.01, p = 0.319, ns). RT differences between 
PD-CNL and PD-pMCI on the shape position task demonstrated a trend to 
significance (t-Test (df 33, n = 58) = 1.66, p = 0.106, ns) and comparisons 
for all other visual battery tasks were significant (Angle: t-Test (df 28, n = 
56) = 2.98, p = 0.006; Clock: (df 33, n = 57) = 2.39, p = 0.023; Inverted 
clock: (df 23, n = 56) = 3.47, p = 0.002; Overlap: (df 27, n = 56) = 3.41, p = 
0.002). RT was significantly longer for PDD subjects when compared to 
both PD-CNL (Angle: t-Test (df 24, n = 57) = 5.47, p = <0.001; Clock: (df 
24, n = 55) = 4.80, p = <0.001; Inverted clock: (df 16, n = 50) = 5.42, p = 
<0.001; Shape: (df 22, n = 57) = 4.08, p = <0.001; Overlap: (df 23, n = 57) 
= 5.31, p = <0.001) and PD-pMCI (Angle: t-Test (df 33, n = 43) = 3.28, p = 
0.002; Clock: (df 40, n = 42) = 2.69, p = 0.010; Shape: (df 26, n = 43) = 
3.19, p = 0.004; Overlap: (df 34, n = 43) = 2.79, p = 0.009) with the 
exception of the RT between PD-pMCI and PDD for the inverted clock task 
(t-Test (df 36, n = 38) = 1.35, p = 0.184, ns).
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7.3.5 Exploration strategy by diagnostic group
In general, HC subjects were first to fixate the correct IA, with PD-CNL, 
PD-pMCI and PDD subjects taking progressively longer (Table 17 & 
Figure 22). The comparison between HC and PD-CNL reached 
significance only for the clock task (Angle: t-Test (df 62, n = 64) = 1.58, p = 
0.120, ns; Clock: (df 62, n = 64) = 2.38, p = 0.021; Inverted clock: (df 61, n 
= 62) = 0.92, p = 0.362, ns; Shape: (df 63, n = 65) = 1.60, p = 0.114, ns; 
Overlap: (df 61, n = 63) = 1.59, p = 0.118, ns) and there was a strong trend 
to significance when comparing PD-CNL and PD-pMCI subjects (Angle: t-
Test (df 54, n = 56) = 1.80, p = 0.078, ns; Clock: (df 55, n = 57) = 2.00, p = 
0.051, ns; Inverted clock: (df 26, n = 56) = 3.62, p = 0.054, ns; Shape: 
Angle: (df 29, n = 57) = 1.35, p = 0.187, ns; Overlap: (df 28, n = 56) = 
1.65, p = 0.110, ns). There were, however, significant differences between 
both PD-CNL and PDD groups for all five tasks (Angle: t-Test (df 29, n = 
56) = 5.56, p = <0.001; Clock: (df 25, n = 55) = 4.85, p = <0.001; Inverted 
clock: (df 18, n = 50) = 3.62, p = 0.002; Shape: (df 24, n = 57) = 4.33, p = 
<0.001; Overlap: (df 27, n = 57) = 3.36, p = 0.002) and PD-pMCI and PDD 
groups for angle, clock and shape position tasks (Angle: t-Test (df 41, n = 
43) = 3.00, p = 0.005; Clock: (df 40, n = 42) = 2.75, p = 0.001; Inverted 
clock: (df 36, n = 40) = 1.39, p = 0.174, ns; Shape: (df 42, n = 43) = 2.87, p 
= 0.007; Overlap: (df 41, n = 43) = 1.61, p = 0.116, ns).
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Table 17. Exploration strategy by study groups.
a = HC vs. PD-CNL, b = PD-CNL vs. PD-MCI, c = PD-CNL vs. PDD, d = PD-MCI vs. PDD
HC
n = 29
PD-CNL
n = 35
PD-MCI
n = 22
PDD
n = 22
p
Fixation duration (msec)
Angle 185 (24) 201 (33) 218 (36) 239 (40)
†0.033a, 0.066b (ns), <0.001c, 0.077d 
(ns)
Clock 180 (24) 198 (35) 209 (35) 237 (37) †0.022a, 0.252b (ns), <0.001c, 0.016d
Inverted Clock 191 (23) 208 (33) 236 (47) 254 (47) †0.021a, 0.013b, <0.001c, 0.236d (ns)
Shape 170 (26) 185 (32) 204 (26) 226 (38) †0.035a, 0.031b, <0.001c, 0.026d
Overlap 201 (25) 217 (29) 238 (39) 267 (40) †0.022a, 0.027b, <0.001c, 0.022d
Time to first fixation in correct interest area (msec)
Angle 1155 (189) 1251 (275) 1437 (501) 1894 (496)
†0.120a (ns), 0.078b (ns), <0.001c,
0.005d
Clock 1425 (351) 1665 (439) 1981 (758) 2672 (867) †0.021a, 0.051b (ns), <0.001c, 0.001d
Inverted Clock 2384 (640) 2523 (558) 3117 (1307) 3700 (1244)
†0.362a (ns), 0.054b (ns), 0.002c,0.174d 
(ns)
Shape 1865 (450) 2046 (454) 2301 (809) 3149 (1115)
†0.114a (ns), 0.187b (ns), <0.001c,
0.007d
Overlap 1995 (371) 2190 (561) 2568 (955) 3096 (1182)
†0.118a (ns), 0.110b (ns), 0.002c,0.116d 
(ns)
Run count (central)
Angle 2.58 (0.44) 2.47 (0.52) 2.69 (0.43) 3.26 (0.98)
†0.354a (ns), 0.096b (ns), <0.001c, 
0.019d 
Clock 2.16 (0.37) 1.94 (0.50) 2.28 (0.59) 2.33 (0.44)
†0.053a (ns), 0.025b, 0.006c, 0.757d 
(ns)
Inverted Clock 2.05 (0.53) 1.83 (0.54) 2.53 (1.06) 2.61 (0.79)
†0.097a (ns), 0.007b, <0.001c, 0.794d 
(ns)
Shape 3.78 (0.73) 3.56 (0.66) 3.56 (0.58) 4.44 (1.21)
†0.195a (ns), 0.999b (ns), <0.001c, 
0.005d
Overlap 4.63 (0.70) 4.52 (0.66) 4.63 (0.83) 5.08 (0.77)
†0.529a (ns), 0.604b (ns), 0.005c,
0.072d (ns)
Run count ratio
Angle 0.51 (0.13) 0.51 (0.10) 0.55 (0.12) 0.61 (0.12)
†0.975a (ns), 0.156b (ns), <0.001c, 
0.087d (ns)
Clock 0.39 (0.11) 0.41 (0.11) 0.44 (0.12) 0.43 (0.10) ‡0.508 (ns)
Inverted Clock 0.47 (0.09) 0.48 (0.12) 0.61 (0.18) 0.64 (0.24)
†0.786a (ns), 0.001b, 0.020c, 0.678d 
(ns)
Shape 0.35 (0.11) 0.34 (0.09) 0.33 (0.09) 0.47 (0.19)
†0.727a (ns), 0.693b (ns), 0.010c, 
0.008d
Overlap 0.59 (0.11) 0.53 (0.09) 0.63 (0.12) 0.66 (0.12) †0.038a, <0.001b, <0.001c, 0.391d (ns)
Values expressed as means (±SD)
Statistical tests: ‡ANOVA; † t Test
(ns = non-significant)
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Figure 22. Time to first fixation in the correct interest area by study 
group.
There was a trend to lower central RC in PD-CNL than HC for both clock 
and inverted clock tasks (clock: t-Test (df 62, n = 64) = 1.98, p = 0.053, ns; 
inverted clock: (df 61, n = 63) = 1.69, p = 0.097, ns) but in other respects, 
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Test (df 62, n = 64) = 0.93, p = 0.354, ns; shape: (df 63, n = 65) = 1.31, p = 
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ns; overlap: (df 54, n = 56) = 0.52, p = 0.604, ns). As with time to first 
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both PD-CNL and PDD for all five tasks (Angle: t-Test (df 55, n = 57) = 
4.02, p = <0.001; Clock: (df 53, n = 55) = 2.88, p = 0.006; Inverted clock: 
(df 48, n = 50) = 4.16, p = <0.001; Shape: (df 55, n = 57) = 3.57, p = 
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<0.001; Overlap: (df 55, n = 57) = 2.91, p = 0.005). PD-pMCI and PDD 
groups had similar central RCs for clock and inverted clock tasks but PDD 
subjects revisited the central angle, shape and overlapping figures stimuli 
more frequently than their PD-pMCI counterparts (Angle: t-Test (df 29, n = 
43) = 2.49, p = 0.019; Clock: (df 40, n = 42) = 0.31, p = 0.757, ns; Inverted 
clock:(df 36, n = 38) = 0.26, p = 0.794, ns; Shape: (df 28, n = 43) = 3.02, p 
= 0.005; Overlap: (df 41, n = 43) = 1.85, p = 0.072, ns) (Figure 23).
The RC ratio for the clock task was equivalent for all four diagnostic 
groups (ANOVA (df 3, n = 106) = 0.78, p = 0.508, ns). HC and PD-CNL 
groups demonstrated similar strategies as defined by the RC ratio, with 
the exception of a lower RC ratio in the PD-CNL group for the overlapping 
figures task (angle: t-Test (df 62, n = 64) = 0.03, p = 0.975, ns; inverted 
clock: (df 61, n = 62) = 0.27, p = 0.786, ns; shape: (df 63, n = 65) = 0.35, p 
= 0.727, ns; overlap: (df 61, n = 63) = 2.13, p = 0.038). RC ratio for the two 
most challenging tasks (inverted clock, overlapping figures) was 
significantly higher in PD-pMCI than PD-CNL (inverted clock: t-Test (df 54, 
n = 56) = 2.55, p = 0.020; overlap: (df 54, n = 56) = 3.50, p = <0.001) but 
strategy on the other two tasks was equivalent (angle: t-Test (df 54, n = 
56) = 1.44, p = 0.156, ns; shape: (df 56, n = 58) = 0.693, ns). PDD 
subjects differed from PD-CNL subjects in RC ratio for all tasks except the 
aforementioned clock task (angle: t-Test (df 55, n = 57) = 3.65, p = <0.001; 
inverted clock: (df 18, n = 50) = 2.55, p = 0.020; shape: (df 25, n = 57) = 
2.77, p = 0.010; overlap: (df 55, n = 57) = 4.62, p = <0.001). A comparison 
between PD-pMCI and PDD subjects demonstrated that PD-pMCI 
subjects had similar RC ratios for the inverted clock and overlapping 
figures tasks (inverted clock: t-Test (df 36, n = 38) = 0.42, p = 0.678, ns; 
overlap: (df 41, n = 43) = 0.87, p = 0.391, ns) and lower RC ratios for 
angle and shape tasks, although the former failed to reach significance 
(angle: t-Test (df 41, n = 43) = 1.75, p = 0.087, ns; shape: (df 29, n = 43) = 
2.86, p = 0.008) (Figure 23).
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Figure 23. Central run count and run count ratio by diagnostic group.
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7.3.6 Exploration strategy by error groups
The time for first fixation in the correct IA was significantly longer in the 
high error (HE) group for angle, inverted clock, shape and overlapping 
figures tasks (Table 18 & Figure 24) (Angle: t-Test (df 20, n = 78) = 3.19, 
p = 0.005; Inverted clock: (df 19, n = 72) = 2.65, p = 0.016; Shape: (df 21, 
n = 79) = 3.10, p = 0.005; Overlap: (df 36, n = 77) = 3.41, p = 0.002). 
Central RC, reflecting the frequency with which subjects re-checked the 
central stimulus against the comparators, was significantly greater in HE 
subjects for angle, inverted clock, shape and overlapping figures tasks 
(Figure 25) (Angle: t-Test (df 19, n = 77) = 3.15, p = 0.005; Inverted clock: 
(df 70, n = 72) = 2.62, p = 0.011; Shape: (df 22, n = 79) = 2.55, p = 0.012; 
Overlap: (df 76, n = 78) = 3.11, p = 0.003). The task requiring least “re-
checking” was the inverted clock, followed by the angle, shape and 
overlapping figures tasks. The RC ratio, a reflection of the degree with 
which subjects compare correct and incorrect comparators, was also 
significantly higher for HE subjects in the angle, inverted clock, shape and 
overlapping figures tasks (Figure 25) (Angle: t-Test (df 76, n = 78) = 2.78, 
p = 0.007; Inverted clock: (df 70, n = 72) = 5.16, p = <0.001; Shape: (df 21, 
n = 79) = 4.59, p = <0.001; Overlap: (df 76, n = 78) = 8.31, p = <0.001). 
For the overlapping figures task, regression analysis identified only the IP 
sub-scale score as an independent predictor of inefficient visual 
exploration, suggesting a “dysexecutive” component to the breakdown of 
exploration strategy. The model predicted only 16% of the variance in RC 
ratio, however, suggesting other unmeasured factors are also important 
((df 1, n = 77) = 14.60, p = < 0.001). In an identical approach, using the 
angle task RC ratio, IP also emerged as the only cognitive sub-scale score 
predictive of RC ratio. Again, although the model was significant ((df 1, n = 
77) = 9.09, p = 0.004), it predicted only 11% of the variance in the RC 
ratio. 
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Table 18. Exploration strategy by error group.
Low error High error p
Fixation duration (msec)
n = 61 n = 17
Angle 211 (34) 237 (48) †0.046
n = 54 n = 18
Inverted Clock 215 (32) 264 (56) †0.002
n = 60 n = 19
Shape 195 (32) 212 (43) †0.068 (ns)
n = 49 n = 29
Overlap 226 (34) 256 (46) †0.015
Time to first correct fixation (msec)
Angle 1372 (384) 1878 (622) †0.005
Inverted Clock 2700 (655) 3765 (1665) †0.016
Shape 2194 (643) 3092 (1210) †0.005
Overlap 2238 (526) 2928 (1000) †0.002
RC central
Angle 2.58 (0.50) 3.19 (0.74) †0.005
Inverted Clock 2.07 (0.80) 2.66 (0.90) †0.011
Shape 3.61 (0.67) 4.37 (1.26) †0.012
Overlap 4.51 (0.66) 5.04 (0.82) †0.003
RC ratio
Angle 0.53 (0.11) 0.61 (0.13) †0.007
Inverted Clock 0.50 (0.13) 0.72 (0.21) †<0.001
Shape 0.33 (0.08) 0.52 (0.17) †<0.001
Overlap 0.53 (0.08) 0.71 (0.10) †<0.001
Values expressed as means (± SD)
Statistical tests: † t Test
(ns = non-significant)
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Figure 24. Time to first fixation in the correct interest area by error 
group.
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Figure 25. Central run count and run count ratio by error group.
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7.3.7 Association between exploration strategy, CVH and gait 
freezing
We examined the association between CVH and exploration strategy, as 
defined by time to first fixation in the correct IA, central RC and RC ratio. 
by performing logistic regression analysis. The overall model was 
significant ((df 1, n = 77) = 9.96, p = 0.019), but explained only 10% of the 
variance in frequency of CVH in the PD/PDD cohort. No single strategy 
measure made a uniquely significant contribution to the model (time to first 
fixation in the correct IA, p = 0.150, ns; central RC, p = 0.312, ns; RC ratio, 
p = 0.196, ns). We also performed a regression analysis using FOG as the 
dependent variable. On this occasion, the full model was not significant (df 
3, n = 77) = 1.57, p = 204, ns).
7.3.8 Fixation duration
The average duration of fixations during the visual battery was shorter in 
HC than PD-CNL subjects regardless of task (Angle: t-Test (df 62, n = 64) 
= 2.18, p = 0.033; Clock: (df 62, n = 64) = 2.34, p = 0.022; Inverted clock: 
(df 59, n = 62) = 2.37, p = 0.021; Shape: (df 63, n = 65) = 2.16, p = 0.035; 
Overlap: (df 61, n = 63) = 2.34, p = 0.022) (Table 17 & Figure 26). A 
similar trend was seen when comparing PD-CNL and PD-pMCI subjects, 
although this only reached significance for the shape, inverted clock and 
overlapping figures tasks (Angle: t-Test (df 54, n = 56) = 1.88, p = 0.066, 
ns; Clock: (df 55, n = 57) = 1.16, p = 0.252, ns; Inverted clock: (df 54, n = 
56) = 2.58, p = 0.013; Shape: (df 56, n = 58) = 2.21, p = 0.031; Overlap: 
(df 54, n = 56) = 2.27, p = 0.027). This trend to prolonged fixation 
durations was replicated when comparing PD-pMCI and PDD subjects 
although the angle and inverted clock task comparisons did not reach 
significance (Angle: t-Test (df 41, n = 43) = 1.82, p = 0.077, ns; Clock: (df 
40, n = 42) = 2.51, p = 0.016; Inverted clock: (df 36, n = 38) = 1.20, p = 
0.236, ns; Shape: (df 41, n = 43) = 2.30, p = 0.026; Overlap: (df 41, n = 
43) = 2.38, p = 0.022). The comparison between fixation duration in 
cognitively normal PD subjects and those with dementia was the most 
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striking, with fixations in the PDD group lasting, on average, 38-50 msec 
longer than the PD-CNL group (Angle: t-Test (df 55, n = 57) = 4.00, p = 
<0.001; Clock: (df 53, n = 55) = 3.89, p = <0.001; Inverted clock: (df 48, n 
= 50) = 4.05, p = <0.001; Shape: (df 55, n = 57) = 4.31, p = <0.001; 
Overlap: (df 55, n = 57) = 5.39, p = <0.001).
Figure 26. Average fixation duration by diagnostic and error groups.
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When fixation duration was examined in the LE and HE groups, there 
were significantly longer fixation durations for angle, inverted clock and 
overlapping figures tasks (angle: t-Test (df 21, n = 78) = 2.12, p = 0.046; 
inverted clock: (df 21, n = 72) = 3.50, p = 0.002; overlap: (df 25, n = 72) = 
2.62, p = 0.015) and a strong trend to significance for the shape position 
task (t-Test (df 72, n = 74) = 1.85, p = 0.068, ns) in the HE group (Table 
18). There was a significant negative correlation between AEMSS and 
fixation duration (r = -.44, n = 76, p = <0.001) and a strong positive 
correlation between UPDRS III and fixation duration (r = .55, n = 76, p = 
<0.001). There was a weak, and non-significant, correlation between 
fixation duration and LED (r = .18, n = 78, p = 0.098, ns). Controlling for 
UPDRS III scores, the relationship between cognition and fixation duration 
was weakened (r = -.29) whereas the correlation between UPDRS III and 
fixation duration was less affected by controlling for cognition (r = .46).  
Multiple regression was used to assess the contribution that AEMSS and 
UPDRS III made to duration of fixations during the overlapping figures 
task. A model containing both measures was significant (df 2, n = 76) = 
12.52, p = <0.001, predicting 34% of the variance in fixation duration. As 
suggested by the correlation analysis, UPDRS III positively correlated with 
fixation duration (Std Beta 0.44, p = <0.001) and contributed most to the 
model, whereas AEMSS was negatively correlated with fixation duration 
and made a weaker, but still significant, contribution to the overall 
predictive value of the model (Std Beta -0.27, p = 0.013).
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7.4 Discussion
To the best of our knowledge, this is the first study to report on visual 
cognition and visual exploration strategy in a variety of PD cognitive sub-
groups. We have shown eye tracking to be a viable technique for 
analysing the complex interplay between visual exploration strategies, 
cognitive sub-domain function and performance on a visual assessment 
battery. 
Our results highlight the cognitive heterogeneity present in a cross-
sectional cohort of PD and PDD patients. This is particularly true of non-
demented PD cohorts, where a significant proportion of subjects are likely 
to have cognitive impairment (Foltynie et al., 2004). In particular, non-
demented PD patients are reported to have impairments in executive 
function, memory and visuospatial and visuoperceptual abilities 
(Muslimovic et al., 2005; Mosimann et al., 2004b, Uc et al., 2005, 
Williams-Gray et al., 2007). In the absence of published criteria, we relied 
upon global and sub-scale cognitive scores to identify those PD subjects 
who, although not fulfilling diagnostic criteria for PDD, clearly did not score 
in the normal range – a group we defined as “possible MCI”. Although we 
did not perform detailed neuropsychological assessments used in some 
previous studies of PD-MCI (Caviness et al., 2007; Janvin et al., 2006a; 
Petersen et al., 2009), our analyses would suggest that our approach did 
indeed generate an group with a cognitive phenotype very different from 
the PD-CNL group.
With respect to performance on the eye tracking battery, we found very 
similar, low error rates for both HC and PD-CNL groups, and no evidence 
to suggest a specific visuospatial or visuoperceptual deficit in PD subjects 
with normal cognition. In contrast, the performance of the PD-pMCI 
subjects was strikingly different, with higher error rates on visuospatial 
(angle, inverted clock) and visuoperceptual (overlapping figures) tasks 
than the cognitively normal PD subjects. PDD subjects exhibited a similar, 
albeit more marked, pattern of deficits but were additionally impaired on 
the shape position task. Interestingly, clock reading and matching was not 
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markedly impaired in the PDD group (5% error rate), perhaps reflecting 
the over-learned nature of the task. 
The RT of PD-CNL subjects was marginally longer for all tasks when 
compared to the HC subjects, although the comparison failed to reach 
significance. In general, PD-CNL subjects offered a verbal response to the 
onset of the stimulus 120 – 370 msecs later than HC, depending on task 
complexity. This prolongation of RT may reflect a more cautious and 
measured approach to the assessment battery in PD or impairments in 
cognitive function too subtle to be picked up by our screening methods. In 
comparison to the PD-CNL group, those subjects with PD-pMCI showed 
much longer delays between stimulus onset and response, between 700 – 
2300 msecs, depending on task. As one might expect from the error rates, 
inverted clock and overlapping figures tasks generated the longest RT, 
providing further objective evidence that PD subjects with possible MCI 
found these visuospatial and visuoperceptual measures more difficult than 
their cognitively normal counterparts.
Exploration strategy, as defined by time to first correct fixation, central run 
count and run count ratio, was identical for controls and cognitively normal 
PD subjects. PD-CNL and PDD subjects differed markedly in all strategy 
measures across all tasks (except the clock task RC ratio). The 
comparison between PD-pMCI and the two other PD groups is more 
complex. Although the comparisons were not always significant at the p 
<0.05 level, in general, the time to first correct fixation increased steadily 
as cognitive function worsened. For some of the tasks (clock, inverted 
clock) the tendency to revisit the central stimulus (central RC) in PD-pMCI 
more closely matched that of PDD subjects, whereas in the angle, shape 
and overlapping figures tasks, the strategy better matched that of the PD-
CNL group. In contrast, the PD-pMCI and PDD subjects showed similar 
RC ratios for all tasks apart from the shape task, where PD-pMCI strategy 
resembled that of cognitively normal subjects.
An alternative approach to the analysis of exploration strategy would have 
been to split the total recorded trials into those where correct and incorrect 
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responses were given. Due to the experimental design, this information 
was not readily available for analysis and, for HC and PD-CNL groups, the 
number of error trials would naturally be very low. We therefore opted to 
dichotomise the entire PD cohort into high- and low-error makers based on 
task-by-task performance on the visual battery. We reasoned that this 
would provide insight into how visual exploration proceeds in those most 
effective at solving the visual tasks in the eye tracking battery and validate 
our choice of strategy measures. One of the strengths of this approach is 
the inclusion of multiple correct trials even in the “high-error” group, 
meaning that, where significant differences are observed, these are likely 
to be a more robust finding. As expected, we were unable to run this 
analysis for the clock task due to the low number of errors made even by 
those subjects with PDD. 
For the remaining four tasks, the HE group took longer to fixate the correct 
interest area, suggesting that visual exploration proceeds in a non-
stochastic fashion and those prone to errors are more likely be drawn to 
irrelevant comparators than those in the LE group. High-error makers were 
also compelled to revisit the central stimulus more frequently than the LE 
group. Similarly, the RC ratio, reflecting the requirement to check correct 
and incorrect comparators against each other, was higher for angle, 
shape, inverted clock and overlapping figures tasks. Of note, the RC ratio 
was lowest for the shape task, reflecting the visual simplicity of the 
component parts (triangle, square) and a strategy favouring more 
checking against the central stimulus. In contrast, the RC ratio was highest 
(i.e. worst) for overlapping figures and inverted clock tasks, highlighting a 
strategy of comparator-to-comparator, as well as comparator-to-stimulus 
checking. Our regression model suggested that frontal executive 
dysfunction, as measured by the DRS IP score, is associated with 
increased the RC ratio. A more detailed neuropsychological assessment is 
necessary to confirm this finding in future work. We found no relationship 
between strategic performance on a putative ventral stream task 
(overlapping figures) and the presence of CVH. Similarly, we examined the 
strategic performance of a putative dorsal stream task (angle matching) as 
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a predictor of gait freezing and found no association. We had 
hypothesised that gaze strategies on ventral and dorsal stream tasks 
would be predictive of visual and motor symptoms. Our failure to confirm 
this hypothesis may, in part, be due to the small number of iterations within 
each task and further work with a larger battery may prove more revealing.
Despite being well matched for error rates, PD-CNL subjects made 
consistently longer fixations on all tasks than did the HC subjects. In 
general, the prolongation of fixation duration was of the magnitude of 15 – 
18 msecs, and was relatively independent of task complexity. One 
potential explanation for this would be a PD-specific oculomotor deficit, 
resulting from disruption of basal ganglia or cortical saccadic circuitry, 
leading to an inability to disengage fixations and initiate subsequent 
saccades in an efficient manner. Saccadic latency may be prolonged in 
PD both for reflexive-biased and cognitively-biased saccades (Rascol et 
al., 1989, Kennard and Lueck, 1989, Briand et al., 1999, Hood et al., 
2007), although other studies have not demonstrated such changes 
(Vidailhet et al., 1994, Briand et al., 1999, Briand et al., 2001, Mosimann et 
al., 2005, Lueck et al., 1990, Vidailhet et al., 1999, Mosimann et al., 2005). 
There is little information on the metrics of fixations and saccades during 
more “naturalistic” scene viewing in PD. One study reported prolonged 
fixations during reading in PD (Gottlob et al., 2004) but in a study of visual 
exploration duration the Tower of London task, Hodgson et al. (2002) 
showed that despite strategic differences between PD and HC subjects, 
fixation durations were identical.  Fixation duration during facial emotion 
viewing is influenced by executive function in PD (Clark et al., 2010) and 
the impact of cognitive impairment on fixation characteristics is therefore 
an important factor in interpreting our results. 
In the absence of specific measurements of the temporal characteristics of 
the saccades of our subjects, we can only speculate that greater saccadic 
latencies result in longer fixation durations for the PD cohort. An 
alternative explanation would be that impairment of visual cognition, 
executive function or attention, too subtle to be picked up by cognitive 
screening, is influencing the characteristics of the fixations and saccades 
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even in PD-CNL subjects. Such impairment could result in small changes 
both in RT and fixation duration without necessarily causing higher error 
rates on the visual battery itself. Both PD severity and global cognition, 
reflected by UPDRS III and AEMSS scores respectively, were important 
predictors of fixation duration in our regression modelling. What is clear is 
that, as cognition declines, fixation duration becomes significantly longer, 
with more demanding tasks showing the most dramatic changes. The 
longer fixation duration is therefore a potential reflection not just of 
subcortical oculomotor deficits, but may also serve to highlight the 
involvement of fronto-parietal eye fields and/or dorsal and ventral streams 
in PD. It has been argued that saccadic measurements may act as a 
surrogate biomarker for disease progression in clinical trials of PD 
although the interaction between medication effects and the influence of 
both cortical and subcortical structures on saccadic metrics makes such 
an approach potentially challenging (Barker and Michell, 2009).
There are limitations to our study in terms of recruitment and sample size. 
We effectively excluded patients under the age of 50 years in order to 
allow adequate age matching of the study groups but, as the average age 
of the PD population in clinic and community-based studies is 70-72 years 
(Lo et al., 2009, Newman et al., 2009), we feel our results are likely to 
have considerable external validity.  We employed consecutive recruitment 
for the PD group to minimise potential bias but the PDD cohort was a 
convenience sample. Our sample sizes were relatively small compared to 
other studies of cognition in PD and withdrawals from the study, technical 
issues and an inability to complete the protocol resulted in a degree of 
data loss, most evident in the PDD group. We chose tasks of differing 
complexity to avoid a ceiling effect in the results from the PDD subjects 
but found instead a floor effect in terms of clock reading that made further 
analysis of strategy impossible. In addition, concerns over deteriorating 
performance and drop-outs associated with a longer assessment battery 
dictated that we use a relatively small number of images within each task 
category. Refinement of the battery to those tasks most likely to 
discriminate cognitive sub-groups, would allow a greater number of 
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iterations to be run. Despite these limitations, we feel our results have 
been achieved in a representative sample of PD patients, that the 
normative data from the HC group is reliable and the conclusions from our 
results are robust. 
In summary, we have demonstrated that impairments on putative tests of 
visuospatial and visuoperceptual function can be demonstrated in both 
PD-pMCI and PDD patients, distinct from the cognitive performance of 
either a control or PD-CNL cohort. Visual exploration strategies are less 
efficient in cognitively impaired PD subjects, with the most striking 
impairment seen in the PDD cohort. In addition, the strategy employed by 
high-error makers may reflect the interaction between visuocognitive and 
frontal executive impairments in PD. Finally, we have demonstrated a 
disease-specific prolongation of fixation duration in PD subjects, possibly 
due to disruption of subcortical and/or cortical oculomotor regions in 
cognitively normal PD subjects, but amplified by the cortical 
neurodegeneration that is the hallmark of PDD. 
Further studies are warranted to confirm these findings a larger cohort, 
perhaps incorporating assessment of reflexive and cognitively-biased 
saccades in addition to more naturalistic scene/object viewing. A more 
detailed cognitive examination would also be helpful in defining the 
domains most closely associated with changes in exploration strategy. 
Finally, how strategic impairments in visual exploration correlate with 
important day-to-day clinical symptoms and outcome measures, such as 
visual hallucinations and gait freezing, remains to be clarified.
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8. Conclusions and Future Studies
Parkinson’s disease, with its ever widening clinical phenotype, and range 
of both motor and non-motor symptoms, poses considerable challenges 
not just for patients and carers, but also for medical staff involved in their 
care. In an ageing population, and with advancing age the key risk factor 
for the development of PD, the impact on society is likely to increase. Non-
motor symptoms such as dementia and visual hallucinations are important 
determinants of long-term outcome and quality of life. Attempting to better 
understand these issues was the primary motivation behind the study.
What has emerged from the first part of the thesis is a more complete 
appreciation both of the wide range of visual symptoms experienced by 
patients with PD, and their rising frequency as cognitive impairment 
develops. This is the first study to have examined visual symptoms and 
impairments in a systematic fashion, whilst attempting to correlate these 
with demographic, cognitive and ocular features. Our study has taken the 
first steps towards understanding common, but under-appreciated, visual 
problems in PD such as diplopia and difficulty reading. It also provides 
justification for future work in defining their impact on quality of life and the 
therapeutic approaches most likely to alleviate them. We have also 
highlighted the need to consider the four main “hallucinatory” experiences 
in PD - illusory misperception, sensations of presence and passage and 
complex visual hallucinations - as pathophysiologically separate entities. 
We hope that our findings will be incorporated into the methodology of 
future studies, ultimately leading to a better understanding, not only of 
“hallucinatory” experiences in PD and PDD, but also in other conditions 
such as Alzheimer’s disease, dementia with Lewy bodies and narcolepsy.
We attempted to set up a study that would avoid one of the common 
pitfalls of research in PD, namely how to localise visual impairments and 
symptoms to a specific region of the visual pathway. For example, 
reported reductions in visual acuity in PD could be accounted for by a 
disease-specific effect on the retina, damage to the early visual cortex or 
even poor test performance. One of the a priori hypotheses of the study 
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was that cognitive performance would have a significant impact on 
measures of visual acuity. However, when we correlated measures of 
basic visual function with global cognition, controlling for disease severity, 
we failed to detect a significant interaction. This led us to to an alternative 
hypothesis, namely that the seeds of visual impairment in PD may be 
sown in the retina itself.
Previously published OCT and electroretinogram data argue strongly in 
favour of PD-related neurodegeneration in the retina. Therefore, we 
hypothesised that we would detect differences between PD and control 
groups both in terms of retinal morphology and electrophysiological 
response, that could subsequently be correlated with impairments in visual 
acuity and contrast sensitivity. Our results challenge previous OCT 
evidence in two key ways. First, we did not see evidence of retinal thinning 
either in the macula itself or in the peri-papillary region. This somewhat 
surprising finding suggests that a well-designed, appropriately powered 
longitudinal study is the only way to address questions over whether 
disease progression in PD leads to detectable changes in retinal 
morphology and what, if any, impact this might have both in terms of visual 
function and visual symptoms. Our results also challenge the assertion 
that OCT may be a useful biomarker for disease progression, not only due 
to the lack of difference between the study groups, but also because of the 
number of individuals excluded from the final analysis due to co-morbid 
ocular disease.
The PERG and VEP study was challenging in terms of protocol 
development and data acquisition and the lack of group differences 
rendered interpretation of the results difficult. Our experimental 
hypothesis, surrounding a potential magnocellular pathway basis for 
sensations of passage, remains theoretically sound. However, with a novel 
and largely unvalidated methodology it is difficult to reject this hypothesis 
on the basis of our results. Peripheral retinal responses between HC and 
PD subjects, and between PD subjects with and without passage 
symptoms, did not differ to pattern stimuli but further work is required to 
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validate this experimental protocol before “peripheral retinal” can be 
equated with “magnocellular” responses. 
We did find PERG evidence correlating retinal dysfunction with the 
intriguing and robust reductions in visual acuity and contrast sensitivity 
that we, and many others, have noted in PD. However, association is not 
causation and further work is needed before we can assert with 
confidence that acuity and contrast sensitivity are not merely serving as 
markers of early visual cortex dysfunction in PD.  
The final part of the thesis focused on visual cognition in PD, with 
particular respect to visual exploration strategies employed when 
interacting with visually-presented information. Ours is the first study to 
report on visual cognition in a variety of PD cognitive sub-groups and, 
despite the limitations in our definition of “possible mild cognitive 
impairment” and the fact that we did not use a validated battery of 
perceptual tests, the results are noteworthy. In addition to significant 
differences in memory, attentional and frontal-executive abilities, PD-pMCI 
subjects performed worse on tasks with a putative visuospatial and 
visuoperceptual basis (angle, inverted clock and overlapping figures). The 
extent of these deficits was intermediate between the PD-CNL group, who 
performed as controls, and the PDD group, with the highest error rates. 
Visual exploration strategy is an important marker of error rates, as 
evidenced by the clear separation in strategic measures between low-error 
and high-error rate subjects. Although the tasks in the eye tracking battery 
have previously been used to study visuospatial and visuoperceptual 
function, it is clear from the “goal-directed” nature of visual exploration that 
other cognitive domains, not least executive function, are also involved. A 
much more detailed cognitive assessment battery is needed in future 
studies to better define the interaction between attention, executive 
function, working memory and the perceptual and spatial abilities required 
to efficiently dissect out these visual tasks. Such an approach might also 
help to define how such strategic differences contribute to functional 
impairments such as visual symptoms and gait freezing. Finally, visual 
167
exploration strategies, in conjunction with measures such as fixation 
duration, might provide an alternative means not only of assessing and 
quantifying cognitive impairment in PD, but also of monitoring response to 
novel disease-modifying agents and cognitive-enhancers as and when 
they become available.
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11. Appendix B - Questionnaires
UPDRS II.  ACTIVITIES OF DAILY LIVING
1. Speech:
! 0 = Normal
! 1 = Mildly affected. No difficulty being understood
 ! 2 = Moderately affected. Sometimes asked to repeat statements
! 3 = Severely affected. Frequently asked to repeat statements
! 4 = Unintelligible most of the time
2.  Salivation:
! 0 = Normal
! 1 = Slight but definite excess of saliva in mouth; may have nighttime 
! drooling
! 2 = Moderately excessive saliva; may have minimal drooling
! 3 = Marked excess of saliva with some drooling
! 4 = Marked drooling; requires constant use of tissue or 
! handkerchief
!
3.  Swallowing:
! 0 = Normal
! 1 = Rare choking
! 2 = Occasional choking
! 3 = Requires soft food
! 4 = Requires nasogastric (NG) tube or gastrostomy tube
4.  Handwriting:
! 0 = Normal
! 1 = Slightly slow or small
! 2 = Moderately slow or small; all words are legible
! 3 = Severely affected; not all words are legible
! 4 = The majority of words are not legible
5.  Cutting food and handling utensils
! 0 = Normal
! 1 = Somewhat slow and clumsy, but no help needed
! 2 = Can cut most foods, although clumsy and slow; some help 
! needed
! 3 = Food must be cut by someone, but can still feed slowly
! 4 = Needs to be fed
6.  Dressing
! 0 = Normal
! 1 = Somewhat slow, but no help needed
! 2 = Occasional assistance with buttoning, getting arms into sleeves
! 3 = Considerable help required, but can do some things alone
! 4 = Helpless
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7.  Hygiene
! 0 = Normal
! 1 = Somewhat slow, but no help needed
! 2 = Needs help to shower or bathe; or very slow in hygienic cares
! 3 = Requires assistance for washing, brushing teeth, combing hair, 
! going to bathroom
! 4 = Foley catheter or other mechanical aids
8.  Turning in bed / Adjusting bed clothes
! 0 = Normal
! 1 = Somewhat slow and clumsy, but no help needed
! 2 = Can turn alone or adjust sheets, but with great difficulty
! 3 = Can initiate attempt, but not turn or adjust sheets alone
! 4 = Helpless
9.  Falling – unrelated to freezing
! 0 = None
! 1 = Rare falling
! 2 = Occasionally falls, less than once daily
! 3 = Falls on average of once daily
! 4 = Falls more than once daily
10. Freezing when walking
! 0 = None
! 1 = Rare freezing when walking; may have start hesitation
! 2 = Occasional freezing when walking
! 3 = Frequent freezing. Occasional falls from freezing
! 4 = Frequent falls from freezing
11. Walking 
! 0 = Normal
! 1 = Mild difficulty. May not swing arms or may tend to drag leg
! 2 = Moderate difficulty, but requires little or no assistance
! 3 = Severe disturbance of walking, requiring assistance
! 4 = Cannot walk at all, even with assistance
12. Tremor (symptomatic complaint of tremor in any part of body)
! 0 = Absent
! 1 = Slight and infrequently present
! 2 = Moderate; bothersome to patient
! 3 = Severe; interferes with many activities
! 4 = Marked; interferes with most activities
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13. Sensory complaints related to parkinsonism
! 0 = None
! 1 = Occasionally has numbness, tingling or mild aching
! 2 = Frequently has numbness, tingling or aching; not distressing
! 3 = Frequent painful sensations
! 4 = Excruciating pain
Total UPDRS II Score:
UPDRS III. MOTOR EXAMINATION 
14. Speech:
! 0 = Normal
! 1 = Slight loss of expression, diction and/or volume
! 2 = Monotone, slurred but understandable; moderately impaired
! 3 = Marked impairment, difficult to understand
! 4 = Unintelligible
15. Facial expression
! 0 = Normal
! 1 = Minimal hypomimia; could be normal ʻ poker faceʼ
! 2 = Slight but definitely abnormal diminution of facial expression
! 3 = Moderate hypomimia; lips parted some of the time
! 4 = Masked or fixed faces, with severe or complete loss of facial 
! expression; lips parted 1/4 inch or more !
16. Tremor at rest
! 0 = Absent
! 1 = Slight and infrequently present
! 2 = Mild in amplitude and persistent, or moderate in amplitude but 
! only intermittently present
! 3 = Moderate in amplitude and present most of the time
! 4 = Marked in amplitude and present most of the time
! !
! ! Face / chin! ________! !
! ! Left arm! ________! Right arm ! ________
! ! Left leg! ________! Right leg! ________
17. Action or postural tremor of hands
! 0 = Absent
! 1 = Slight: present with action
! 2 = Moderate in amplitude; present with action
! 3 = Moderate in amplitude ; present with posture holding as well as 
      !       with action
! 4 = Marked in amplitude ; interferes with feeding
! ! Left! ! ________! Right! ! ________
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18. Rigidity (judged on passive movement of major joints with patient 
relaxed in sitting position: ʻ cog wheelingʼ to be ignored):
! 0 = Absent
! 1 = Slight or detectable only when activated by mirror or other 
     !       movements
! 2 = Mild to moderate
! 3 = Marked, but full range of motion easily achieved
! 4 = Severe ; range of motion achieved with difficulty
! ! Neck! ! ________
! ! Left arm! ________! Right arm! ________
! ! Left leg! ________! Right leg! ________
19. Finger taps (patient taps thumb with index finger in rapid succession 
with widest amplitude possible, each hand separately):
! 0 = Normal ( > 15 / 5 s)
! 1 = Mild slowing and / or reduction in amplitude ( 11 - 14 / 5 s)
! 2 = Moderately impaired : definite and early fatiguing: may have 
      !       occasional arrests in movement ( 3 -6 / 5s)
! 3 = Severely impaired; frequent hesitation in initiating movements 
! or arrests in ongoing movements
! 4 = Can barely perform the task ( 0-2 / 5 s)
! ! Left! ! ________! Right! ! ________
20. Hand movements (patient opens and closes hands in rapid succession 
      with widest amplitude possible, each hand separately) :
! 0 = Normal
! 1 = Mild slowing and or reduction in amplitude
! 2 = Moderately impaired ; definite and early fatiguing; may have 
      !       occasional arrests in movement
! 3 = Severely impaired; frequent hesitation in initiating movements 
! or arrests in ongoing movement
! 4 = Can barely perform the task
! ! Left! ! ________! Right! ! ________
21. Rapid alternating movements of hand (pronation- supination 
movements of hands, vertically or horizontally, with as large an amplitude 
as possible, both hands simultaneously):
! 0 = Normal
! 1 = Mild slowing and or reduction in amplitude
! 2 = Moderately impaired ; definite and early fatiguing; may have 
      !       occasional arrests in movement
! 3 = Severely impaired; frequent hesitation in initiating movements 
! or arrests in ongoing movement
! 4 = Can barely perform the task
! ! Left! ! ________! Right! ! ________
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22. Leg agility (patient taps heel on ground in rapid succession, picking up 
      entire leg; amplitude should be about 3 inches):
! 0 = Normal
! 1 = Mild slowing and or reduction in amplitude
! 2 = Moderately impaired ; definite and early fatiguing; may have 
      !        occasional arrests in movement
! 3 = Severely impaired; frequent hesitation in initiating movements 
! or arrests in ongoing movement
! 4 = Can barely perform the task
! ! Left! ! ________! Right! ! ________
 23. Arising from chair ( patient attempts to arise from a straight-backed 
wood or metal chair, with arms folded across chest):
! 0 = Normal
! 1 = Slow, or may need more than one attempt
! 2 = Pushes self up from arms of seat
! 3 = Tends to fall back and may have to try more than one time but 
! can get up without help
! 4 = Unable to arise without help
24. Posture:
! 0 = Normal erect
! 1 = Not quite erect, slightly stooped posture; could be normal for 
! older person
! 2 = Moderately stooped posture, definitely abnormal; can be 
! leaning to one side
! 3 = Severely stooped posture with kyphosis; can be moderately 
! leaning to one side
! 4 = Marked flexion, with extreme abnormality of posture
25. Gait :
! 0 = Normal
! 1 = Walks slowly; may shuffle with short steps, but no festination or 
      !       propulsion
! 2 = Walks with difficulty but requires little or no assistance; may 
! have some festination, short steps or propulsion
! 3 = Severe disturbance of gait; requires assistance
! 4 = Cannot walk at all, even with assistance
26. Postural stability (response to sudden posterior displacement 
produced by pull on shoulders while patient is erect, with eyes open and 
feet slightly apart; patient is prepared):
! 0 = Normal
! 1 = Retropulsion, but recovers unaided
! 2 = Absence of postural response; would fall if not caught by 
! examiner
! 3 = Very unstable; tends to lose balance spontaneously
! 4 = Unable to stand without assistance
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 27. Body bradykinesia and hypokinesia (combining slowness, hesitancy, 
       decreased arm swing, small amplitude, and poverty of movement in 
       general):
! 0 = None
! 1 = Minimal slowness, giving movement a deliberate character; 
! could be normal for some persons; possibly reduced amplitude
! 2 = Mild degree of slowness and poverty of movement that is 
! definitely abnormal; alternatively, some reduced amplitude
! 3 = Moderate slowness; poverty or small amplitude of movement
! 4 = Marked slowness; poverty or small amplitude of movement
       
Total UPDRS III Score : 
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FREEZING OF GAIT QUESTIONNAIRE (FOGQ)
1.1. During your worst state—Do you walk:
0 Normally
1 Almost normally—somewhat slow
2 Slow but fully independent
3 Need assistance or walking aid
4 Unable to walk
1.2. Are your gait difficulties affecting your daily activities
and independence?
0 Not at all
1 Mildly
2 Moderately
3 Severely
4 Unable to walk
1.3. Do you feel that your feet get glued to the floor while
walking, making a turn or when trying to initiate walking
(freezing)?
0 Never
1 Very rarely—about once a month
2 Rarely—about once a week
3 Often—about once a day
4 Always—whenever walking
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1.4. How long is your longest freezing episode?
0 Never happened
1 1–2 s
2 3–10 s
3 11–30 s
4 Unable to walk for more than 30 s
1.5. How long is your typical start hesitation episode
(freezing when initiating the first step)?
0 None
1 Takes longer than 1 s to start walking
2 Takes longer than 3 s to start walking
3 Takes longer than 10 s to start walking
4 Takes longer than 30 s to start walking
1.6. How long is your typical turning hesitation: (freezing
when turning)
0 None
1 Resume turning in 1–2 s
2 Resume turning in 3–10 s
3 Resume turning in 11–30 s
4 Unable to resume turning for more than 30 s
         TOTAL
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EPWORTH SLEEPINESS SCORE
How likely are you to doze off or fall asleep in the following 
situations, in contrast to feeling just tired? This refers to your usual 
way of life in recent times. Even if you have not done some of these 
things recently try to work out how they would have affected you.
Use the following scale to choose the most appropriate number for 
each situation:
0 = no chance of dozing 
1 = slight chance of dozing 
2 = moderate chance of dozing 
3 = high chance of dozing 
Situation Chance Of Dozing
Sitting and reading
Watching TV
Sitting inactive in a public place (e.g. a theatre or 
a meeting)
As a passenger in a car for an hour without a 
break
Lying down to rest in the afternoon when 
circumstances permit
Sitting and talking to someone
Sitting quietly after a lunch without alcohol
In a car, while stopped for a few minutes in traffic
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REM SLEEP BEHAVIOR DISORDER SCREENING QUESTIONS
1. Have you ever seen the patient appear to “act out his/her dreams” 
while sleeping? (punched or flailed arms in the air; shouted or 
screamed) 
YES   NO
2. Has the patient told you about dreams of being chased, attacked, 
or that involve defending himself or herself? 
YES   NO 
 
(Adapted from Mayo Sleep Questionnaire – informant. “Yes” response to 
both of these questions: SN 85% & SP 100%)
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PARKINSON’S DISEASE QUALITY OF LIFE QUESTIONNAIRE (PDQ 8)
Due to having Parkinson’s disease, how often have you experienced the 
following, during the last month? Please circle the number beside the 
statement you picked.  If several statements in the group seem to apply 
equally well, circle each one.  Be sure to read all the statements in each 
group before making your choice.
1. Had difficulty getting around in public?
   Never
   Occasionally
   Sometimes
   Often
   Always (or cannot do at all)
2. Had difficulty dressing yourself?
   Never
   Occasionally
   Sometimes
   Often
   Always (or cannot do at all)
3. Felt depressed?
   Never
   Occasionally
   Sometimes
   Often
   Always (or cannot do at all)
4. Had problems with your close personal relationships?
   Never
   Occasionally
   Sometimes
   Often
   Always (or cannot do at all)
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5. Had problems with your concentration, e.g. when reading or 
 watching TV?
   Never
   Occasionally
   Sometimes
   Often
   Always (or cannot do at all)
Felt unable to communicate with people properly?
   Never
   Occasionally
   Sometimes
   Often
   Always (or cannot do at all)
7. Had painful muscle cramps or spasms?
   Never
   Occasionally
   Sometimes
   Often
   Always (or cannot do at all)
8. Felt embarrassed in public due to having Parkinson’s disease?
   Never
   Occasionally
   Sometimes
   Often
   Always (or cannot do at all)
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THE BRISTOL ACTIVITIES OF DAILY LIVING SCALE (BADLS)
This questionnaire is designed to reveal the everyday ability of people who 
have memory difficulties of one form or another. For each activity (Nos. 
1-20), statements a-e refer to a different level of ability. 
Thinking of the last 2 weeks, circle the letter that represents your 
relative's/friend's ability. Only 1 letter should be circled for each 
activity. 
(If in doubt about which letter to circle, choose the level of ability which 
represents their average performance over the last 2 weeks)
FOOD
a. Selects and prepares food as required 
b. Able to prepare food if ingredients set out 
c. Can prepare food if prompted step by step
d. Unable to prepare food even with prompting and supervision
e. Not applicable
EATING
a. Eats appropriately using correct cutlery
b. Eats appropriately if food made manageable and/or uses spoon
c. Uses fingers to eat food
d. Needs to be fed
e. Not applicable
DRINK
a. Selects and prepares drinks as required
b. Can prepare drinks if ingredients left available
c. Can prepare drinks if prompted step by step
d. Unable to make a drink even with prompting and supervision
e. Not applicable
DRINKING
a. Drinks appropriately
b. Drinks appropriately with aids, beaker/straw etc.
c. Does not drink appropriately even with aids but attempts to 
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d. Has to have drinks administered (fed)
e. Not applicable
DRESSING
a. Selects appropriate clothing and dresses self
b. Puts clothes on in wrong order and/or back to front and/or dirty clothing
c. Unable to dress self but moves limbs to assist
d. Unable to assist and requires total dressing
e. Not applicable
HYGIENE
a. Washes regularly and independently
b. Can wash if given soap, flannel, towel
c. Can wash self is prompted and supervised
d. Unable to wash self and needs full assistance
e. Not applicable
TEETH
a. Cleans own teeth/dentures regularly and independently
b. Cleans teeth/dentures if given appropriate items
c. Requires some assistance, toothpaste on brush, brush to mouth, etc.
d. Full assistance given
e. Not applicable
BATH/SHOWER
a. Bathes regularly and independently
b. Needs bath to be drawn/shower turned on but washes independently
c. Needs supervision and prompting to wash
d. Totally dependent needs full assistance
e. Not applicable
TOILET/COMMODE
a. Uses toilet appropriately when required
b. Needs to be taken to the toilet and given assistance
c. Incontient of urine or faeces
d. Incontinent of urine and faeces
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e. not applicable
TRANSFERS
a. Can get in/out of chair unaided 
b. Can get into a chair but needs help to get out
c. Needs help getting in and out of a chair
d. Totally dependent on being put onto and lifted from chair
e. Not applicable
MOBILITY 
a. Walks independently
b. Walks with assistance, i.e. furniture, arm for support
c. Uses aids to mobilize, i.e. frame, sticks etc.
d. Unable to walk
e. Not applicable
ORIENTATION - TIME
a. Fully orientated to time/day/date etc
b. Unaware of time/day etc but seems unconcerned
c. Repeatedly asks the time/day/date
d. Mixes up night and day
e. Not applicable
ORIENTATION—SPACE
a. Fully orientated to surroundings
b. Orientated to familiar surroundings only
c. Gets lost in home, needs reminding where bathroom is
d. Does not recognise home as own and attempts to leave
e. Not applicable
COMMUNICATION
a. Able to hold appropriate conversation
b. Shows understanding and attempts to respond verbally with gestures
c. Can make self understood but difficulty understanding others
d. Does not respond to or communicate with others
e. Not applicable
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TELEPHONE
a. Uses telephone appropriately, including obtaining correct number
b. Uses telephone if number given verbally/visually or pre-dialed
c. Answers telephone but does not make calls
d. Unable/unwilling to use telephone at all
e. Not applicable
HOUSEWORK/GARDENING
a. Able to do housework/gardening to previous standard
b. Able to do housework/gardening but not to previous standard
c. Limited participation even with a lot of supervision
d. Unwilling/unable to participate in previous activities
e. Not applicable
SHOPPING
a. Shops to previous standard
b. Only able to shop for 1 or 2 items without a list
c. Unable to shop alone, but participates when accompanied
d. Unable to participate in shopping even when accompanied
e. Not applicable
FINANCES
a. Responsible for own finances at previous level
b. Unable to write cheque but can sign name and recognizes money 
values
c. Can sign name but unable to recognize money values
d. Unable to sign name or recognize money values
e. Not applicable
GAMES/HOBBIES
a. Participates in pastimes/activities to previous standard
b. Participates but needs instruction/ supervision
c. Reluctant to join in, very slow, needs coaxing
d. No longer able or willing to join in
e. Not applicable
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TRANSPORT
a. Able to drive, cycle or use public transport independently
b. Unable to drive but uses public transport or bike etc
c. Unable to use public transport alone 
d. Unable/unwilling to use transport even when accompanied 
e. Not applicable
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NEUROPSYCHIATRIC INVENTORY QUESTIONNAIRE (NPI-Q)
Informant: Spouse / Child / Other : _________________________
Please ask the following questions based upon changes. Indicate "yes" 
only if the symptom has been present in the past month; otherwise, 
indicate "no".
 
For each item marked "Yes":
Rate the SEVERITY of the symptom (how it affects the patient):
1 = Mild (noticeable, but not a significant change)
2 = Moderate (significant, but not a dramatic change)
3 = Severe (very marked or prominent; a dramatic change)
AND ALSO
Rate the DISTRESS you experience because of the symptom (how it 
affects you):
0 = Not distressing at all
1 = Minimal (slightly distressing, not a problem to cope with)
2 = Mild (not very distressing, generally easy to cope with)
3 = Moderate (fairly distressing, not always easy to cope with)
4 = Severe (very distressing, difficult to cope with)
5 = Extreme or very severe (extremely distressing, unable to cope with)
 
Please answer each question honestly and carefully. Ask for assistance if 
you are not sure how to answer any question.
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DELUSIONS: Does the patient believe that others are stealing from 
him or her, or planning to harm him or her in some way?
 Yes  No (circle)
if “Yes”
 
 Severity? 1 2 3  (circle)
 Distress? 1 2 3 4 5 (circle)
HALLUCINATIONS: Does the patient act as if he or she hears voices? 
Does he or she talk to people who are not there?
 Yes  No (circle)
if “Yes”
 
 Severity? 1 2 3  (circle)
 Distress? 1 2 3 4 5 (circle)
AGITATION OR AGGRESSION: Is the patient stubborn and resistive 
to help from others?
 Yes  No (circle)
if “Yes”
 
 Severity? 1 2 3  (circle)
 Distress? 1 2 3 4 5 (circle)
219
DEPRESSION OR DYSPHORIA: Does the patient act as if he or she is 
sad or in low spirits? Does he or she cry?
 Yes  No (circle)
if “Yes”
 
 Severity? 1 2 3  (circle)
 Distress? 1 2 3 4 5 (circle)
ANXIETY: Does the patient become upset when separated from you? 
Does he or she have any other signs of nervousness, such as 
shortness of breath, sighing, being unable to relax, or feeling 
excessively tense?
 Yes  No (circle)
if “Yes”
 
 Severity? 1 2 3  (circle)
 Distress? 1 2 3 4 5 (circle)
ELATION OR EUPHORIA: Does the patient appear to feel too good or 
act excessively happy?
 Yes  No (circle)
if “Yes”
 
 Severity? 1 2 3  (circle)
 Distress? 1 2 3 4 5 (circle)
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APATHY OR INDIFFERENCE: Does the patient seem less interested 
in his or her usual activities and in the activities and plans of others?
 Yes  No (circle)
if “Yes”
 
 Severity? 1 2 3  (circle)
 Distress? 1 2 3 4 5 (circle)
DISINHIBITION: Does the patient seem to act impulsively? For 
example, does the patient talk to strangers as if he or she knows 
them, or does the patient say things that may hurt people’s feelings?
 Yes  No (circle)
if “Yes”
 
 Severity? 1 2 3  (circle)
 Distress? 1 2 3 4 5 (circle)
IRRITABILITY OR LABILITY: Is the patient impatient or cranky? Does 
he or she have difficulty coping with delays or waiting for planned 
activities?
 Yes  No (circle)
if “Yes”
 
 Severity? 1 2 3  (circle)
 Distress? 1 2 3 4 5 (circle)
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MOTOR DISTURBANCE: Does the patient engage in repetitive 
activities, such as pacing around the house, handling buttons, 
wrapping string, or doing other things repeatedly?
 Yes  No (circle)
if “Yes”
 
 Severity? 1 2 3  (circle)
 Distress? 1 2 3 4 5 (circle)
NIGHTTIME BEHAVIORS: Does the patient awaken you during the 
night, rise too early in the morning, or take excessive naps during 
the day?
 Yes  No (circle)
if “Yes”
 
 Severity? 1 2 3  (circle)
 Distress? 1 2 3 4 5 (circle)
APPETITE AND EATING: Has the patient lost or gained weight, or had 
a change in the food he or she likes?
 Yes  No (circle)
if “Yes”
 
 Severity? 1 2 3  (circle)
 Distress? 1 2 3 4 5 (circle)
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NORTH EAST VISUAL HALLUCINATIONS INVENTORY III - PATIENT 
VERSION
Please ask about any visual hallucinations or unusual visual experiences.  
Questions (i-iv) should be asked, where a positive answer is given, record as 
much as possible of what is said in the box below.  
Where descriptions are given please ask about motion, colour, size, contour, 2D/
3D and whether what is seen is life like. (If information is lacking, encourage the 
patient to give more detail)
Section A - screening questions
(i) “Do you feel like your eyes ever play tricks on you? Have you ever seen 
something (or things) that other people could not see?”    Y  /  N
(ii)  “Have you ever looked at an object or pattern and something else suddenly 
appeared or disappeared?”  Y  /  N
(iii) a “Have you ever had the feeling of the presence of somebody or something, 
in the corner of your eye?”  Y  /  N  
(iii) b “Have you ever seen somebody or something, like a shadow, in the corner 
of your eye?”    Y  /  N 
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(iv)  “Have you ever had other visual experiences?”  Y  /  N
2) “Have you experienced seeing dots, flashes, patterns of light or similar that 
were not there?”  Y  /  N
Please gather as much information as possible and please do the frequency 
ratings for each question answered with yes.
Section B - Frequency rating 
Frequency ratings for questions 1 i) - 1 iv) and 2: 
Rating refers to question i ii iii iv 2
3. When did your hallucinations first start?
About one month ago
Between one month and one year ago
More than one year ago
4. When was the last time you experienced any of the things 
we have spoken about?
Within the last month
Between one month and one year ago
More than one year ago
5. How often have you had hallucinations in the last month?
Less than once a week
1-6 times per week
Every day   
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Where there have been no hallucinations experienced within the last 
month please stop here
The following questions all relate to hallucinations experienced 
within the last month. 
Please indicate whether the ratings refer to - i / ii / iii a / iii b / iv or 2
 
6.  Approximately how long do your 
hallucinations usually last?
1      Less than 5 minutes
2      5 minutes to 2 hours
3      Longer than two hours
14. Do your hallucinations make you worry 
that you are losing your mind?  
0      Not at all 
1      Somewhat
2      A lot
7. At what time of the day do your 
hallucinations usually occur?
1      Night time
2      Day time
3      They can occur at anytime
15. Do you find your close relationships 
(e.g. with family) difficult because of 
your hallucinations?
0     Not at all
1     Somewhat
2     Very
8. Are your hallucinations associated 
with falling asleep or waking up?
1      Never
2      Sometimes
3      Always
16. Whilst you are having a hallucination do 
you ever believe it is real?
0      Never
1      Sometimes
2      Always
9. Do you find your hallucinations 
irritating or frustrating?
0      Not at all
1      Somewhat
2      Very
17. Do you ever act out your 
hallucinations?
0      Never          
1      Sometimes
2      Always
10. Do you find your hallucinations 
frightening or distressing?
0      Not at all
1      Somewhat
2      Very
18. Are you able to ignore your 
hallucinations?
0      Always
1      Sometimes
2      Never
11. Do the hallucinations ever speak 
or make noises?
0      Never
1      Sometimes 
2      Always
19. Have you stopped doing things you 
used to because of your hallucinations?
0      Not at all
1      Somewhat
2      A lot
12. Are your hallucinations associated 
with an odd smell or taste?
0      Never
1      Sometimes 
2      Always
20. Do your hallucinations go together with 
beliefs that others say are not true?
0      Never
1      Sometimes
2      Always
13. Does it ever feel like the 
hallucinations are touching you?
0      Never
1      Sometimes 
2      Always
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“Is there anything else you can tell me about your hallucinations that we 
have not spoken about?”
Please record any comments made by the participant    
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